RESULT_COUNT: 1116,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences Stock: Performance in 3Q17,2017-10-20 18:39:34 +0000,http://finance.yahoo.com/r/2df21a19-9571-3056-900a-f39065cef5bf/gilead-sciences-stock-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Gilead Sciences stock has risen ~15.2% in 3Q17 and 13.9% year-to-date as of October 20, 2017."
INCY,INCY:UW,BBG000BNQ132,"QURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated",2017-10-19 22:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c6hxw_GNNdI/qure-on-fast-track-music-to-cnces-ears-crbp-gets-a-facelift-obln-deflated-20171019-01689,"QURE On Fast Track, Music To CNCE's Ears, CRBP Gets A Facelift, OBLN Deflated"
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-10-19 12:03:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120336866.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?,2017-10-18 13:54:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bnIzrtRjhE/eli-lilly-lly-to-report-q3-earnings-whats-in-store-cm861192,Eli Lilly and Company LLY will report third quarter 2017 results on Oct 24 before the market opens Last quarter the company delivered a positive earnings surprise of 6 73 Lilly s shares have risen 17 this year so far while the industry recorded an increase of 18 2 Lilly
INCY,INCY:UW,BBG000BNQ132,Incyte Might Win a Cancer-Drug Battle But Lose the War,2017-10-16 19:04:18 +0000,http://finance.yahoo.com/r/8c3c4859-6aea-319e-a33b-ea16f6a78090/incyte-ido-inhibitor-lawsuit-competition-fierce-no-matter-what?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Even if its suit over alleged IP theft succeeds, the competition is already fierce."
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : October 16, 2017",2017-10-16 13:54:33 +0000,http://finance.yahoo.com/r/295c062a-288a-3276-a0f6-81a3c2862c7b/etfs-with-exposure-to-incyte-corp-october-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease,2017-10-16 13:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sONgkph384Q/incyte-cancer-treatment-uses-patients-immune-system-to-fight-disease-cm859976,Among the biotech companies chasing next generation cancer treatments that work with patients own immune systems Incyte INCY stands out with a treatment analysts say could prove to be a blockbuster ibd display video id 2326965 width 50 float left autostart true
INCY,INCY:UW,BBG000BNQ132,IBD Biotech Innovator Awards,2017-10-16 13:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kHgIl9n9Ak8/ibd-biotech-innovator-awards-cm859972,Investor s Business Daily has created the IBD Biotech Innovator Awards to recognize leading companies with groundbreaking treatments already on the market or close to final approvals Recipients of the inaugural awards are Celgene CELG Biogen BIIB
INCY,INCY:UW,BBG000BNQ132,6 Top Biotech Companies In Innovation Earn Recognition In New Awards,2017-10-16 12:01:09 +0000,http://finance.yahoo.com/r/6c7c83e3-cdcb-3b9b-a44f-7114dc6f5297/top-biotech-companies-innovation-6-biotech-stocks-recognized?src=A00220&yptr=yahoo&.tsrc=rss,Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
INCY,INCY:UW,BBG000BNQ132,Incyte Cancer Treatment Uses Patients&apos; Immune System To Fight Disease,2017-10-16 11:50:57 +0000,http://finance.yahoo.com/r/0706e3ad-a898-3397-bc9c-6b5feb0e391e/incyte-cancer-treatment-uses-patients-immune-system?src=A00220&yptr=yahoo&.tsrc=rss,Incyte stands out among biotech companies chasing next-generation treatments that work with patients&apos; own immune systems to combat cancer.
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Third Quarter Financial Results,2017-10-12 20:10:00 +0000,https://finance.yahoo.com/news/incyte-report-third-quarter-financial-201000336.html?.tsrc=rss,"Incyte Corporation announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017."
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Abandon or Sell Short for Gains,2017-10-12 16:19:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O2YGG7PkFyM/5-toxic-stocks-to-abandon-or-sell-short-for-gains-cm858881,Investors who can precisely differentiate between overpriced stocks and fairly priced stocks emerge winners However in this complicated market place these two types of stocks are intertwined in such a way that it is very tough to identify them Investors who can pick the toxic
INCY,INCY:UW,BBG000BNQ132,5 Game-Changing Cancer Drug Innovations Being Developed Right Now,2017-10-12 11:13:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wHSNlY8m4nY/5-game-changing-cancer-drug-innovations-being-developed-right-now-cm858560,Image source Getty Images The emperor of all maladies the king of terrors 160 This phrase was used by a 19th century surgeon to describe cancer More than a century later the description unfortunately still applies Oncologist 160 Siddhartha Mukherjee even used the first
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,603.55.",2017-10-11 20:48:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i6KEFjhlfFA/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-660355-cm858457,Wednesday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 6 603 55 up 16 3 for the day The index had a previous high 6590 18035 on 10 06 2017 The total shares traded for the NASDAQ was over 1 88 billion Wednesday s session closes with the
INCY,INCY:UW,BBG000BNQ132,"VOT, ADSK, INCY, EW: Large Outflows Detected at ETF",2017-10-10 17:13:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/65F4gQseB6Y/vot-adsk-incy-ew-large-outflows-detected-at-etf-cm857683,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Mid Cap Growth ETF Symbol VOT where we have detected an approximate 27 7 million dollar outflow that s a 0 6 decrease week over week from 39 904
INCY,INCY:UW,BBG000BNQ132,One Of Biotech's Hottest Names Embraces Pharma's Bygone Era,2017-10-10 11:30:00 +0000,http://finance.yahoo.com/r/a41044aa-1cf3-30db-b366-1f8373264af0/incyte-pharmaceuticals-finds-the-right-chemistry-for-success?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag&yptr=yahoo&.tsrc=rss,"Incyte has one cancer blockbuster, and it's got Wall Street banking on another. Its secret: embracing an older age of pharma."
INCY,INCY:UW,BBG000BNQ132,Take a look: Incyte unveils new global headquarters in Wilmington,2017-10-06 18:58:27 +0000,http://finance.yahoo.com/r/a36d622b-37e5-3b37-bd87-90729ce5808b/incy-incyte-pharma-global-headquarters-wilmington.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"While one may expect to have to go to a local park to find a walking trail, community gardens, putting green and a pickleball court side by side, employees of Incyte Corp. will find all those outdoor amenities at the biopharmaceutical company's new global headquarters in Wilmington.  Incyte CEO Herve Hoppenot said the expansion was needed to provide more space for the company's growing research and development activities."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: COST, INCY",2017-10-06 16:43:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_tnYTi5AwP0/nasdaq-100-movers-cost-incy-cm856311,In early trading on Friday shares of Incyte topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 3 Year to date Incyte registers a 15 8 gain And the worst performing Nasdaq 100 component thus far on the day is Costco Wholesale trading down 5
INCY,INCY:UW,BBG000BNQ132,Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware,2017-10-06 13:00:00 +0000,https://finance.yahoo.com/news/incyte-cancer-support-community-delaware-130000839.html?.tsrc=rss,"Incyte Corporation and Cancer Support Community Delaware today announced the establishment of the Incyte Cancer Care Assistance Fund for Delaware which will provide emergency financial assistance for cancer patients, their caregivers and family members living in Delaware."
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : October 5, 2017",2017-10-05 15:06:50 +0000,http://finance.yahoo.com/r/a7829f4a-77c9-3cee-ad88-53af63e16a8e/etfs-with-exposure-to-incyte-corp-october-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Cancer-Cure Makers Make Great Takeover Stocks,2017-10-04 15:40:00 +0000,http://finance.yahoo.com/r/1e7d01db-ac15-3e75-87c8-b95756b3c226/cancer-cure-makers-make-great-takeover-stocks?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag&yptr=yahoo&.tsrc=rss,This company's impressive technology portfolio make it a great acquisition candidate.
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, PAYX",2017-10-03 14:54:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XhrNncvXuNg/nasdaq-100-movers-incy-payx-cm854505,In early trading on Tuesday shares of Paychex PAYX topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 9 Year to date Paychex registers a 2 0 gain And the worst performing Nasdaq 100 component thus far on the day is Incyte
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Leaders: Healthcare, Consumer Products",2017-09-29 19:33:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1PsjdFxhySQ/friday-sector-leaders-healthcare-consumer-products-cm853242,In afternoon trading on Friday Healthcare stocks are the best performing sector higher by 0 6 Within the sector Incyte Corporation Symbol INCY and Regeneron Pharmaceuticals Inc Symbol REGN are two large stocks leading the way showing a gain of 2 3 and 2 2 respectively
INCY,INCY:UW,BBG000BNQ132,"3 Stocks That Turned $7,000 Into $130,200",2017-09-29 01:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzMB5npOmyg/3-stocks-that-turned-7000-into-130200-cm852914,The meteoric rise of Netflix over the past decade has been nothing short of phenomenal with its stock rising nearly 7 000 in that time period The S amp P 500 component also surpassed the index itself which didn t even double in value Of course not every stock can be
INCY,INCY:UW,BBG000BNQ132,"3 Stocks That Turned $7,000 Into $130,200",2017-09-28 23:32:00 +0000,http://finance.yahoo.com/r/ccafa6db-591b-386e-8fe0-13cf7eda6532/3-stocks-that-turned-7000-into-130200.aspx?yptr=yahoo&.tsrc=rss,"There have been some big winners over the past decade, but few have surpassed Priceline Group, Regeneron Pharmaceuticals, and Incyte."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: QVCA, AAL",2017-09-28 15:44:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nbjc5pGCaHQ/nasdaq-100-movers-qvca-aal-cm852514,In early trading on Thursday shares of American Airlines Group AAL topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 1 Year to date American Airlines Group registers a 2 4 gain And the worst performing Nasdaq 100 component thus far on
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Remains Focused on Drug Development Programs,2017-09-28 14:46:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ifJ_UwRI0J8/agenus-agen-remains-focused-on-drug-development-programs-cm852562,We issued an updated research report on Agenus Inc AGEN on Sep 26 2017 Notably Agenus is an immuno oncology company focused on the discovery and development of checkpoint modulators vaccines and adjuvants for the treatment of cancer In fact the company has collaboration agreements with
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Remains Focused on Drug Development Programs,2017-09-28 13:20:01 +0000,https://finance.yahoo.com/news/agenus-agen-remains-focused-drug-132001495.html?.tsrc=rss,Agenus&apos; (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
INCY,INCY:UW,BBG000BNQ132,Tech Bounces Back,2017-09-27 13:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tgfE4vVIgsc/tech-bounces-back-cm851466,With Apple putting together its first positive session 1 72 in five days the technology space managed to bounce back from yesterday s malaise Consequently the NASDAQ was the best performing index of the Big 3 on Tuesday with a gain of 0 15 to 6380 2 160 Meanwhile the S amp
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-09-27 12:06:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120607128.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $8.79 billion."
INCY,INCY:UW,BBG000BNQ132,J&J's Arthritis Candidate Sirukumab Denied FDA Approval,2017-09-26 13:57:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E_YDM-Zy_KQ/jjs-arthritis-candidate-sirukumab-denied-fda-approval-cm850880,Johnson amp Johnson JNJ announced that the FDA has denied approval to its investigational rheumatoid arthritis RA treatment sirukumab an IL 6 inhibitor for want of additional safety data The FDA issued a complete response letter CRL for J amp J s Biologics License Application BLA
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-09-26 12:06:06 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120606793.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,12 Stocks That Will Push the S&P 500 Higher,2017-09-25 18:30:00 +0000,http://finance.yahoo.com/r/a4ddc632-0ef7-3df0-a05d-dc22614c47db/12-stocks-will-push-sp-500-higher?partner=YahooSA&yptr=yahoo&.tsrc=rss,Goldman Sachs says sales growth will be the key ingredient driving stocks higher
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite",2017-09-25 14:51:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3hbk2SlqgC0/zackscom-featured-highlights-ptc-apache-incyte-titan-international-and-carbonite-cm850311,For Immediate Release Chicago IL September 25 2017 Stocks in this week s article include PTC Inc 160 Nasdaq PTC 160 Free Report Apache Corporation 160 NYSE APA 160 Free Report 160 Incyte Corp 160 Nasdaq INCY 160 Free Report Titan
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : September 25, 2017",2017-09-25 14:40:11 +0000,http://finance.yahoo.com/r/56670aac-baca-399c-9b75-a9289fd05bd9/etfs-with-exposure-to-incyte-corp-september-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite",2017-09-25 12:46:12 +0000,https://finance.yahoo.com/news/zacks-com-featured-highlights-ptc-124612798.html?.tsrc=rss,"Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite"
INCY,INCY:UW,BBG000BNQ132,3 Monster Biotech Stocks in the Making,2017-09-24 14:47:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FyF3LstFq3A/3-monster-biotech-stocks-in-the-making-cm850149,Were the biggest biotechs in the world today always so big Of course not They all started out as much smaller companies Along the way each of today s big biotechs had a successful product that helped them launch yet another successful product They made a few acquisitions to drive
INCY,INCY:UW,BBG000BNQ132,3 Monster Biotech Stocks in the Making,2017-09-24 13:09:00 +0000,http://finance.yahoo.com/r/a6e5ceb3-18b3-357a-8851-0cf528211cee/3-monster-biotech-stocks-in-the-making.aspx?yptr=yahoo&.tsrc=rss,They&apos;ve got successful drugs. They&apos;re profitable. All these biotechs need to become huge is a little luck and time.
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Discard or Sell Short for Profit,2017-09-22 14:39:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vs1cO-0zYPY/5-toxic-stocks-to-discard-or-sell-short-for-profit-cm849520,Investors who can accurately distinguish between overpriced and rightly priced stocks emerge as winners at the end However in this tricky market place these two types of stocks are inter mixed in such a way that it is very tough to differentiate them Investors who can appropriately spot
INCY,INCY:UW,BBG000BNQ132,"VOT, FISV, INCY, EW: ETF Outflow Alert",2017-09-21 19:38:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/upTSxSr-APY/vot-fisv-incy-ew-etf-outflow-alert-cm849226,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Mid Cap Growth ETF Symbol VOT where we have detected an approximate 258 8 million dollar outflow that s a 5 1 decrease week over week from 41 779
INCY,INCY:UW,BBG000BNQ132,Implied BBH Analyst Target Price: $150,2017-09-21 15:39:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rp9AQQjccAw/implied-bbh-analyst-target-price-150-cm849034,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
INCY,INCY:UW,BBG000BNQ132,3 Small-Cap Biotech Stocks to Buy This Fall,2017-09-21 13:38:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oCubhAT53go/3-small-cap-biotech-stocks-to-buy-this-fall-cm848876,Hundreds of small cap biotech stocks are available for investors All of them come with relatively high levels of risk With that high risk though also comes the potential for high returns But which small cap biotech stocks have the best risk reward profiles Celldex
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-09-21 12:03:22 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120322372.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,3 Small-Cap Biotech Stocks to Buy This Fall,2017-09-21 11:47:00 +0000,http://finance.yahoo.com/r/262b3fec-0462-3921-bf72-50121a831e5c/3-small-cap-biotech-stocks-to-buy-this-fall.aspx?yptr=yahoo&.tsrc=rss,"Why small-cap biotechs Celldex Therapeutics, Idera Pharmaceuticals, and NewLink Genetics could be big winners."
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-09-20 12:01:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120133094.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding INCY totaled $456 million."
INCY,INCY:UW,BBG000BNQ132,Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress,2017-09-19 20:05:00 +0000,https://finance.yahoo.com/news/merus-announces-second-quarter-2017-200500350.html?.tsrc=rss,"UTRECHT, The Netherlands, Sept. 19, 2017-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second ..."
INCY,INCY:UW,BBG000BNQ132,Interesting INCY Put And Call Options For November 17th,2017-09-19 15:40:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gC_XsdQmbLo/interesting-incy-put-and-call-options-for-november-17th-cm847847,Investors in Incyte Corporation Symbol INCY saw new options begin trading this week for the November 17th expiration At Stock Options Channel our YieldBoost formula has looked up and down the INCY options chain for the new November 17th contracts and identified one put and one call
INCY,INCY:UW,BBG000BNQ132,5 of the Toughest Stocks to Withstand a Downturn,2017-09-18 19:35:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HGpgoyhmHaI/5-of-the-toughest-stocks-to-withstand-a-downturn-cm847364,InvestorPlace Stock Market News Stock Advice amp Trading Tips According to leading banks the evidence of an upcoming downturn is growing 160 HSBC Citigroup and Morgan Stanley have all noted a trading pattern breakdown a signal to get out soon according to Bloomberg
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation (Nasdaq: INCY) to Ring The Nasdaq Stock Market Closing Bell,2017-09-18 14:00:00 +0000,https://finance.yahoo.com/news/incyte-corporation-nasdaq-incy-ring-140000958.html?.tsrc=rss,"What: Incyte Corporation, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, will visit the Nasdaq MarketSite in Times Square. In honor ..."
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study,2017-09-15 15:41:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GptKyODlHc8/lillyincytes-baricitinib-meets-endpoint-in-eczema-study-cm846253,Eli Lilly and Company LLY and partner Incyte Corporation INCY announced that its pipeline candidate baricitinib met the primary endpoint in a phase II study in patients with moderate to severe atopic dermatitis AD a type of eczema So far this year Lilly s shares have underperformed
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte&apos;s Baricitinib Meets Endpoint in Eczema Study,2017-09-15 13:51:01 +0000,https://finance.yahoo.com/news/lilly-incyte-apos-baricitinib-meets-135101219.html?.tsrc=rss,Eli Lilly and Company (LLY) and partner Incyte announced that baricitinib met its primary endpoint in a phase II study in people with moderate-to-severe atopic dermatitis.
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte pill beats placebo in mid-stage eczema trial,2017-09-14 18:49:16 +0000,https://finance.yahoo.com/news/lilly-incyte-pill-beats-placebo-184916406.html?.tsrc=rss,"Eli Lilly and Co and Incyte Corp  on Thursday said a mid-stage trial of their oral drug  baricitinib showed that at the highest dose it worked better  than placebo for people with moderate-to-severe atopic  dermatitis.  The finding could be a boost for the drug's prospects, which  suffered a setback earlier this year after U.S. regulators  turned down an application for its use in rheumatoid arthritis,  saying that more data was needed.  Baricitinib, in a class of drugs known as Jak inhibitors, is  sold in the European Union under the brand name Olumiant for  treating rheumatoid arthritis."
INCY,INCY:UW,BBG000BNQ132,Have Investors Already Priced In Incyte Corporation’s (INCY) Growth?,2017-09-14 17:19:10 +0000,https://finance.yahoo.com/news/investors-already-priced-incyte-corporation-171910946.html?.tsrc=rss,Today we’re going to take a look at the well-established Incyte Corporation (NASDAQ:INCY). The company’s stock See our latest analysis for INCY What is INCY worth? INCY appears to beRead More...
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte pill beats placebo in mid-stage eczema trial,2017-09-14 15:35:18 +0000,https://finance.yahoo.com/news/lilly-incyte-pill-beats-placebo-130000312.html?.tsrc=rss,"Eli Lilly and Co and Incyte Corp  on Thursday said a mid-stage trial of their oral drug  baricitinib showed that at the highest dose it worked better  than placebo for people with moderate-to-severe atopic  dermatitis.  The finding could be a boost for the drug's prospects, which  suffered a setback earlier this year after U.S. regulators  turned down an application for its use in rheumatoid arthritis,  saying that more data was needed.  Baricitinib, in a class of drugs known as Jak inhibitors, is  sold in the European Union under the brand name Olumiant for  treating rheumatoid arthritis."
INCY,INCY:UW,BBG000BNQ132,Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,2017-09-14 13:00:00 +0000,https://finance.yahoo.com/news/baricitinib-meets-primary-endpoint-phase-130000044.html?.tsrc=rss,- Results presented at EADV show baricitinib significantly improved clinical and patient-reported outcomes compared to placebo in moderate-to-severe atopic dermatitis patients - Improvements seen as early ...
INCY,INCY:UW,BBG000BNQ132,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib,2017-09-14 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KTWtKkhO53o/lilly-announces-new-safety-and-efficacy-data-from-phase-2-study-of-baricitinib-20170914-00684,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : September 13, 2017",2017-09-13 22:39:08 +0000,http://finance.yahoo.com/r/15dbfd0d-985d-3654-acd9-91bf4382f6c6/etfs-with-exposure-to-incyte-corp-september-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,This Analyst Predicts Bullish Growth Outlook For Incyte,2017-09-12 13:28:49 +0000,https://finance.yahoo.com/news/analyst-predicts-bullish-growth-outlook-132849765.html?.tsrc=rss,"Argus said in a note that it sees bullish growth outlook for Incyte Corporation (NASDAQ: INCY ) given its solid late-stage pipeline and key strategic R&D partnerships with companies such as Merck & Co., ..."
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017",2017-09-11 18:30:45 +0000,http://finance.yahoo.com/r/d0818f56-04b6-3d20-91c7-e0c7127f4118/incyte-corp-incy-us-earnings-analysis-q2-2017-by-the-numbers-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Incyte Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Incyte Corp. – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : September 11, 2017",2017-09-11 14:44:23 +0000,http://finance.yahoo.com/r/cee89a5a-ed87-3e5c-bc3b-c4a070eaac2c/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-september-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,"[$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances",2017-09-11 14:21:29 +0000,"http://finance.yahoo.com/r/faf7390b-3b0a-342b-8d84-509b4618286f/8532671a-9651-11e7-b83c-9588e51488a0,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss",Investor hopes of making money from cutting-edge cancer treatments were given a boost on Monday with particularly positive data from UK-based drugmaker AstraZeneca sending shares higher. Other results ...
INCY,INCY:UW,BBG000BNQ132,Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma,2017-09-09 12:49:00 +0000,https://finance.yahoo.com/news/progression-free-survival-data-echo-124900464.html?.tsrc=rss,"Incyte Corporation today announced updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® , an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ USA , in patients with advanced melanoma."
INCY,INCY:UW,BBG000BNQ132,Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melanoma,2017-09-09 12:45:00 +0000,https://finance.yahoo.com/news/progression-free-survival-data-echo-124500523.html?.tsrc=rss,"Incyte Corporation and Merck , known as MSD outside the United States and Canada, today announced updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® , Merck’s anti-PD-1 therapy, in patients with advanced melanoma."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,360.19 down -37.68 points",2017-09-08 20:49:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rQNc4DjSng0/market-close-report-nasdaq-composite-index-closes-at-636019-down-3768-points-cm843173,Friday s session closes with the NASDAQ Composite Index at 6 360 19 The total shares traded for the NASDAQ was over 1 77 billion Friday s session closes with the NASDAQ Composite Index at 6 360 19 The total shares traded for the NASDAQ was over 1 77 billion Advancers stocks led declining by 1
INCY,INCY:UW,BBG000BNQ132,"Notable Friday Option Activity: OKTA, RH, INCY",2017-09-08 16:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sb4h6hMXqMk/notable-friday-option-activity-okta-rh-incy-cm842991,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Okta Inc Symbol OKTA where a total volume of 2 226 contracts has been traded thus far today a contract volume which is representative of approximately 222 600
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, SYMC",2017-09-08 15:53:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VU5QhuN92_A/nasdaq-100-movers-incy-symc-cm842943,In early trading on Friday shares of Symantec Corp SYMC topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 6 Year to date Symantec Corp registers a 32 6 gain And the worst performing Nasdaq 100 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers,2017-09-08 14:39:00 +0000,http://finance.yahoo.com/r/39525ed3-b442-31a9-90d9-7c4378635c06/clovis-rises-on-comprehensive-phase-3-data-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.
INCY,INCY:UW,BBG000BNQ132,"Incyte Announces Pricing of Public Offering of 4,945,000 Shares of Common Stock",2017-09-08 12:35:00 +0000,https://finance.yahoo.com/news/incyte-announces-pricing-public-offering-123500224.html?.tsrc=rss,"Incyte Corporation today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The Company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock."
INCY,INCY:UW,BBG000BNQ132,"Incyte Announces Proposed Public Offering of 4,945,000 Shares of Common Stock",2017-09-07 21:28:00 +0000,https://finance.yahoo.com/news/incyte-announces-proposed-public-offering-212800999.html?.tsrc=rss,"Incyte Corporation today announced that the Company intends to offer to sell, subject to market and other conditions, 4,945,000 shares of its common stock in an underwritten public offering."
INCY,INCY:UW,BBG000BNQ132,Here's Why NewLink Genetics Is Vaulting 45% Higher Today,2017-09-07 18:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C15CiY86ilw/heres-why-newlink-genetics-is-vaulting-45-higher-today-cm842496,What happened After updating data from its ongoing phase 2 trial of IDO inhibitor indoximod in advanced melanoma shares in NewLink Genetics Corporation NASDAQ NLNK shares are jumping 45 at 12 15 p m EDT Thursday So what NewLink Genetics IDO inhibiting cancer drug
INCY,INCY:UW,BBG000BNQ132,Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation,2017-09-06 15:12:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7XYkrK6D_uI/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-cm841662,"Shutterstock photo    While the pure technology sector is the engine of innovation for much of what we consider the highest technology advancements of our age, there is a host of other industries represented in the Nasdaq-100 that are trailblazing. These companies that lie outside the pure tech sphere are some of"
INCY,INCY:UW,BBG000BNQ132,Alexion: Quite a Comeback,2017-09-05 15:50:00 +0000,http://finance.yahoo.com/r/76e782ab-6a7d-3e0d-abae-bfafcc337361/alexion-quite-a-comeback-1504626651?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"J.P. Morgan analyst Anupam Rama and his team are rethinking their stance on Alexion Pharmaceuticals (ALXN).  Today, Rama has reversed course, resuming a bullish stance on Alexion, restoring his previous Overweight rating and lifting his price target from $163 a share to $175 a share.  On the 2Q earnings call, Alexion prudently set low expectations for the 2H17 earnings and we believe Street focus is shifting to 2H17 / 1H18 clinical catalysts as key drivers over the next 6-12 months."
INCY,INCY:UW,BBG000BNQ132,The Key Reason Incyte Corporation Added $850 Million in Market Cap in August,2017-09-05 14:46:00 +0000,http://finance.yahoo.com/r/67f3ef89-f1b4-3640-922e-25a7caa0809a/the-key-reason-incyte-corporation-added-850-millio.aspx?yptr=yahoo&.tsrc=rss,An update on bariticinib&apos;s review timeline has Wall Street rightly excited.
INCY,INCY:UW,BBG000BNQ132,"Top Research Reports for Bank of America, Pepsi & American Express",2017-09-01 23:49:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WkhW15VWbd0/top-research-reports-for-bank-of-america-pepsi-american-express-cm840539,Friday September 1 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Bank of America BAC American Express AXP and Pepsi PEP These research reports have been hand
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda,2017-09-01 23:48:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g0_TUDGoc5w/incyte-incy-reports-positive-data-on-epacadostatkeytruda-cm840524,Incyte Corporation INCY announced that the European Society for Medical Oncology ESMO published an abstract containing new and updated data from the ongoing phase I II ECHO 202 trial on epacadostat The ECHO 202 study NCT02178722 is evaluating the safety and efficacy of Incyte s
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda,2017-09-01 21:32:09 +0000,https://finance.yahoo.com/news/incyte-incy-reports-positive-data-213209189.html?.tsrc=rss,Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
INCY,INCY:UW,BBG000BNQ132,"Top Research Reports for Bank of America, Pepsi & American Express",2017-09-01 21:04:09 +0000,https://finance.yahoo.com/news/top-research-reports-bank-america-210409560.html?.tsrc=rss,"Top Research Reports for Bank of America, Pepsi & American Express"
INCY,INCY:UW,BBG000BNQ132,Better Buy: Eli Lilly and Company vs. Pfizer Inc.,2017-09-01 19:49:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v6omtrCe_NM/better-buy-eli-lilly-and-company-vs-pfizer-inc-cm840443,Two of the biggest pharmaceutical companies in the world have been around since the 19th century Eli Lilly and Company NYSE LLY was founded in 1876 while Pfizer Inc NYSE PFE began operations even earlier in 1849 Overall Pfizer stock has been the better investment That
INCY,INCY:UW,BBG000BNQ132,Incyte Supports the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month,2017-09-01 13:00:00 +0000,https://finance.yahoo.com/news/incyte-supports-myeloproliferative-neoplasm-mpn-130000513.html?.tsrc=rss,"Incyte Corporation is proud to recognize and support the patients of the MPN community throughout September in honor of Blood Cancer Awareness Month. MPNs are a group of rare, chronic blood cancers, which include myelofibrosis , polycythemia vera , and essential thrombocythemia , that are estimated to affect about 200,000 people in the U.S."
INCY,INCY:UW,BBG000BNQ132,Thursday's ETF with Unusual Volume: BBH,2017-08-31 17:48:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jsRmZudX38o/thursdays-etf-with-unusual-volume-bbh-cm839844,The Biotech ETF is seeing unusually high volume in afternoon trading Thursday with over 127 000 shares traded versus three month average volume of about 31 000 Shares of BBH were up about 1 6 on the day Components of that ETF with the highest volume on Thursday were Gilead
INCY,INCY:UW,BBG000BNQ132,"Why $475,000 isn&apos;t actually that expensive for Novartis&apos;s new drug",2017-08-31 17:39:08 +0000,https://finance.yahoo.com/news/475000-isnt-actually-expensive-novartiss-new-drug-173908081.html?.tsrc=rss,The price tag on Novartis&apos; new cancer drug may be a bargain
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected,2017-08-31 16:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HANSn7KYG40/lillyincyte-to-re-file-baricitinib-nda-faster-than-expected-cm839768,Eli Lilly amp Company LLY and partner Incyte Corporation INCY announced that they will re submit the new drug application NDA for its rheumatoid arthritis RA drug baricitinib much faster than previously expected The NDA is expected to be re submitted in January next year In July
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: CTRP, MYL",2017-08-31 15:53:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sb2ruSylb6Y/nasdaq-100-movers-ctrp-myl-cm839750,In early trading on Thursday shares of Mylan topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 7 Year to date Mylan has lost about 17 6 of its value And the worst performing Nasdaq 100 component thus far on the day is Ctrip com
INCY,INCY:UW,BBG000BNQ132,Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected,2017-08-31 15:10:03 +0000,https://finance.yahoo.com/news/lilly-incyte-file-baricitinib-nda-151003842.html?.tsrc=rss,"Lilly (LLY) and Incyte announced that they will re-submit the new drug application (NDA) for their rheumatoid arthritis (RA) drug, baricitinib much faster than previously expected."
INCY,INCY:UW,BBG000BNQ132,Incyte and Gilead Sciences: S&P 500’s Top Gainers on August 30,2017-08-31 13:08:46 +0000,http://finance.yahoo.com/r/a6105f92-ddb1-359f-89b7-18189ebc6156/incyte-gilead-sciences-sp-500s-top-gainer-august-30?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte and Gilead Sciences were the S&P 500's top gainers on August 30. Incyte rose 10.6% and closed the day at $138.27.
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : August 31, 2017",2017-08-31 12:55:11 +0000,http://finance.yahoo.com/r/0aa4776c-2824-36bb-b3e6-35ab0c4219d8/incyte-corp-breached-its-50-day-moving-average-in-a-bullish-manner-incy-us-august-31-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update",2017-08-31 12:42:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-car-t-124212645.html?.tsrc=rss,It&apos;s all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
INCY,INCY:UW,BBG000BNQ132,"Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation",2017-08-31 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000395.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 31, 2017 / U.S. markets were lifted higher Wednesday as stronger-than-expected economic data outweighed the recent rising geopolitical tensions. The Dow Jones Industrial ..."
INCY,INCY:UW,BBG000BNQ132,5 Biotech Stocks That Are Breaking Higher,2017-08-31 00:48:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9gpEQanX48/5-biotech-stocks-that-are-breaking-higher-cm839469,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S equities are continuing to melt higher on Wednesday as fears over the North Korean missile strike earlier in the week are fading amid a fresh focus on possible tax reform legislation Source Shutterstock Also we
INCY,INCY:UW,BBG000BNQ132,New Data for Epacadostat in Combination with KEYTRUDA® (pembrolizumab) Demonstrate Durable Responses in Patients with Advanced Melanoma,2017-08-30 23:05:00 +0000,https://finance.yahoo.com/news/data-epacadostat-combination-keytruda-pembrolizumab-230500870.html?.tsrc=rss,"Incyte Corporation today announced that the European Society for Medical Oncology has published an abstract containing new and updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with the anti-PD-1 KEYTRUDA® , marketed by Merck & Co., Inc., Kenilworth, N.J., USA , in patients with advanced melanoma."
INCY,INCY:UW,BBG000BNQ132,The Hot Stocks: Incyte Jumps 11%,2017-08-30 20:58:00 +0000,http://finance.yahoo.com/r/7e20f5f9-f898-3da2-bda3-4fefa8f6d75a/the-hot-stocks-incyte-jumps-11-1504126725?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte (INCY) soared to the top of the S&P 500 today on reports that it--and partner Eli Lilly (LLY)--plans to try to get its rheumatoid arthritis drug approved by the FDA after getting delayed earlier this year.  Incyte gained 11% to $138.27 today, while the S&P 500 rose 0.5% to 2,457.59.  Eli Lilly gained 2.5% to $80.49."
INCY,INCY:UW,BBG000BNQ132,"NASDAQ Composite Index closes up 18.87 points for the week, rising for the 3rd straight day",2017-08-30 20:49:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K-0Be386X4I/nasdaq-composite-index-closes-up-1887-points-for-the-week-rising-for-the-3rd-straight-day-cm839394,Wednesday s session closes with the NASDAQ Composite Index 66 42 This is the 3rd straight day of increase for the index The total shares traded for the NASDAQ was over 1 74 billion Wednesday s session closes with the NASDAQ Composite Index 66 42 This is the 3rd straight day of increase for
INCY,INCY:UW,BBG000BNQ132,What Analysts Recommend for United Therapeutics in August 2017,2017-08-30 20:43:37 +0000,http://finance.yahoo.com/r/fd329a45-d69f-3e2c-9162-a21cd16d3697/what-analysts-recommend-for-united-therapeutics-in-august-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants."
INCY,INCY:UW,BBG000BNQ132,"Wednesday Sector Leaders: Technology & Communications, Healthcare",2017-08-30 19:48:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WdWxZ-0NvqA/wednesday-sector-leaders-technology-communications-healthcare-cm839354,The best performing sector as of midday Wednesday is the Technology amp Communications sector up 1 0 Within that group Analog Devices Inc Symbol ADI and Advanced Micro Devices Inc Symbol AMD are two large stocks leading the way showing a gain of 4 5 and 3 7 respectively
INCY,INCY:UW,BBG000BNQ132,Incyte shares surge 10% on news that it and Eli Lilly will re-file for arthritis drug approval,2017-08-30 19:23:45 +0000,http://finance.yahoo.com/r/e318d3a7-02ad-3008-8fe2-691aaf764b03/Story.aspx?guid=C7176A63-6AB4-447B-82C0-FA4E578E9D09&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Incyte Corp. shares soared 10.1% in extremely heavy Wednesday trade after news that it and Eli Lilly & Co. plan to reapply for approval of rheumatoid arthritis drug baricitinib by the end of January 2018, ..."
INCY,INCY:UW,BBG000BNQ132,Trump can lower U.S. drug prices by fixing NAFTA,2017-08-30 18:27:53 +0000,https://finance.yahoo.com/news/trump-fix-nafta-lower-u-s-drug-prices-182753415.html?.tsrc=rss,"Without intellectual property, there is no innovation—and as we’re rapidly discovering, no customers."
INCY,INCY:UW,BBG000BNQ132,"Wednesday's ETF Movers: BBH, GDXJ",2017-08-30 17:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIes7EkpQpk/wednesdays-etf-movers-bbh-gdxj-cm839285,In trading on Wednesday the Biotech ETF is outperforming other ETFs up about 1 9 on the day Components of that ETF showing particular strength include shares of Bluebird Bio about 11 7 and shares of Incyte Genomics up about 6 2 on the day And underperforming other ETFs today is
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: HRB, ADI",2017-08-30 15:50:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-tnWz_XPBFM/sp-500-movers-hrb-adi-cm839152,In early trading on Wednesday shares of Analog Devices topped the list of the day s best performing components of the S amp P 500 index trading up 4 8 Year to date Analog Devices registers a 14 8 gain And the worst performing S amp P 500 component thus far on the day is H amp
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: WDC, ADI",2017-08-30 15:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_kfFFNqWGH8/nasdaq-100-movers-wdc-adi-cm839146,In early trading on Wednesday shares of Analog Devices topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 6 Year to date Analog Devices registers a 14 5 gain And the worst performing Nasdaq 100 component thus far on the day is Western
INCY,INCY:UW,BBG000BNQ132,Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers,2017-08-30 13:46:00 +0000,http://finance.yahoo.com/r/aad88e1b-1351-3caf-9d12-0a5e4370009d/otonomy-shares-fall-on-disappointing-phase-3-data-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
INCY,INCY:UW,BBG000BNQ132,Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018,2017-08-30 10:45:00 +0000,https://finance.yahoo.com/news/lilly-file-baricitinib-resubmission-u-104500221.html?.tsrc=rss,"INDIANAPOLIS , Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) ..."
INCY,INCY:UW,BBG000BNQ132,Wall Street To Open In Greener Zone,2017-08-30 07:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qADRvhGq9M4/wall-street-to-open-in-greener-zone-20170830-00323,Wall Street To Open In Greener Zone
INCY,INCY:UW,BBG000BNQ132,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018,2017-08-30 07:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqEaXVzncOE/lilly-to-resubmit-nda-for-baricitinib-to-fda-before-end-of-january-2018-20170830-00267,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018
INCY,INCY:UW,BBG000BNQ132,2 Stocks Fall on Earnings Report,2017-08-29 19:26:37 +0000,https://finance.yahoo.com/news/2-stocks-fall-earnings-report-192637303.html?.tsrc=rss,Hain Celestial Group and Best Buy decline despite beating estimates
INCY,INCY:UW,BBG000BNQ132,"Tuesday's ETF Movers: FBT, XOP",2017-08-29 17:49:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o1vPE1KZRKg/tuesdays-etf-movers-fbt-xop-cm838716,In trading on Tuesday the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs up about 1 2 on the day Components of that ETF showing particular strength include shares of Juno Therapeutics up about 19 8 and shares of Incyte Genomics up about 2 9 on the
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-29 12:05:12 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120512043.html?.tsrc=rss,Incyte Corp NASDAQ/NGS:INCY
INCY,INCY:UW,BBG000BNQ132,IBD Rating Upgrades: Incyte Shows Improved Price Strength,2017-08-29 07:00:00 +0000,http://finance.yahoo.com/r/ad4a5f2e-3473-3f12-a712-20a683d8c7cb/ibd-rating-upgrades-incyte-shows-improved-price-strength?src=A00220&yptr=yahoo&.tsrc=rss,"Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating"
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-28 12:05:09 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120450771.html?.tsrc=rss,Incyte Corp NASDAQ/NGS:INCY
INCY,INCY:UW,BBG000BNQ132,4 of the Highest-Growth Stocks in Biotech Today,2017-08-24 16:39:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qgR39DTR7ek/4-of-the-highest-growth-stocks-in-biotech-today-cm836626,Investing in the biotech industry can be a risky business In most instances the deck is stacked against a company succeeding The vast majority of preclinical studies will fail to reach human trials and there s no guarantee that a compound in clinical trials will reach pharmacy
INCY,INCY:UW,BBG000BNQ132,4 of the Highest-Growth Stocks in Biotech Today,2017-08-24 14:35:00 +0000,http://finance.yahoo.com/r/2c003ae5-c604-3e98-b01c-63fda8d763e8/4-of-the-highest-growth-stocks-in-biotech-today.aspx?yptr=yahoo&.tsrc=rss,"How does a compound annual growth rate of 50%, 60%, or 70% sound?"
INCY,INCY:UW,BBG000BNQ132,"Commit To Purchase Incyte Corporation At $100, Earn 9.7% Using Options",2017-08-23 16:40:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kab8i1T0M90/commit-to-purchase-incyte-corporation-at-100-earn-97-using-options-cm836019,Investors eyeing a purchase of Incyte Corporation Symbol INCY stock but cautious about paying the going market price of 123 26 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January
INCY,INCY:UW,BBG000BNQ132,Incyte Had These Key Collaborations and Developments in 2Q17,2017-08-23 15:53:09 +0000,http://finance.yahoo.com/r/d44557c7-fd8b-305b-a230-e06f99622b1d/incyte-had-these-key-collaborations-and-developments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets."
INCY,INCY:UW,BBG000BNQ132,Inside Incyte’s Jakafi Performance in 2Q17,2017-08-23 13:07:28 +0000,http://finance.yahoo.com/r/c0265097-65a9-3a6f-8737-63ba618a4e60/inside-incytes-jakafi-performance-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.
INCY,INCY:UW,BBG000BNQ132,Behind Incyte’s 2Q17 Product Portfolio,2017-08-23 11:37:35 +0000,http://finance.yahoo.com/r/0bacd429-0f0b-3652-9874-9a31ff34327b/behind-incytes-2q17-product-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.
INCY,INCY:UW,BBG000BNQ132,Understanding Incyte’s 2Q17 Revenue Stream,2017-08-22 18:05:53 +0000,http://finance.yahoo.com/r/c5b7b710-8803-38ec-972c-961e8e32b384/understanding-incytes-2q17-revenue-stream?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
INCY,INCY:UW,BBG000BNQ132,Assessing Incyte’s 2Q17 Revenue Growth,2017-08-22 16:35:55 +0000,http://finance.yahoo.com/r/60adc7c7-40eb-31de-801f-daeae8b9127c/assessing-incytes-2q17-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte's consolidated revenues rose ~32.5% to ~$326.4 million in 2Q17, compared with ~$246.3 million in 2Q16."
INCY,INCY:UW,BBG000BNQ132,Inside Incyte’s Valuation after the 2Q17 Earnings,2017-08-22 14:56:50 +0000,http://finance.yahoo.com/r/765256ce-1eba-3522-ba3b-e3043f789149/inside-incytes-valuation-after-the-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte reported revenues of ~$326.4 million for 2Q17, compared with ~$246.3 million for 2Q16."
INCY,INCY:UW,BBG000BNQ132,3 Most Promising Cancer Drugs in Late-Stage Development,2017-08-22 12:38:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6xD44vzVHVs/3-most-promising-cancer-drugs-in-late-stage-development-cm835114,Progress marches on in the fight against cancer While more biosimilars 160 are becoming available for top cancer drugs of the past biopharmaceutical companies are developing newer and more powerful treatments Market research firm EvaluatePharma evaluated all of the
INCY,INCY:UW,BBG000BNQ132,3 Most Promising Cancer Drugs in Late-Stage Development,2017-08-22 11:23:00 +0000,http://finance.yahoo.com/r/02493484-59aa-3b65-a97f-cd2369e2d302/3-most-promising-cancer-drugs-in-late-stage-develo.aspx?yptr=yahoo&.tsrc=rss,"Eli Lilly, Incyte, and Johnson & Johnson could have the most exciting late-stage oncology candidates."
INCY,INCY:UW,BBG000BNQ132,3 Top Biotech Stocks Under $5,2017-08-19 20:37:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zq3eM_Nae6E/3-top-biotech-stocks-under-5-cm834351,The biotech field is littered with stocks under 5 160 that probably won t walk away from the crash landings that made them look so cheap You ll be glad to know that sifting through the wreckage to find hidden gems is one daunting task that you don t need to slog through I
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-17 12:04:16 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120416119.html?.tsrc=rss,Incyte Corp NASDAQ/NGS:INCY
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-16 12:02:43 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120351002.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. – Value Analysis (NASDAQ:INCY) : August 15, 2017",2017-08-15 21:57:35 +0000,http://finance.yahoo.com/r/f16aa6b3-a978-3409-a8ea-9473f7e06f48/incyte-corp-value-analysis-nasdaqincy-august-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Incyte Corp. a score of 53. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Why Gilead Sciences Might Not Make an Oncology Acquisition,2017-08-15 20:22:00 +0000,http://finance.yahoo.com/r/7073c7dc-fc6b-3075-8dbd-f9d84ffe0986/why-gilead-sciences-might-not-make-an-oncology-acq.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences&apos; CEO hints that buying a biotech with an oncology focus might not happen. Here&apos;s what this could mean for the big biotech.
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-14 12:03:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120338107.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?,2017-08-13 19:34:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7QOdJOxSe7Y/why-has-2017-been-a-horrible-year-so-far-for-biotech-acquisitions-cm831433,How many big biotech acquisitions can you name that have occurred so far in 2017 Johnson amp Johnson NYSE JNJ spent 30 billion to buy Swiss biotech Actelion That s one Then there s well actually that s it J amp J s acquisition of Actelion is the only truly big
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 1-Aug-17 2:00pm GMT,2017-08-13 07:36:06 +0000,https://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-204046595.html?.tsrc=rss,Q2 2017 Incyte Corp Earnings Call
INCY,INCY:UW,BBG000BNQ132,"Bb Biotech Ag Buys AveXis Inc, Sells Regeneron Pharmaceuticals Inc, Puma Biotechnology Inc, PTC ...",2017-08-12 15:34:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UVUjaV_SnhA/bb-biotech-ag-buys-avexis-inc-sells-regeneron-pharmaceuticals-inc-puma-biotechnology-inc-ptc-cm831321,Bb Biotech Ag Added Positions RDUS ALXN NBIX TSRO HALO AVXS ESPR ALDR ITCI VRTX Reduced Positions REGN CELG KITE SAGE IONS ALNY Sold Out PBYI PTCT Added Positions RDUS ALXN NBIX TSRO HALO AVXS ESPR ALDR
INCY,INCY:UW,BBG000BNQ132,See what the IHS Markit Score report has to say about Incyte Corp.,2017-08-12 12:04:32 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120432742.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,Forbes Magazine Names Incyte One of the World’s Most Innovative Companies for Third Consecutive Year,2017-08-10 12:45:00 +0000,https://finance.yahoo.com/news/forbes-magazine-names-incyte-one-124500650.html?.tsrc=rss,"Incyte Corporation today announced it has been ranked 6th on Forbes magazine’s 2017 list of the World’s Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 17 development candidates against 14 different molecular ..."
INCY,INCY:UW,BBG000BNQ132,IHS Markit Score Update: Drop in demand for ETFs holding Incyte Corp is a negative sign for its shares,2017-08-10 12:04:39 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120439328.html?.tsrc=rss,"The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Index (PMI) data, output in the Healthcare sector is rising."
INCY,INCY:UW,BBG000BNQ132,"Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong",2017-08-02 16:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e_mI3CYOJII/incyte-incy-q2-loss-wider-than-expected-jakafi-strong-cm825857,Shares of Incyte Corporation INCY were down 3 4 after the company reported a loss in the second quarter of 2017 Incyte reported a loss of 6 cents a penny wider than the Zacks Consensus Estimate of a loss of 5 cents Incyte had reported earnings of 18 cents per share in the year
INCY,INCY:UW,BBG000BNQ132,"Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong",2017-08-02 15:05:03 +0000,https://finance.yahoo.com/news/incyte-incy-q2-loss-wider-150503047.html?.tsrc=rss,Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : August 2, 2017",2017-08-02 13:19:58 +0000,http://finance.yahoo.com/r/38df8d0d-cf53-3af3-bbe9-16a981a8d9d7/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-august-2-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Incyte Corporation,2017-08-02 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000190.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / AcelRx Pharmaceuticals saw a big drop in Tuesday trading after announcing second quarter results that failed to meet expectations. The company did, however, ..."
INCY,INCY:UW,BBG000BNQ132,Incyte reports 2Q loss,2017-08-02 02:56:46 +0000,https://finance.yahoo.com/news/incyte-reports-2q-loss-112700176.html?.tsrc=rss,"On a per-share basis, the Wilmington, Delaware-based company said it had a loss of 6 cents. The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ..."
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation (INCY) Shares Drop on Q2 Loss,2017-08-01 19:53:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lplRf1uqNy0/incyte-corporation-incy-shares-drop-on-q2-loss-cm825268,InvestorPlace Stock Market News Stock Advice amp Trading Tips Incyte Corporation NASDAQ INCY posted its quarterly earnings results today The pharmaceutical company unveiled earnings at a loss of six cents per share wider than
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: IDXX, NCLH",2017-08-01 16:57:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ei0Ag8ivaq8/nasdaq-100-movers-idxx-nclh-cm825058,In early trading on Tuesday shares of Norwegian Cruise Line Holdings NCLH topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 5 Year to date Norwegian Cruise Line Holdings registers a 32 8 gain And the worst performing Nasdaq 100
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation (INCY) Shares Drop on Q2 Loss,2017-08-01 15:41:55 +0000,https://finance.yahoo.com/news/incyte-corporation-incy-shares-drop-154155830.html?.tsrc=rss,"InvestorPlace - Stock Market News, Stock Advice &#38; Trading Tips"
INCY,INCY:UW,BBG000BNQ132,Investor Network: Incyte Corporation to Host Earnings Call,2017-08-01 12:00:00 +0000,https://finance.yahoo.com/news/investor-network-incyte-corporation-host-120000882.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 1, 2017 / Incyte Corporation (NASDAQ: INCY ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 01, 2017 at 10:00 AM Eastern ..."
INCY,INCY:UW,BBG000BNQ132,Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs,2017-08-01 11:00:00 +0000,https://finance.yahoo.com/news/incyte-reports-2017-second-quarter-110000637.html?.tsrc=rss,"Incyte Corporation today reports 2017 second-quarter financial results, highlighting strong revenue growth driven by increased sales of Jakafi® in the U.S."
INCY,INCY:UW,BBG000BNQ132,Incyte Q2 17 Earnings Conference Call At 10:00 AM ET,2017-08-01 09:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-6CaEUpI4ss/incyte-q2-17-earnings-conference-call-at-1000-am-et-20170801-00969,Incyte Q2 17 Earnings Conference Call At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,"Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY",2017-07-31 14:30:02 +0000,https://finance.yahoo.com/news/drug-stocks-q2-earnings-releases-143002654.html?.tsrc=rss,The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.
INCY,INCY:UW,BBG000BNQ132,"Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline",2017-07-26 15:04:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sgm9HM4zjag/key-takeaways-from-lillys-lly-q2-call-baricitinib-cancer-pipeline-cm821750,Yesterday big pharma player Eli Lilly and Company LLY reported better than expected second quarter results and raised its outlook for the year However shares were down 3 with investors focusing on the company s update regarding its investigational rheumatoid arthritis RA
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug",2017-07-26 14:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/02xDNr1AwQk/biotech-stock-roundup-amgen-biogen-top-q2-estimates-update-on-incyte-ra-drug-cm821419,Key biotech stocks Amgen AMGN and Biogen BIIB reported second quarter results yesterday both companies surpassed earnings and sales estimates There were several other key updates as well from companies like Incyte INCY and The Medicines Co MDCO 160 Recap of the Week s
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug",2017-07-26 12:15:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-amgen-biogen-121512704.html?.tsrc=rss,Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
INCY,INCY:UW,BBG000BNQ132,Gilead Faces 6th Quarter of Falling Revenue,2017-07-26 10:00:00 +0000,http://finance.yahoo.com/r/4c8fc31b-51e8-30cc-92a7-932e1b0b0235/gilead-faces-6th-quarter-falling-revenue?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Gilead Sciences, Inc.'s revenue is estimated to decline by just over 18% when it reports its Q2 results."
INCY,INCY:UW,BBG000BNQ132,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX",2017-07-26 02:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TRAnoGhx_E/positive-data-ignites-ttph-mdco-makes-a-good-tango-wait-continues-for-egrx-20170726-00106,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX"
INCY,INCY:UW,BBG000BNQ132,Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug,2017-07-25 20:17:00 +0000,http://finance.yahoo.com/r/4fdc3bb4-8563-3902-a2d0-645d393744da/eli-lilly-shares-lower-after-update-on-rheumatoid-arthritis-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
INCY,INCY:UW,BBG000BNQ132,Eli Lilly Tumbles On Arthritis Drug Delay,2017-07-25 20:02:36 +0000,http://finance.yahoo.com/r/1845a25d-f5e5-3087-b0aa-160ab732fd3f/eli-lilly-dives-after-q2-sales-come-up-light-though-profits-top?src=A00220&yptr=yahoo&.tsrc=rss,A delay in getting its rheumatoid arthritis drug to market by at least 18 months sent Eli Lilly shares lower Tuesday.
INCY,INCY:UW,BBG000BNQ132,Eli Lilly: What the Heck Just Happened?,2017-07-25 16:10:00 +0000,http://finance.yahoo.com/r/9b6b22f9-d18a-36f2-8733-c66b072aa4d1/eli-lilly-what-the-heck-just-happened-1500999026?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly (LLY) beat earnings forecasts today, but all anyone wants to talk about is a delayed filing for its the rheumatoid arthritis drug it's developing with Incyte (INCY).  Eli Lilly reported an adjusted profit of $1.11, topping the Street consensus for $1.05, on sales of $5.82 billion, above expectations for $5.59 billion.  Unfortunately, Eli Lilly and Incyte announced that their resubmission of a New Drug Application for their rheumatoid arthritis drug, baricitinib, would be delayed."
INCY,INCY:UW,BBG000BNQ132,"Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed",2017-07-25 16:08:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XznaTXdlKG4/lilly-lly-q2-earnings-top-baricitinib-re-filing-delayed-cm821037,Eli Lilly and Company LLY reported second quarter 2017 adjusted earnings per share of 1 11 which beat the Zacks Consensus Estimate of 1 04 by 6 7 Earnings rose 29 from the year ago quarter backed by volume driven pharma sales growth and higher profits Revenues Beat Quarterly
INCY,INCY:UW,BBG000BNQ132,Eli Lilly (LLY)'s Seemingly Illogical Reaction To Earnings Beat,2017-07-25 14:28:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JRBCD-8cQk/eli-lilly-llys-seemingly-illogical-reaction-to-earnings-beat-cm820820,"When pharma giant Eli Lilly ( LLY ) released their second quarter results early this morning, they appeared to be positive in every way. Adjusted EPS came in at $1.11, a nice beat of the $1.05 consensus expectation, and sales of $5.82 billion easily outstripped the $5.59 billion that analysts had predicted.  Both of"
INCY,INCY:UW,BBG000BNQ132,Eli Lilly beats profit and sales expectations; NDA for RA treatment to be delayed,2017-07-25 10:58:24 +0000,http://finance.yahoo.com/r/018e22d1-d60d-3788-80e4-b2bc36c18061/Story.aspx?guid=AE48D431-A7F1-4DB4-947E-B34829782C69&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. reported a second-quarter net profit that rose to $1.01 billion, or 95 cents a share, from $747.7 million, or 71 cents a share, in the same period a year ago. Excluding non-recurring items, ..."
INCY,INCY:UW,BBG000BNQ132,Lilly and Incyte Provide Update on Baricitinib,2017-07-25 10:15:00 +0000,https://finance.yahoo.com/news/lilly-incyte-baricitinib-101500123.html?.tsrc=rss,"INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), will be delayed beyond 2017.  The companies will be further discussing the path forward with the agency and evaluating options for resubmission, including the potential for an additional clinical study, as requested by the FDA."
INCY,INCY:UW,BBG000BNQ132,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib,2017-07-25 06:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VhT_ZibysEg/eli-lilly--incyte-issue-update-on-resubmission-of-nda-for-baricitinib-20170725-00237,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib
INCY,INCY:UW,BBG000BNQ132,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't,2017-07-21 20:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IM7_-ts66fs/2-reasons-incyte-is-a-better-growth-stock-than-exelixis-and-1-reason-it-isnt-cm819529,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks on the market We re talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70 so far this year Exelixis is simply put a fantastic growth stock But
INCY,INCY:UW,BBG000BNQ132,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn&apos;t,2017-07-21 18:42:00 +0000,http://finance.yahoo.com/r/9efdd973-40b9-31c0-b41e-1203bf4ca5a9/2-reasons-incyte-is-a-better-growth-stock-than-exe.aspx?yptr=yahoo&.tsrc=rss,Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
INCY,INCY:UW,BBG000BNQ132,3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?,2017-07-21 03:02:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PcU5QIOFpvk/3-hottest-biotech-stocks-of-2017-are-they-still-buys-now-cm819044,Biotechnology s top performing stocks this year have already given investors envy inspiring returns but there s reason to believe that Calithera Biosciences NASDAQ CALA Aurinia Pharmaceuticals NASDAQ AUPH and Esperion Therapeutics NASDAQ ESPR could still go
INCY,INCY:UW,BBG000BNQ132,"AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK",2017-07-21 01:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lV9LhW75kgs/aezs-gets-down-to-serious-work-apvo-surges-fda-tentative-nod-for-mrk-20170721-00023,"AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK"
INCY,INCY:UW,BBG000BNQ132,Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease,2017-07-20 11:30:00 +0000,https://finance.yahoo.com/news/incyte-announces-first-patient-treated-113000508.html?.tsrc=rss,"Incyte Corporation today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease ."
INCY,INCY:UW,BBG000BNQ132,We Did The Math FBT Can Go To $127,2017-07-19 14:03:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wzCGG7VT1Y8/we-did-the-math-fbt-can-go-to-127-cm817944,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
INCY,INCY:UW,BBG000BNQ132,Why Gilead Won't Buy Incyte and Vertex,2017-07-18 10:00:00 +0000,http://finance.yahoo.com/r/7b999817-73f6-3844-9ff7-b322697b7c92/why-gilead-wont-buy-incyte-and-vertex?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Despite rampant rumors, Gilead is not likely to acquire either Incyte or Vertex. Here's why."
INCY,INCY:UW,BBG000BNQ132,"Monday Sector Laggards: Healthcare, Technology & Communications",2017-07-17 19:45:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sLaIjk3lWAo/monday-sector-laggards-healthcare-technology-communications-cm817092,The worst performing sector as of midday Monday is the Healthcare sector showing a 0 1 loss Within the sector Incyte Corporation Symbol INCY and Medtronic PLC Symbol MDT are two of the day s laggards showing a loss of 3 0 and 2 6 respectively Among healthcare ETFs one
INCY,INCY:UW,BBG000BNQ132,"3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months",2017-07-15 11:45:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aqMrzpHwZCs/3-stocks-that-turned-1000-into-at-least-2017-in-12-months-cm816473,Although there is some truth in the saying that it takes money to make money that doesn t mean investors can t start small and reap big rewards With little more than 1 000 in your account you can turn what seems to be a tiny grubstake into a weighty retirement nest egg Let s look
INCY,INCY:UW,BBG000BNQ132,Gilead Could Acquire This Biotech — But Vertex Is Still Better: Analyst,2017-07-14 20:44:14 +0000,http://finance.yahoo.com/r/b8063aa5-e679-3d44-8dd8-b187b9cab236/gilead-could-acquire-this-biotech-but-vertex-is-still-better-analyst?src=A00220&yptr=yahoo&.tsrc=rss,"Gilead could fill a hole in its portfolio by acquiring Incyte, an analyst suggested Friday, offering one caveat — Vertex would still be a less risky bet."
INCY,INCY:UW,BBG000BNQ132,Could Q2 Surprise Spike This Beleaguered Biotech&apos;s Stock?,2017-07-14 18:37:55 +0000,http://finance.yahoo.com/r/fa266e36-c89c-33f0-9814-ea0bafc11d0c/could-q2-surprise-spike-this-beleaguered-biotechs-stock?src=A00220&yptr=yahoo&.tsrc=rss,"A key hepatitis C drug from Gilead could top Wall Street&apos;s Q2 expectations, but investors want to hear more about potential M&A activity."
INCY,INCY:UW,BBG000BNQ132,Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results,2017-07-11 20:06:02 +0000,https://finance.yahoo.com/news/merus-announces-first-quarter-2017-200602235.html?.tsrc=rss,Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies ...
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Second Quarter Financial Results,2017-07-11 12:00:00 +0000,https://finance.yahoo.com/news/incyte-report-second-quarter-financial-120000426.html?.tsrc=rss,"Incyte Corporation announced today that it has scheduled its second quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, August 1, 2017."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: TSLA, LILA",2017-07-10 15:46:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aZSFIwKuYJw/nasdaq-100-movers-tsla-lila-cm813776,In early trading on Monday shares of Liberty Global LILA topped the list of the day s best performing components of the Nasdaq 100 index trading up 8 4 Year to date Liberty Global registers a 10 1 gain And the worst performing Nasdaq 100 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,What Analysts Recommend for United Therapeutics in June 2017,2017-07-04 14:37:39 +0000,http://finance.yahoo.com/r/8a7b600d-8566-38d4-b274-1e11694167e7/what-analysts-recommend-for-united-therapeutics-in-june-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”
INCY,INCY:UW,BBG000BNQ132,Incyte & Lilly's Olumiant Gets Marketing Approval in Japan,2017-07-04 13:45:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y32zXwOVkZM/incyte-lillys-olumiant-gets-marketing-approval-in-japan-cm811536,Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that Japan s Ministry of Health Labor and Welfare MHLW granted marketing approval for Olumiant baricitinib 2 mg and 4 mg tablets The drug will be used for treating rheumatoid arthritis RA including the
INCY,INCY:UW,BBG000BNQ132,Incyte & Lilly&apos;s Olumiant Gets Marketing Approval in Japan,2017-07-04 11:53:11 +0000,https://finance.yahoo.com/news/incyte-lilly-apos-olumiant-gets-115311158.html?.tsrc=rss,Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
INCY,INCY:UW,BBG000BNQ132,Keytruda’s Developments in June 2017,2017-07-04 11:36:36 +0000,http://finance.yahoo.com/r/0aa72c66-9f54-3c47-bdcc-55b0f371b3a2/keytrudas-developments-in-june-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On June 12, 2017, Merck released updated data for Keytruda’s two phase III studies—KEYNOTE-183 and KEYNOTE-185—which evaluate Keytruda in combination with other drugs for the treatment of multiple myeloma...."
INCY,INCY:UW,BBG000BNQ132,"Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",2017-07-03 12:00:00 +0000,https://finance.yahoo.com/news/japan-ministry-health-labor-welfare-120000225.html?.tsrc=rss,"INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.  The Olumiant approval is based on the results of the baricitinib development program, which includes four phase 3 clinical trials enrolling various populations of more than 3,000 moderate-to-severe RA patients worldwide, including more than 500 Japanese patients.  In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies."
INCY,INCY:UW,BBG000BNQ132,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts,2017-07-03 08:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WSLlkvYcl-s/eli-lilly-reports-japan-marketing-approval-for-olumiant--quick-facts-20170703-00283,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts
INCY,INCY:UW,BBG000BNQ132,Better Buy: Agenus Inc. vs. Kite Pharma,2017-07-02 13:42:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HjW81HzAIsU/better-buy-agenus-inc-vs-kite-pharma-cm810938,Cancer therapy is not only the largest drug market by a wide margin but it s also the fastest growing Specifically EvaluatePharma expects cancer drug and therapy sales to rise at a compound annual growth of 12 7 over the course of 2016 to 2022 Interestingly enough the bulk of
INCY,INCY:UW,BBG000BNQ132,Gilead And Vertex Should Join — But Don&apos;t Hold Your Breath: Analyst,2017-06-30 20:13:46 +0000,http://finance.yahoo.com/r/20646e9a-04f5-3540-89b1-5cce1a03ebbf/gilead-could-forge-a-big-merger-but-dont-hold-your-breath?src=A00220&yptr=yahoo&.tsrc=rss,"Gilead would be better of acquiring Vertex than an oncology asset like Tesaro or Incyte, an analyst suggested Friday."
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : June 30, 2017",2017-06-30 19:04:04 +0000,http://finance.yahoo.com/r/03917262-7144-3f8d-94b7-1af7c12f4dd6/etfs-with-exposure-to-incyte-corp-june-30-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Stock Exchange: Time For Evidence-Based Trading?,2017-06-30 14:05:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3WApMZEZ0Q4/stock-exchange-time-for-evidence-based-trading-cm810336,By Jeff Miller ByJeff Miller Our Stock Exchange is all about trading Each week we do the following Our Stock Exchange Stock ExchangeStock Exchange is all about trading Each week we do the following Discuss an important issue for traders Highlight several technical
INCY,INCY:UW,BBG000BNQ132,"Thursday Sector Laggards: Technology & Communications, Healthcare",2017-06-29 20:02:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/le5xwi2q4AA/thursday-sector-laggards-technology-communications-healthcare-cm810181,Looking at the sectors faring worst as of midday Thursday shares of Technology amp Communications companies are underperforming other sectors showing a 2 3 loss Within that group Advanced Micro Devices Inc Symbol AMD and Lam Research Corp Symbol LRCX are two of the day s
INCY,INCY:UW,BBG000BNQ132,Aduro Starts Phase II Combo Study with CRS-207 & Keytruda,2017-06-29 16:09:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/spSxsnYeoOc/aduro-starts-phase-ii-combo-study-with-crs-207-keytruda-cm810014,Aduro Biotech Inc ADRO has announced initiation of a phase II study to evaluate a combination therapy of its lead LADD live attenuated double deleted based candidate CRS 207 in combination with Merck amp Co Inc s MRK anti PD 1 therapy Keytruda pembrolizumab for treatment
INCY,INCY:UW,BBG000BNQ132,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca",2017-06-29 15:08:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kh6QkYi0BYs/zacks-industry-outlook-highlights-johnson-johnson-incyte-pfizer-novartis-and-astrazeneca-cm809831,For Immediate Release Chicago IL June 29 2017 Today Zacks Equity Research discusses the Industry Pharmaceuticals including Johnson amp Johnson NYSE JNJ Free Report Incyte NASDAQ INCY Free Report Pfizer NYSE PFE Free Report Novartis NYSE NVS
INCY,INCY:UW,BBG000BNQ132,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca",2017-06-29 13:30:01 +0000,https://finance.yahoo.com/news/zacks-industry-outlook-highlights-johnson-133001328.html?.tsrc=rss,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca"
INCY,INCY:UW,BBG000BNQ132,Better Days Ahead for the Pharma Sector?,2017-06-28 22:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3MnO6tocceA/better-days-ahead-for-the-pharma-sector-cm809665,We are halfway through 2017 and the pharma and biotech sector has bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 12 9 while the NASDAQ Biotechnology Index is up 17 2 This is in sharp contrast to 2016 which was a tough year for pharma and biotech stocks with the
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 4-May-17 2:00pm GMT,2017-06-27 16:44:20 +0000,https://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-123058768.html?.tsrc=rss,Q1 2017 Incyte Corp Earnings Call
INCY,INCY:UW,BBG000BNQ132,Seattle Genetics: A Disappointing Study…Or Was It?,2017-06-26 18:52:00 +0000,http://finance.yahoo.com/r/6af3866f-8299-3e70-b1cc-b4d07210c8ee/seattle-genetics-a-disappointing-studyor-was-it-1498503146?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress.  The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint.  Altogether, lots of uncertainty whether these data could support a robust commercial adoption."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: NTES, MU",2017-06-26 15:50:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b_K_CqBGraM/nasdaq-100-movers-ntes-mu-cm808062,In early trading on Monday shares of Micron Technology MU topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 9 Year to date Micron Technology registers a 49 0 gain And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,The Reason for the Big Rise in Biotech Stocks,2017-06-26 10:00:00 +0000,http://finance.yahoo.com/r/bb87573d-590a-38db-a1ea-e99e069063d4/reason-big-rise-biotech-stocks?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biotech shares have surged during the week of June 19.
INCY,INCY:UW,BBG000BNQ132,Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger,2017-06-22 22:19:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AEaNQnJCSgY/stocks-to-fight-cancer-why-immunotherapy-is-a-gamechanger-cm807149,1 10 What Is the ASCO Conference And Why Is It Important 5 50 What Has Changed In The World Of Oncology Over The Years 9 00 What Cancers Is Immunotherapy Focused On Now 10 55 Incyte INCY Combination Trials 13 15 Are
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : June 22, 2017",2017-06-22 12:15:11 +0000,http://finance.yahoo.com/r/a731be33-618c-3bac-878b-9e5025aa2357/incyte-corp-breached-its-50-day-moving-average-in-a-bullish-manner-incy-us-june-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Today's Research Reports on Stocks to Watch: Amgen and Incyte,2017-06-22 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000449.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 22, 2017 / It wasn't quite clear why Incyte Corporation shares exploded on Wednesday to close in the green up nearly 8%, especially as there was no news from the company. ..."
INCY,INCY:UW,BBG000BNQ132,Update: Wall Street Weighed Down By Oil Declines as Health Stocks Lift Nasdaq,2017-06-21 20:59:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mCtcAJUOrXw/update-wall-street-weighed-down-by-oil-declines-as-health-stocks-lift-nasdaq-cm806535,Another day of selling in oil pushed the S amp P 500 and the Dow Jones Industrial Average into the red for a second straight session while gains in health stocks helped the Nasdaq Composite buck the weaker trend Another day of selling in oil pushed the S P 500 and the Dow Jones Industrial
INCY,INCY:UW,BBG000BNQ132,"Wednesday Sector Leaders: Healthcare, Technology & Communications",2017-06-21 20:20:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P34MV8dqXM4/wednesday-sector-leaders-healthcare-technology-communications-cm806478,In afternoon trading on Wednesday Healthcare stocks are the best performing sector higher by 1 1 Within the sector Incyte Corporation Symbol INCY and Regeneron Pharmaceuticals Inc Symbol REGN are two of the day s stand outs showing a gain of 7 7 and 5 6 respectively
INCY,INCY:UW,BBG000BNQ132,4 Stocks & ETFs to Buy on Clovis&apos; Positive Drug Data,2017-06-21 16:42:04 +0000,https://finance.yahoo.com/news/4-stocks-etfs-buy-clovis-164204661.html?.tsrc=rss,Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: MAT, CA",2017-06-21 16:25:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/62Vw3JMFenE/nasdaq-100-movers-mat-ca-cm806273,In early trading on Wednesday shares of CA CA topped the list of the day s best performing components of the Nasdaq 100 index trading up 13 7 Year to date CA registers a 13 0 gain And the worst performing Nasdaq 100 component thus far on the day is Mattel MAT trading
INCY,INCY:UW,BBG000BNQ132,"Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More",2017-06-21 15:25:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZllTJ5jWXYA/small-cancer-biotech-space-in-focus-3-stocks-up-100-more-cm806187,The oncology space has always been keenly watched by investors interested in the pharma biotech sector Cancer is the second most common cause of death in the U S preceded only by heart disease According to a report by the American Cancer Society almost 1 7 million cancer cases are expected
INCY,INCY:UW,BBG000BNQ132,"Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More",2017-06-21 13:35:01 +0000,https://finance.yahoo.com/news/small-cancer-biotech-space-focus-133501277.html?.tsrc=rss,The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks To Watch And Pharma Industry News,2017-06-20 18:39:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
INCY,INCY:UW,BBG000BNQ132,Three must-own cancer stocks for your biotechnology portfolio,2017-06-19 21:37:14 +0000,http://finance.yahoo.com/r/b2441b68-dff3-3de8-8a32-052f777f0e2d/Story.aspx?guid=3EF38AAE-5506-11E7-8A25-2D3DE571C970&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Michael Brush describes medical advances that can save lives — and make you money.
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : June 19, 2017",2017-06-19 19:32:23 +0000,http://finance.yahoo.com/r/d567951f-5fb1-324d-b86a-91a435327d52/etfs-with-exposure-to-incyte-corp-june-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,A Surprising Disappointment Derails NewLink Genetics -- What's Next?,2017-06-19 13:22:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-AeuWMSWqmU/a-surprising-disappointment-derails-newlink-genetics-whats-next-cm804898,Roche Holdings NASDAQOTH RHHBY surprisingly cut ties with NewLink Genetics NASDAQ NLNK 160 on GDC 0919 last week and that decision puts NewLink Genetics further back behind Incyte Corporation in the race 160 to develop a new class of cancer fighting
INCY,INCY:UW,BBG000BNQ132,A Surprising Disappointment Derails NewLink Genetics -- What&apos;s Next?,2017-06-19 12:00:00 +0000,http://finance.yahoo.com/r/67a60dfd-de49-377e-bdb3-a6a769b78875/a-surprising-disappointment-derails-newlink-geneti.aspx?yptr=yahoo&.tsrc=rss,"Roche Holdings has decided to walk away from co-developing NewLink Genetics IDO-inhibitor, GDC-0919."
INCY,INCY:UW,BBG000BNQ132,5 Answers to Questions Gilead Sciences' Investors Probably Have,2017-06-18 17:19:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8dAXvPkMCYQ/5-answers-to-questions-gilead-sciences-investors-probably-have-cm804819,If you re a Gilead Sciences NASDAQ GILD shareholder or you re thinking about buying the stock you probably have a lot of questions And if you don t you should have It hasn t been a pretty picture for the biotech for quite a while now Gilead s hepatitis C virus
INCY,INCY:UW,BBG000BNQ132,"Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...",2017-06-17 19:18:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nJ8GTrEIjno/baker-bros-advisors-lp-buys-incyte-corp-avexis-inc-la-jolla-pharmaceutical-co-sells-abbvie-cm804758,Baker Bros Advisors Lp New Purchases ANAB JNCE TNXP BPMX WINT Added Positions INCY AVXS LJPC ASND AQXP HRTX BCRX CBAY DERM SGMO Reduced Positions ARRY EXEL ZGNX VSAR AGLE CRBP JUNO NTRA PRTO Sold Out ABBV DSCI ADHD ENTA
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks That Could Become M&A Targets,2017-06-17 12:20:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fp5gOJQfjGM/3-biotech-stocks-that-could-become-ma-targets-cm804682,Biotech firms Mallinckrodt PLC NYSE MNK Tesaro Inc NASDAQ TSRO and Incyte Corp NASDAQ INCY could all be M amp A targets and if buyers appear for them owning their shares could pay off However these are risky stocks and there s no guarantee that deals
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks That Could Become M&A Targets,2017-06-17 10:42:00 +0000,http://finance.yahoo.com/r/42ea15c0-553d-30ff-b63b-10096d826a49/3-biotech-stocks-that-could-become-ma-targets.aspx?yptr=yahoo&.tsrc=rss,"There are reasons to think other drugmakers might see Mallinckrodt, Tesaro, and Incyte as tempting acquisitions, which makes them potential opportunities for risk-tolerant investors."
INCY,INCY:UW,BBG000BNQ132,3 Beaten-Down Stocks Ready to Bounce Back,2017-06-16 20:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xepzFibZZx0/3-beaten-down-stocks-ready-to-bounce-back-cm804563,While a rising tide is supposed to lift all boats some stocks seem determined to sink despite the market hitting new highs More than a few of them are likely in real trouble but some could be ready for a rebound We asked three top Motley Fool contributors to come up with a
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017",2017-06-16 16:16:26 +0000,http://finance.yahoo.com/r/ba8d35bf-3863-3ab4-bad7-576b8e76f582/incyte-corp-incy-us-earnings-analysis-q1-2017-by-the-numbers-june-16-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Incyte Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Incyte Corp. – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Investor Update: Incyte’s Key Developments in 1Q17,2017-06-16 11:36:27 +0000,http://finance.yahoo.com/r/94b81c76-9f9f-3b1b-9ac9-41535254b745/investor-update-incytes-key-developments-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.
INCY,INCY:UW,BBG000BNQ132,InPlay from Briefing.com,2017-06-16 08:51:55 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
INCY,INCY:UW,BBG000BNQ132,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,2017-06-16 08:15:00 +0000,https://finance.yahoo.com/news/safety-long-term-efficacy-data-081500901.html?.tsrc=rss,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
INCY,INCY:UW,BBG000BNQ132,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,2017-06-16 08:15:00 +0000,https://finance.yahoo.com/news/safety-long-term-efficacy-data-081500887.html?.tsrc=rss,"INDIANAPOLIS, June 16, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents.  Additionally, new data from the long-term extension (LTE) of Phase 3 trials showed that two years of baricitinib treatment significantly lowered the rate of joint damage progression and maintained an overall low disease activity (LDA) throughout the treatment period in these patients."
INCY,INCY:UW,BBG000BNQ132,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib",2017-06-16 05:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gNY6vXR_lIg/eli-lilly-incyte-announce-positive-results-from-pooled-analysis-of-baricitinib-20170616-00126,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib"
INCY,INCY:UW,BBG000BNQ132,How Incyte’s Jakafi Performed in 1Q17,2017-06-15 14:37:25 +0000,http://finance.yahoo.com/r/edce9106-ea1e-337a-b137-984745e05c66/how-incytes-jakafi-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte’s (INCY) Jakafi (ruxolitinib) is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, both of which are rare types of blood cancer."
INCY,INCY:UW,BBG000BNQ132,How Did Incyte’s Product Portfolio Look in 1Q17?,2017-06-15 13:07:51 +0000,http://finance.yahoo.com/r/ec25bbe5-7330-39da-b1fc-0e0a365a4625/how-did-incytes-product-portfolio-look-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.
INCY,INCY:UW,BBG000BNQ132,Analyzing Incyte’s Revenue Streams in 1Q17,2017-06-15 11:37:06 +0000,http://finance.yahoo.com/r/77097dd8-5021-34c2-8fef-5911b58253d0/analyzing-incytes-revenue-streams-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16."
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At Nasdaq 36th Investor Program; Webcast At 6:00 AM ET,2017-06-15 05:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lWhtUmDdIqY/incyte-to-present-at-nasdaq-36th-investor-program-webcast-at-600-am-et-20170615-00137,Incyte To Present At Nasdaq 36th Investor Program; Webcast At 6:00 AM ET
INCY,INCY:UW,BBG000BNQ132,How Incyte’s Revenues Trended in 1Q17,2017-06-14 20:36:44 +0000,http://finance.yahoo.com/r/1919144f-add8-30de-b227-bc84db3c5b8b/how-incytes-revenues-trended-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's (INCY) consolidated revenues rose ~45.7% to $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
INCY,INCY:UW,BBG000BNQ132,How Incyte’s Valuation Has Changed since 1Q17 Results,2017-06-14 19:04:42 +0000,http://finance.yahoo.com/r/50f68cda-5a9f-3067-a485-3f7e0d77a5aa/how-incytes-valuation-has-changed-since-1q17-results?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At Goldman Sachs Conference; Webcast At 1:40 PM ET,2017-06-14 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JZ8XI_sWkxg/incyte-to-present-at-goldman-sachs-conference-webcast-at-140-pm-et-20170614-00878,Incyte To Present At Goldman Sachs Conference; Webcast At 1:40 PM ET
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At William Blair Growth Conference; Webcast At 11:00 AM ET,2017-06-14 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1nHl84o7MeA/incyte-to-present-at-william-blair-growth-conference-webcast-at-1100-am-et-20170614-00694,Incyte To Present At William Blair Growth Conference; Webcast At 11:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017),2017-06-13 22:01:00 +0000,https://finance.yahoo.com/news/lilly-present-data-olumiant-baricitinib-220100628.html?.tsrc=rss,"Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz INDIANAPOLIS , June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: ..."
INCY,INCY:UW,BBG000BNQ132,This Biotech Name Could Be Best In Breed For 2017,2017-06-13 12:46:11 +0000,https://finance.yahoo.com/news/biotech-name-could-best-breed-124611927.html?.tsrc=rss,"The biotech sector has seen better times this year after the disappointing showing in 2016. Calithera Biosciences Inc (NASDAQ: CALA ) has been a stand-out performer in the sector, clocking gains in excess ..."
INCY,INCY:UW,BBG000BNQ132,"Roche-NewLink Drug Move Shouldn&apos;t Impact Incyte, Says Analyst",2017-06-09 20:27:37 +0000,http://finance.yahoo.com/r/108fc104-a1f1-3225-add2-f55079ab3f58/roche-newlink-drug-flop-shouldnt-impact-incyte-says-analyst?src=A00220&yptr=yahoo&.tsrc=rss,"Roche returned a licensed immuno-oncology drug to NewLink on low efficacy, but analysts say that shouldn&apos;t impact Incyte which has a rivaling drug."
INCY,INCY:UW,BBG000BNQ132,"BIB, CELG, AMGN, INCY: ETF Inflow Alert",2017-06-09 16:30:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vfFaGmpkUtI/bib-celg-amgn-incy-etf-inflow-alert-cm801286,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra Nasdaq Biotechnology Symbol BIB where we have detected an approximate 63 0 million dollar inflow that s a 17 3 increase week over week
INCY,INCY:UW,BBG000BNQ132,"Gilead Sciences, Inc.: The Bear Case From a Bull",2017-06-09 13:29:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k9g5a15FQkM/gilead-sciences-inc-the-bear-case-from-a-bull-cm801037,It s been hard to be bullish on Gilead Sciences NASDAQ GILD over the last year or so The big biotech s stock has plunged more than 30 since the beginning of 2016 Still though I have held on to the Gilead shares I bought several years ago I ve remained positive about
INCY,INCY:UW,BBG000BNQ132,"Gilead Sciences, Inc.: The Bear Case From a Bull",2017-06-09 12:03:00 +0000,http://finance.yahoo.com/r/de2466f5-907b-33d9-a874-9bbd21a9db67/gilead-sciences-inc-the-bear-case-from-a-bull.aspx?yptr=yahoo&.tsrc=rss,A pessimistic view of Gilead Sciences&apos; prospects from a long-time fan of the big biotech.
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?,2017-06-09 10:28:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pb5rLVVSm3k/incyte-incy-up-34-since-earnings-report-can-it-continue-cm800975,It has been about a month since the last earnings report for Incyte Corporation INCY Shares have added about 3 4 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before we
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?,2017-06-09 08:42:08 +0000,https://finance.yahoo.com/news/incyte-incy-3-4-since-084208057.html?.tsrc=rss,Incyte (INCY) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
INCY,INCY:UW,BBG000BNQ132,Why Is NewLink Genetics Losing One-Third of Its Value Today?,2017-06-08 20:28:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jUaPu8t7w1A/why-is-newlink-genetics-losing-one-third-of-its-value-today-cm800835,What happened After a surprising decision by Roche Holding NASDAQOTH RHHBY to exit its co development deal on a new cancer drug NewLink Genetics Corporation NASDAQ NLNK shares were crashing 32 as of 1 p m EDT So what Hope that success for NewLink
INCY,INCY:UW,BBG000BNQ132,Why Is NewLink Genetics Losing One-Third of Its Value Today?,2017-06-08 18:28:00 +0000,http://finance.yahoo.com/r/944fae62-c670-3b7d-8988-3f319294fd21/why-is-newlink-genetics-losing-one-third-of-its-va.aspx?yptr=yahoo&.tsrc=rss,Roche Holdings will no longer collaborate with NewLink Genetics on GDC-0919.
INCY,INCY:UW,BBG000BNQ132,"Cramer Remix: What the dreaded rise in stocks, gold & Bitcoin means for your money",2017-06-07 22:59:59 +0000,http://finance.yahoo.com/r/27303107-daef-31c6-b7c0-39417bb40da7/104516177?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104516177&yptr=yahoo&.tsrc=rss,"Jim Cramer dissects one scary investment combination and how to play it, despite scary media headlines."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,297.38 up 22.32 points",2017-06-07 20:48:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SPp3kxDuCeY/market-close-report-nasdaq-composite-index-closes-at-629738-up-2232-points-cm800282,Wednesday s session closes with the NASDAQ Composite Index at 6 297 38 The total shares traded for the NASDAQ was over 1 82 billion Wednesday s session closes with the NASDAQ Composite Index at 6 297 38 The total shares traded for the NASDAQ was over 1 82 billion Advancers stocks led
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2017-06-07 20:15:00 +0000,https://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-201500312.html?.tsrc=rss,Incyte Corporation announced today that it will present at the following investor conferences during the month of June:
INCY,INCY:UW,BBG000BNQ132,ASCO Was A Bust For Biotech,2017-06-07 16:56:00 +0000,http://finance.yahoo.com/r/178aa1da-6eb2-3749-8f4f-e84b484ddea4/asco-was-a-bust-for-biotech-1496854582?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The American Society of Clinical Oncology meeting is one of the most closely watched medical conferences of the year.  The Wall Street Journal’s “Heard on the Street” columnist Charley Grant noted today that this year’s conference, which ended Tuesday, passed “without much of a stir, at least from an investor point of view.” In short, while some individual stocks rose and fell sharply, the broader S&P Biotechnology Select Industry Index essentially hasn’t moved through Tuesday."
INCY,INCY:UW,BBG000BNQ132,"Dow&apos;s Merck Making Massive Strides With Keytruda, Analyst Says",2017-06-06 20:42:39 +0000,http://finance.yahoo.com/r/462fa079-8c20-3ea7-952b-765553e8f813/this-biotech-looks-compelling-on-mashup-with-dows-merck-analyst?src=A00220&yptr=yahoo&.tsrc=rss,"Wall Street is undervaluing the foundation Dow component Merck is making with its immuno-oncological star, Keytruda, an analyst said Tuesday."
INCY,INCY:UW,BBG000BNQ132,"3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene",2017-06-06 20:34:08 +0000,https://finance.yahoo.com/news/3-takeaways-mondays-asco-meetings-203408835.html?.tsrc=rss,The American Society of Clinical Oncology’s annual meeting ended Tuesday. The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings ...
INCY,INCY:UW,BBG000BNQ132,"Incyte Cancer Drug Data Is 'Compelling,' Credit Suisse Says",2017-06-06 17:57:00 +0000,http://finance.yahoo.com/r/98dd2275-e0df-304f-8e86-369ce9efa01d/incyte-cancer-drug-data-is-compelling-credit-suisse-says.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Credit Suisse analyst Alethia Young isn't worried about Incyte.
INCY,INCY:UW,BBG000BNQ132,Incyte: Don't Worry…Be Happy!,2017-06-06 16:47:00 +0000,http://finance.yahoo.com/r/63cbc48a-68a2-33c7-884f-65c549f7b8b4/incyte-dont-worrybe-happy-1496767628?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of the cancer drug maker Incyte (INCY) fell again today, as investors continued to show their disappointment over the drug trial updates the company released at the annual ASCO conference over the weekend.  From the questions we received from investors we think stock may be down due to the controversy around ""missing data"" but we think there is some confusion and are not concerned by this."
INCY,INCY:UW,BBG000BNQ132,Incyte Provides Updated Data on Cancer Combination Therapies,2017-06-06 15:05:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fQa-Qoi6wi8/incyte-provides-updated-data-on-cancer-combination-therapies-cm799315,Incyte Corporation INCY along with partner Bristol Myers Squibb Company BMY announced updated data from phase I II study ECHO 204 evaluating Incyte s epacadostat in combination with the latter s immune oncology drug Opdivo for the treatment of squamous cell carcinoma of the head and
INCY,INCY:UW,BBG000BNQ132,Incyte Provides Updated Data on Cancer Combination Therapies,2017-06-06 13:09:01 +0000,https://finance.yahoo.com/news/incyte-provides-updated-data-cancer-130901158.html?.tsrc=rss,"Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma."
INCY,INCY:UW,BBG000BNQ132,Corporate News Blog - Incyte and Merck Release Phase-1/2 Clinical Trial Data for Epacadostat in Combination with KEYTRUDA(R) for Treatment of NSCLC,2017-06-06 12:15:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-incyte-merck-121500045.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / June 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Incyte Corp. (NASDAQ: INCY ) and Merck & Co., Inc. (NYSE: MRK ). ..."
INCY,INCY:UW,BBG000BNQ132,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Incyte Corporation,2017-06-06 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000353.html?.tsrc=rss,"NEW YORK NY / ACCESSWIRE / June 6, 2017 / Both Juno Therapeutics and Incyte Corporation saw their shares drop on Monday after the companies released disappointing study and trial results over the weekend. ..."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,295.68 down -10.12 points",2017-06-05 20:48:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWmEBAlI1gU/market-close-report-nasdaq-composite-index-closes-at-629568-down-1012-points-cm798994,Monday s session closes with the NASDAQ Composite Index at 6 295 68 The total shares traded for the NASDAQ was over 2 19 billion Declining stocks led advancers by 1 81 to 1 ratio There were 1035 advancers and 1877 decliners for the day On the NASDAQ Stock Exchange 80 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,The Biggest Loser: Incyte Tumbles 5.7%,2017-06-05 20:48:00 +0000,http://finance.yahoo.com/r/614fe369-6674-34fd-b350-ba34a01ce1ee/the-biggest-loser-incyte-tumbles-5-7-1496695738?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte (INCY) tumbled to the bottom of the S&P 500 today after releasing drug trial updates at the ASCO conference over the weekend. Incyte dropped 5.7% to $124.03 today, while the S&P 500 dipped 0.1% ..."
INCY,INCY:UW,BBG000BNQ132,"Dow&apos;s Merck &apos;Clearly Won&apos; Vs. Bristol, Roche In Cancer Trials",2017-06-05 19:54:14 +0000,http://finance.yahoo.com/r/32070a5b-5245-3de6-9bf2-9b72cb227878/dow-stock-merck-clearly-won-vs-bristol-roche-in-cancer-trials?src=A00220&yptr=yahoo&.tsrc=rss,"Dow component Merck clearly won this weekend during the American Society of Clinical Oncology meeting, an analyst said Monday."
INCY,INCY:UW,BBG000BNQ132,Incyte CEO on the future of cancer treatment,2017-06-05 18:04:00 +0000,https://finance.yahoo.com/video/incyte-ceo-future-cancer-treatment-180400655.html?.tsrc=rss,Incyte CEO Herve Hoppenot speaks with CNBC's Meg Tirrell from the ASCO conference on the future of cancer treatment.
INCY,INCY:UW,BBG000BNQ132,Incyte Announces Data on Enzyme Inhibitor with Keytruda,2017-06-05 18:02:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hoXeb8E6q20/incyte-announces-data-on-enzyme-inhibitor-with-keytruda-cm798856,Incyte Corporation INCY and Merck amp Co MRK announced an updated data from the advanced non small cell lung cancer NSCLC patient cohort of the ongoing phase I II ECHO 202 study The study was evaluating Incyte s selective IDO1 enzyme inhibitor epacadostat in combination with Merck
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Squibb: Value Or Value Trap?,2017-06-05 17:59:00 +0000,http://finance.yahoo.com/r/809b5d29-8e2e-348c-b9e4-a4c2b426b460/bristol-myers-squibb-value-or-value-trap-1496685553?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,It doesn’t look like this year’s ASCO is shaping up well for Bristol-Myers Squibb (BMY).  The stock price has fallen 4.6% in recent market action following a slew of drug trial updates at the annual meeting of cancer researchers.  A lack of clarity of how Opdivo can fare as a first-line treatment for lung cancer.
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: ORLY, NTES",2017-06-05 16:02:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IRIt7a6oE3E/nasdaq-100-movers-orly-ntes-cm798686,In early trading on Monday shares of NetEase NTES topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 6 Year to date NetEase registers a 37 6 gain And the worst performing Nasdaq 100 component thus far on the day is O Reilly
INCY,INCY:UW,BBG000BNQ132,Incyte: Much Ado About ASCO Data,2017-06-05 15:46:00 +0000,http://finance.yahoo.com/r/fa8a0eff-5d4b-363d-a7e2-879541b09488/incyte-much-ado-about-asco-data-1496677611?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Data released over the weekend at the annual meeting of the American Society of Clinical Oncology seemed to support the potential for combining Incyte’s cutting edge cancer drug epacadostat with Merck’s (MRK) much heralded immuno-oncology drug Keytruda as a therapy for lung cancer patients.  A question about the data has been raised by Adam Feuerstein of TheStreet, namely that Incyte excluded data from three lung cancer patients who became eligible for evaluation after the study’s abstract was posted, and who might have altered the response rate figure."
INCY,INCY:UW,BBG000BNQ132,Incyte Announces Data on Enzyme Inhibitor with Keytruda,2017-06-05 15:29:03 +0000,https://finance.yahoo.com/news/incyte-announces-data-enzyme-inhibitor-152903908.html?.tsrc=rss,Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
INCY,INCY:UW,BBG000BNQ132,Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017,2017-06-05 12:00:00 +0000,https://finance.yahoo.com/news/incyte-analyst-investor-event-highlight-120000235.html?.tsrc=rss,"Incyte Corporation announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab and nivolumab in multiple tumor types will be discussed at an Analyst and Investor Event this evening, Monday, June 5, 2017."
INCY,INCY:UW,BBG000BNQ132,Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer,2017-06-05 11:30:00 +0000,https://finance.yahoo.com/news/clinical-trial-data-combination-epacadostat-113000741.html?.tsrc=rss,"Incyte Corporation and Bristol-Myers Squibb Company today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, in combination with Opdivo® , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, in multiple advanced solid tumors."
INCY,INCY:UW,BBG000BNQ132,Updated Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types,2017-06-05 11:00:00 +0000,https://finance.yahoo.com/news/updated-data-echo-202-trial-110000601.html?.tsrc=rss,"Incyte Corporation and Merck , known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® , Merck’s anti-PD-1 therapy, will be highlighted in multiple presentations at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago...."
INCY,INCY:UW,BBG000BNQ132,Missing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study,2017-06-04 22:22:00 +0000,http://finance.yahoo.com/r/7f860c84-53b5-3d28-be33-4dd7323d15fa/missing-patients-cloud-view-of-incyte-s-ido-drug-lung-cancer-study.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO."
INCY,INCY:UW,BBG000BNQ132,This Enzyme Is the New Focus for Cancer Treatment,2017-06-04 19:42:50 +0000,http://finance.yahoo.com/r/c78ee6a6-1473-32fa-bb28-753bbf24461c/life-in-womb-death-in-cancer-this-enzyme-is-new-research-focus?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"For a fetus in the womb, it’s an enzyme that means life, a shield from a mother’s immune system that would otherwise fight the embryo as an infection. Gone rogue, it can mean death -- protecting malignant ..."
INCY,INCY:UW,BBG000BNQ132,Combination of Incyte’s Epacadostat plus Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC),2017-06-03 13:00:00 +0000,https://finance.yahoo.com/news/combination-incyte-epacadostat-plus-merck-130000321.html?.tsrc=rss,"Incyte Corporation and Merck , known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer patient cohort of the ongoing Phase 1/2 ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® , Merck’s anti-PD-1 therapy."
INCY,INCY:UW,BBG000BNQ132,Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC),2017-06-03 13:00:00 +0000,https://finance.yahoo.com/news/combination-epacadostat-plus-keytruda-pembrolizumab-130000742.html?.tsrc=rss,"Incyte Corporation today announced updated data from the advanced non-small cell lung cancer patient cohort of the ongoing Phase 1/2 ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with pembrolizumab , an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ USA ."
INCY,INCY:UW,BBG000BNQ132,Incyte 'IDO' Combination Lung Cancer Results Improve Slightly at ASCO17,2017-06-03 13:00:00 +0000,http://finance.yahoo.com/r/82b0ed40-f2e1-3f26-904c-ffb2051f6c34/incyte-ido-combination-lung-cancer-results-improve-slightly-at-asco17.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.
INCY,INCY:UW,BBG000BNQ132,Stocks to watch during ASCO,2017-06-02 16:49:00 +0000,https://finance.yahoo.com/video/stocks-watch-during-asco-164900354.html?.tsrc=rss,"CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in."
INCY,INCY:UW,BBG000BNQ132,Cancer drug prices could double or triple thanks to this popular but unproven drug trend,2017-06-02 10:56:45 +0000,https://finance.yahoo.com/news/cancer-drug-prices-could-double-105645725.html?.tsrc=rss,"There are nearly 800 immuno-oncology combination trials today, up from around 200 in 2015."
INCY,INCY:UW,BBG000BNQ132,Cancer drug prices could double or triple thanks to this popular but unproven drug trend,2017-06-02 10:56:45 +0000,http://finance.yahoo.com/r/b2261002-4768-3d36-a970-820d72301dbc/Story.aspx?guid=15FFEA12-4623-11E7-980C-8D853B065349&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"There are nearly 800 immuno-oncology combination trials today, up from around 200 in 2015."
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : June 1, 2017",2017-06-01 12:44:11 +0000,http://finance.yahoo.com/r/af19092b-0513-3203-8d94-fd276d17b91c/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-june-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,"Broadcom, VMware Touted Ahead Of Earnings; &apos;Baywatch&apos; Flop Hits Viacom",2017-05-31 20:26:40 +0000,http://finance.yahoo.com/r/0e14222d-1342-32a1-8947-a0335f2b1487/broadcom-vmware-touted-ahead-of-earnings-baywatch-flop-hits-viacom?src=A00220&yptr=yahoo&.tsrc=rss,"Analyst actions on Wednesday included price-target hikes for Broadcom and Incyte, an upgrade for VMware and a price-target cut for Viacom."
INCY,INCY:UW,BBG000BNQ132,Biotech Musical Chairs: Who Leads Next,2017-05-31 10:00:00 +0000,http://finance.yahoo.com/r/798fae83-dc19-360c-a154-7db0f1650f11/biotech-musical-chairs-who-leads-next-ibb-nbix?partner=YahooSA&yptr=yahoo&.tsrc=rss,The biotech sector as measured by the iShares Nasdaq Biotech ETF is down another 1.40% today.
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,203.19 down -7 points",2017-05-30 20:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PUB8kd49Nf0/market-close-report-nasdaq-composite-index-closes-at-620319-down-7-points-cm796481,Tuesday s session closes with the NASDAQ Composite Index at 6 203 19 The total shares traded for the NASDAQ was over 1 78 billion Declining stocks led advancers by 1 87 to 1 ratio There were 1017 advancers and 1901 decliners for the day On the NASDAQ Stock Exchange 62 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,A Week's Worth of Gains,2017-05-30 13:30:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gC6gkjtj1ao/a-weeks-worth-of-gains-cm795925,The market s streak of back to back weekly losses came to an end with gusto today Friday s session may have been rather quiet ahead of a three day weekend but it couldn t derail a week s worth of positive performances that actually began last Thursday May 18 As the closing bell rang today
INCY,INCY:UW,BBG000BNQ132,[$$] Four things to watch at the Asco cancer meeting,2017-05-30 09:00:38 +0000,"http://finance.yahoo.com/r/21574aaa-3b4f-3005-84ae-292ed6f8da90/06f54222-4224-11e7-82b6-896b95f30f58,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Each year, 30,000 doctors descend on Chicago for the annual meeting of the American Society of Clinical Oncology (Asco), where they pore over thousands of pieces of clinical research. The event will be ..."
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Laggards: Healthcare, Technology & Communications",2017-05-26 20:31:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kiqE_c6Wyyk/friday-sector-laggards-healthcare-technology-communications-cm795531,The worst performing sector as of midday Friday is the Healthcare sector showing a 0 3 loss Within the sector Incyte Corporation Symbol INCY and DaVita Inc Symbol DVA are two large stocks that are lagging showing a loss of 2 9 and 2 4 respectively Among healthcare ETFs one
INCY,INCY:UW,BBG000BNQ132,"ETFs with exposure to Incyte Corp. : May 26, 2017",2017-05-26 17:12:49 +0000,http://finance.yahoo.com/r/343e8148-edc8-3c5c-b79e-dc0fff537aea/etfs-with-exposure-to-incyte-corp-may-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Incyte Corp. Here are 5 ETFs with the largest exposure to INCY-US. Comparing the performance and risk of Incyte Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Stock Exchange: Time To Reconsider Healthcare?,2017-05-26 14:34:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3YLKtu1icL8/stock-exchange-time-to-reconsider-healthcare-cm795267,By Jeff Miller ByJeff Miller Each week the Stock Exchange highlights the results from different technical trading methods We also provide contrast and often dissent from a fundamental analyst It is always interesting when we find a pick where multiple methods agree This week the
INCY,INCY:UW,BBG000BNQ132,Stock Exchange: Time to reconsider health care?,2017-05-26 12:31:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SgaY6HFjiwg/stock-exchange-time-to-reconsider-health-care-cm795011,By Jeff Miller ByJeff Miller Each week the Stock Exchange highlights the results from different technical trading methods We also provide contrast and often dissent from a fundamental analyst It is always interesting when we find a pick where multiple methods agree This week the
INCY,INCY:UW,BBG000BNQ132,"Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna",2017-05-24 15:31:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZnF0ZIAgoY/edward-owens-buys-abbott-labs-sells-allergan-amgen-aetna-cm793947,Edward Owens has managed the Vanguard Health Care Fund Trades Portfolio since its inception in May 1984 It invests primarily in health care companies Edward Owens has managed theVanguard Health Care Fund Trades Portfolio since its inception in May 1984 It invests primarily
INCY,INCY:UW,BBG000BNQ132,Blog Coverage: Amgen Announces New Data from the FOURIER Trial,2017-05-23 12:15:00 +0000,https://finance.yahoo.com/news/blog-coverage-amgen-announces-data-121500580.html?.tsrc=rss,"Upcoming AWS Coverage on Incyte Post-Earnings Results LONDON, UK / ACCESSWIRE / May 23, 2017 / Active Wall St. blog coverage looks at the headline from Amgen Inc. (NASDAQ: AMGN ) as the Company announced ..."
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2017-05-22 20:15:00 +0000,https://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-201500651.html?.tsrc=rss,Incyte Corporation announced today that it will present at the following investor conferences during the month of June:
INCY,INCY:UW,BBG000BNQ132,Incyte Was the S&P 500’s Top Gainer on May 18,2017-05-22 13:07:20 +0000,http://finance.yahoo.com/r/ddd82423-f15d-339e-a1bf-92ca309440fc/made-incyte-corporation-hot-stock-sp-500-may-18?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte rose to one-month high price levels on May 18. Incyte opened higher on Thursday due to positive results from its lung cancer drug.
INCY,INCY:UW,BBG000BNQ132,Cramer&apos;s lightning round: I&apos;ve got a message for the struggling Gilead Sciences,2017-05-19 22:46:52 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-apos-224652988.html?.tsrc=rss,"Jim Cramer shares his take on caller favorite stocks, including this drugmaker."
INCY,INCY:UW,BBG000BNQ132,Cramer's lightning round: I've got a message for the struggling Gilead Sciences,2017-05-19 22:46:52 +0000,http://finance.yahoo.com/r/ca26a1a2-f435-381d-a642-ee8cbe95dbd2/104481289?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104481289&yptr=yahoo&.tsrc=rss,"Jim Cramer shares his take on caller favorite stocks, including this drugmaker."
INCY,INCY:UW,BBG000BNQ132,Which Stocks Are Showing Rising Relative Strength?,2017-05-19 20:45:35 +0000,http://finance.yahoo.com/r/fa200388-9cb9-3ac3-9950-f37df6d0879f/which-stocks-are-showing-rising-relative-strength?src=A00220&yptr=yahoo&.tsrc=rss,See which stocks just got an IBD RS Rating upgrade.
INCY,INCY:UW,BBG000BNQ132,Bristol-Incyte Match Beats Dow&apos;s Merck In Combination Trials,2017-05-19 20:26:48 +0000,http://finance.yahoo.com/r/030b8444-6598-3c95-ade3-788f272f8a77/bristol-incyte-match-powers-by-dows-merck-in-combination-trials?src=A00220&yptr=yahoo&.tsrc=rss,Incyte stock enjoyed a fifth consecutive day of gains Friday after its immuno-oncology drug proved robust in combination trials with Merck and Bristol.
INCY,INCY:UW,BBG000BNQ132,"Company News for May 19, 2017",2017-05-19 16:12:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UsvsOR1NyDE/company-news-for-may-19-2017-cm791930,160 160 160 Shares of L Brands Inc LB advanced 2 7 after the company reported first quarter 2017 earnings of 0 33 per share surpassing the Zacks Consensus Estimate of 0 29 160 160 160 Pandora Media Inc s P shares gained 5 5 following news that Sirius XM was in talks
INCY,INCY:UW,BBG000BNQ132,"Biotech Breakout Ahead? Incyte Rising On Success With Merk, Bristol-Myers",2017-05-19 15:38:06 +0000,http://finance.yahoo.com/r/5fab0b76-9c67-3dfe-9c93-a6b65d621066/biotech-breakout-incyte-rising-on-cancer-drug-success-with-merk-bristol-myers?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Incyte shows improving technical performance.
INCY,INCY:UW,BBG000BNQ132,"Company News for May 19, 2017",2017-05-19 14:17:02 +0000,https://finance.yahoo.com/news/company-news-may-19-2017-141702920.html?.tsrc=rss,"Companies in the News are: LB,P,INCY,MRK,SHPG"
INCY,INCY:UW,BBG000BNQ132,The Most Notable Abstracts Released Ahead Of ASCO 2017,2017-05-19 12:21:38 +0000,https://finance.yahoo.com/news/most-notable-abstracts-released-ahead-122138426.html?.tsrc=rss,"The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. ..."
INCY,INCY:UW,BBG000BNQ132,"Mercadolibre, Inc. Called a Great Growth Stock and Incyte Corporation Rockets on Positive Breakthrough Data Results",2017-05-19 12:00:00 +0000,https://finance.yahoo.com/news/mercadolibre-inc-called-great-growth-120000869.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 19, 2017 / It has been an impressive month for Mercadolibre, especially after releasing positive first quarter results almost two weeks ago. The stock has been considered ..."
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Announces Positive Data on Enzyme Inhibitor,2017-05-19 00:11:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m1PCYdOSFtg/incyte-incy-announces-positive-data-on-enzyme-inhibitor-cm791628,Incyte Corporation INCY recently announced that new data was published online from the ongoing trial ECHO 202 by the American Society of Clinical Oncology ASCO in advance of its annual meeting in Chicago IL June 2 6 2017 The trial is evaluating Incyte s selective IDO1 enzyme
INCY,INCY:UW,BBG000BNQ132,Where buyers flock after a sell-off,2017-05-18 23:02:00 +0000,https://finance.yahoo.com/video/where-buyers-flock-sell-off-230200513.html?.tsrc=rss,Jim Cramer says that investors tend to buy growth stocks on the day after a market dip.
INCY,INCY:UW,BBG000BNQ132,Where buyers flock after a sell-off,2017-05-18 22:34:00 +0000,https://finance.yahoo.com/video/where-buyers-flock-sell-off-223400487.html?.tsrc=rss,Jim Cramer says that investors tend to buy growth stocks on the day after a market dip.
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Announces Positive Data on Enzyme Inhibitor,2017-05-18 22:13:10 +0000,https://finance.yahoo.com/news/incyte-incy-announces-positive-data-221310640.html?.tsrc=rss,"Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO)."
INCY,INCY:UW,BBG000BNQ132,Incyte Teams Up With Dow&apos;s Merck To Trounce Roche In Cancer,2017-05-18 21:32:19 +0000,http://finance.yahoo.com/r/344c1f5b-394e-3b02-baf3-47302c653313/incyte-teams-up-with-dows-merck-to-trounce-roche-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Incyte stock popped to a month-high Thursday after its immuno-oncology drug proved effective in matchups with Merck&apos;s Keytruda and Bristol&apos;s Opdivo.
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation (INCY) Stock Jumps on Promising Lung Cancer Drug,2017-05-18 21:13:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SMQJlLQVr7E/incyte-corporation-incy-stock-jumps-on-promising-lung-cancer-drug-cm791594,InvestorPlace Stock Market News Stock Advice amp Trading Tips Incyte Corporation NASDAQ INCY stock was up on Thursday on promising results for one of its lung cancer drugs Incyte Corporation s lung cancer drug that saw positive
INCY,INCY:UW,BBG000BNQ132,The Hot Stock: Incyte Climbs,2017-05-18 20:50:00 +0000,http://finance.yahoo.com/r/7ac84036-0dc3-393f-a883-66e46341ed2e/the-hot-stock-incyte-climbs-1495140657?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Incyte (INCY) lead the S&P 500 higher, rising almost 7% as clinical trial data boosted confidence about its experimental cancer drugs. At $128.80 a share, the stock climbed 6.89%, making the ..."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,055.13 up 43.89 points",2017-05-18 20:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a0WTOIRQaxM/market-close-report-nasdaq-composite-index-closes-at-605513-up-4389-points-cm791564,Thursday s session closes with the NASDAQ Composite Index at 6 055 13 The total shares traded for the NASDAQ was over 2 2 billion Thursday s session closes with the NASDAQ Composite Index at 6 055 13 The total shares traded for the NASDAQ was over 2 2 billion Advancers stocks led declining
INCY,INCY:UW,BBG000BNQ132,"Thursday Sector Leaders: Services, Healthcare",2017-05-18 20:11:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cZQUeQJiG7M/thursday-sector-leaders-services-healthcare-cm791505,Looking at the sectors faring best as of midday Thursday shares of Services companies are outperforming other sectors up 0 9 Within the sector Carmax Inc Symbol KMX and Wal Mart Stores Inc Symbol WMT are two of the day s stand outs showing a gain of 7 2 and 3 2 respectively
INCY,INCY:UW,BBG000BNQ132,Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed,2017-05-18 17:03:00 +0000,http://finance.yahoo.com/r/5559dd78-9a1e-3a88-ba92-11304bd20b98/new-incyte-ido-cancer-immunotherapy-combo-data-revealed-ahead-of-asco-17-meeting.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: CSCO, INCY",2017-05-18 16:15:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iX4jqy1JB9k/sp-500-movers-csco-incy-cm791323,In early trading on Thursday shares of Incyte topped the list of the day s best performing components of the S amp P 500 index trading up 6 5 Year to date Incyte registers a 27 9 gain And the worst performing S amp P 500 component thus far on the day is Cisco Systems trading
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: CSCO, INCY",2017-05-18 16:15:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uKXAzauvW9U/nasdaq-100-movers-csco-incy-cm791319,In early trading on Thursday shares of Incyte topped the list of the day s best performing components of the Nasdaq 100 index trading up 6 6 Year to date Incyte registers a 28 1 gain And the worst performing Nasdaq 100 component thus far on the day is Cisco Systems trading down 8
INCY,INCY:UW,BBG000BNQ132,Concert Pharma Falls After Clinical Hold on Hair Loss Drug,2017-05-18 16:14:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_EM6cDgS-Yo/concert-pharma-falls-after-clinical-hold-on-hair-loss-drug-cm791268,Concert Pharmaceuticals Inc CNCE shares were down almost 8 on Wednesday after the company announced that the FDA has placed a clinical hold on a mid stage study evaluating its pipeline candidate CTP 543 for the treatment of alopecia areata Shares of Concert Pharma have outperformed the
INCY,INCY:UW,BBG000BNQ132,Concert Pharma Falls After Clinical Hold on Hair Loss Drug,2017-05-18 14:21:02 +0000,https://finance.yahoo.com/news/concert-pharma-falls-clinical-hold-142102395.html?.tsrc=rss,"Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata."
INCY,INCY:UW,BBG000BNQ132,A $25 billion biotech's stock is popping on its promising cancer data,2017-05-18 13:40:31 +0000,https://finance.yahoo.com/news/25-billion-biotechs-stock-popping-134031816.html?.tsrc=rss,"Incyte, a $25 billion biotech company, revealed some new data about its cancer drugs on..."
INCY,INCY:UW,BBG000BNQ132,A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks,2017-05-18 13:15:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-wkOeSsJRYM/a-doomed-trump-presidency-would-be-a-terrifying-development-for-pharmaceutical-stocks-cm791065,Controversy has clouded the brief presidency of Donald Trump especially after he fired FBI Director James Comey If for some reason Trump doesn t finish out his term in office pharmaceutical stocks could get walloped going forward The long and short of it is that the
INCY,INCY:UW,BBG000BNQ132,US STOCKS-Trump slump set to extend into second day,2017-05-18 13:03:09 +0000,https://finance.yahoo.com/news/us-stocks-trump-slump-set-130309148.html?.tsrc=rss,A selloff in U.S. stocks looked set to  extend into its second day on Thursday as a series of scandals  cast a shadow over Donald Trump's presidency and the future of  his ambitious pro-growth agenda.  Reports that Trump had tried to intervene in an ongoing  federal investigation led to the harshest selloff in U.S. stocks  on Wednesday since his election in November.  Investors unwound positions made on hopes that Trump's  promises such as tax cuts and infrastructure spending would  stoke economic growth and inflation.
INCY,INCY:UW,BBG000BNQ132,US STOCKS-Futures fall as Trump tumult continues,2017-05-18 11:34:49 +0000,https://finance.yahoo.com/news/us-stocks-futures-fall-trump-113449382.html?.tsrc=rss,U.S. stock index futures fell on Thursday as markets across the globe continued to reel under uncertainties about President Donald Trump's political future and its impact on his pro-growth agenda. * A ...
INCY,INCY:UW,BBG000BNQ132,What to watch at ASCO cancer conference,2017-05-18 10:21:00 +0000,https://finance.yahoo.com/video/watch-asco-cancer-conference-102100102.html?.tsrc=rss,CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.
INCY,INCY:UW,BBG000BNQ132,"Merck, Incyte immunotherapy combination effective in lung cancer study",2017-05-17 21:20:16 +0000,https://finance.yahoo.com/news/merck-incyte-immunotherapy-combination-effective-212016381.html?.tsrc=rss,"A combination of the Merck & Co  immunotherapy Keytruda and a different type of drug that also  helps the immune system fight cancer from Incyte Corp  led to a high rate of durable responses in a small, ongoing  study of patients with advanced lung cancer, according to data  released on Wednesday.  Incyte shares rose more than 6 percent to $128 in  post-market trading, after the data became public."
INCY,INCY:UW,BBG000BNQ132,First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017,2017-05-17 21:03:00 +0000,https://finance.yahoo.com/news/first-data-combination-epacadostat-opdivo-210300441.html?.tsrc=rss,"Incyte Corporation today announced that the American Society of Clinical Oncology has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Opdivo® , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor."
INCY,INCY:UW,BBG000BNQ132,New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab),2017-05-17 21:02:00 +0000,https://finance.yahoo.com/news/data-presentation-asco-2017-reinforce-210200583.html?.tsrc=rss,"Incyte Corporation today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® , Merck’s anti-PD-1 therapy."
INCY,INCY:UW,BBG000BNQ132,"Merck, Incyte immunotherapy combination effective in lung cancer study",2017-05-17 21:00:00 +0000,https://finance.yahoo.com/news/merck-incyte-immunotherapy-combination-effective-210000292.html?.tsrc=rss,"A combination of the Merck & Co  immunotherapy Keytruda and a different type of drug that also  helps the immune system fight cancer from Incyte Corp  led to a high rate of durable responses in a small, ongoing  study of patients with advanced lung cancer, according to data  released on Wednesday.  Fourteen of 40, or 35 percent, of patients with advanced  non-small cell lung cancer (NSCLC) who received Keytruda and  Incyte's epacadostat experienced tumor shrinkage of at least 30  percent."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 6,011.24 down -158.63 points",2017-05-17 20:49:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IGx1FpAVQPc/market-close-report-nasdaq-composite-index-closes-at-601124-down-15863-points-cm790870,Wednesday s session closes with the NASDAQ Composite Index at 6 011 24 The total shares traded for the NASDAQ was over 2 36 billion Declining stocks led advancers by 5 55 to 1 ratio There were 453 advancers and 2516 decliners for the day On the NASDAQ Stock Exchange 13 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Aduro Biotech, Merch Team on Cancer Drug Trial",2017-05-17 18:16:00 +0000,http://finance.yahoo.com/r/8f075429-6b65-3b82-96d4-52f4a0516591/aduro-biotech-merch-team-on-cancer-drug-trial.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.
INCY,INCY:UW,BBG000BNQ132,Cancer data deluge set to move stocks,2017-05-17 16:36:00 +0000,https://finance.yahoo.com/video/cancer-data-deluge-set-move-163600676.html?.tsrc=rss,"CNBC's Meg Tirrell reports on the biotech stocks to watch, including a new player Incyte, as well as Johnson and Johnson's analyst day and Amazon's pharmaceutical break in. &quot;Fast Money Halftime Report&quot; traders and Kevin O'Leary weigh in."
INCY,INCY:UW,BBG000BNQ132,A deluge of new cancer research data hits at 5 pm ET: Here’s what to watch,2017-05-17 11:00:00 +0000,http://finance.yahoo.com/r/6b5ef57d-1d28-317a-b60b-4294390392ab/104474250?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104474250&yptr=yahoo&.tsrc=rss,"ASCO's abstract drop reveals the progress being made in attacking cancer and, inevitably, moves stocks both large and small."
INCY,INCY:UW,BBG000BNQ132,A deluge of new cancer research data hits at 5 pm ET: Here’s what to watch,2017-05-17 11:00:00 +0000,https://finance.yahoo.com/news/deluge-cancer-research-data-hits-110000204.html?.tsrc=rss,"ASCO&apos;s abstract drop reveals the progress being made in attacking cancer and, inevitably, moves stocks both large and small."
INCY,INCY:UW,BBG000BNQ132,"Will Incyte Shine Under Oncology Spotlight With Dow&apos;s Merck, Bristol?",2017-05-15 20:13:20 +0000,http://finance.yahoo.com/r/d760f6b5-e497-3260-80c3-a7018e25a772/will-incyte-shine-under-oncology-spotlight-with-dows-merck-bristol?src=A00220&yptr=yahoo&.tsrc=rss,Incyte&apos;s partnerships with Merck and Bristol will grab the spotlight at the American Association of Clinical Oncology meeting next month.
INCY,INCY:UW,BBG000BNQ132,"Noteworthy Friday Option Activity: CASY, INCY, TWTR",2017-05-12 20:33:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3G-d6UfVVjk/noteworthy-friday-option-activity-casy-incy-twtr-cm788797,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Casey s General Stores Inc Symbol CASY where a total of 1 716 contracts have traded so far representing approximately 171 600 underlying shares That amounts to about 47 9
INCY,INCY:UW,BBG000BNQ132,"Bellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...",2017-05-12 16:24:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3WVcSrhdk5I/bellevue-group-ag-buys-align-technology-inc-anthem-inc-walgreens-boots-alliance-inc-sells-cm788614,Bellevue Group AG New Purchases ALGN WBA ABC HRC THC GNMK LIVN XRAY TSRO MDCO Added Positions ANTM AMGN CNC ISRG WMGI LLY ILMN GILD SHPG HZNP Reduced Positions SYK ZLTQ BDX ZBH MDT GMED REGN CERN HCSG JNJ Sold Out ARIA
INCY,INCY:UW,BBG000BNQ132,"Analysts' Actions -- Chemours, Incyte, Visteon, Toyota and More",2017-05-12 13:18:00 +0000,http://finance.yahoo.com/news/analysts-actions-chemours-incyte-visteon-131800623.html?.tsrc=rss,"Here are Friday's top research calls, including upgrades for Chemours, Incyte and Toyota, and new coverage of Visteon."
INCY,INCY:UW,BBG000BNQ132,3 Top Biotech Stocks For May,2017-05-11 15:05:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0UV5v70_W1I/3-top-biotech-stocks-for-may-cm787789,After a dreadful 2016 biotech stocks have rebounded nicely this year for a variety of reasons Most importantly though the specter of government mandated price caps on specialty medicines appears to have faded into the background at least for the time being So to take
INCY,INCY:UW,BBG000BNQ132,3 Top Biotech Stocks For May,2017-05-11 13:17:00 +0000,http://finance.yahoo.com/r/9396a51d-aacf-301d-9ab6-e25289bb2423/3-top-biotech-stocks-for-may.aspx?yptr=yahoo&.tsrc=rss,These three biotechs could be stellar buys this month.
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 4-May-17 2:00pm GMT,2017-05-10 01:31:08 +0000,http://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-123058768.html?.tsrc=rss,Q1 2017 Incyte Corp Earnings Call
INCY,INCY:UW,BBG000BNQ132,"I Still Can&apos;t Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards",2017-05-09 14:12:00 +0000,http://finance.yahoo.com/r/2f431235-3d89-3afd-b625-455af34d4832/i-still-cant-believe-gilead-sciences-inc-spent-147.aspx?yptr=yahoo&.tsrc=rss,Gilead&apos;s M&A targets may be limited because of its sizable shareholder rewards program.
INCY,INCY:UW,BBG000BNQ132,"Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat",2017-05-08 21:01:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E9GXrJIoBuI/incyte-incy-q1-loss-narrower-than-expected-revenues-beat-cm786131,Incyte Corporation INCY reported first quarter 2017 loss of 96 cents a penny narrower than the Zacks Consensus Estimate of a loss of 97 cents Incyte had reported earnings of 12 cents per share in the year ago quarter Quarterly revenues were 384 1 million up 45 8 year over year and
INCY,INCY:UW,BBG000BNQ132,"Monday Sector Laggards: Healthcare, Services",2017-05-08 20:01:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pbcrh7-nm9s/monday-sector-laggards-healthcare-services-cm786083,The worst performing sector as of midday Monday is the Healthcare sector showing a 0 7 loss Within the sector Incyte Corporation Symbol INCY and Alexion Pharmaceuticals Inc Symbol ALXN are two large stocks that are lagging showing a loss of 4 1 and 3 8 respectively Among
INCY,INCY:UW,BBG000BNQ132,"Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat",2017-05-08 18:59:06 +0000,http://finance.yahoo.com/news/incyte-incy-q1-loss-narrower-185906307.html?.tsrc=rss,Incyte&apos;s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.
INCY,INCY:UW,BBG000BNQ132,"KITE Plunges, Take Sector With It",2017-05-08 17:29:00 +0000,http://finance.yahoo.com/r/d954ed25-a03a-3ab2-b79c-70f7d0e1c69f/kite-plunges-take-sector-it-kite-ibb?partner=YahooSA&yptr=yahoo&.tsrc=rss,Kite stock plunged after it reported a clinical study death and worse-than-expected Q1 losses.
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: TSN, NWL",2017-05-08 15:02:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yixz5tJGleo/sp-500-movers-tsn-nwl-cm785779,In early trading on Monday shares of Newell Brands NWL topped the list of the day s best performing components of the S amp P 500 index trading up 11 4 Year to date Newell Brands registers a 15 8 gain And the worst performing S amp P 500 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,These Biotechs Are Grabbing Bullish Views In Wake Of Earnings,2017-05-05 20:27:13 +0000,http://finance.yahoo.com/r/356aa738-2142-37f4-a2ce-5f0beba0a586/which-biotechs-are-grabbing-bullish-post-q1-views-heres-some-incyte?src=A00220&yptr=yahoo&.tsrc=rss,"Incyte stock toppled to a 10-week low Friday on a fourth consecutive quarter of losses, but it was among a slew of biotechs to grab bullish reports."
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Laggards: Healthcare, Financial",2017-05-05 20:25:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bAz58qwobME/friday-sector-laggards-healthcare-financial-cm785211,The worst performing sector as of midday Friday is the Healthcare sector showing a 0 3 loss Within that group Biogen Inc Symbol BIIB and Incyte Corporation Symbol INCY are two large stocks that are lagging showing a loss of 2 8 and 2 2 respectively Among healthcare ETFs one
INCY,INCY:UW,BBG000BNQ132,"VOT, EQIX, APH, INCY: ETF Inflow Alert",2017-05-05 17:25:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqF0aK0WbyU/vot-eqix-aph-incy-etf-inflow-alert-cm785078,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Mid Cap Growth ETF Symbol VOT where we have detected an approximate 66 5 million dollar inflow that s a 1 6 increase week over week in
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, MNST",2017-05-05 16:27:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8ybvEnunHvw/nasdaq-100-movers-incy-mnst-cm785045,In early trading on Friday shares of Monster Beverage MNST topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 7 Year to date Monster Beverage registers a 7 4 gain And the worst performing Nasdaq 100 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: FLR, MTD",2017-05-05 15:27:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t0sQ39rKIkw/sp-500-movers-flr-mtd-cm785030,In early trading on Friday shares of Mettler Toledo International MTD topped the list of the day s best performing components of the S amp P 500 index trading up 8 7 Year to date Mettler Toledo International registers a 34 9 gain And the worst performing S amp P 500 component
INCY,INCY:UW,BBG000BNQ132,How to play ahead of jobs report,2017-05-04 23:38:00 +0000,http://finance.yahoo.com/video/play-ahead-jobs-report-233800166.html?.tsrc=rss,Jim Cramer shares his take on how homegamers can play a confused market ahead of a key report.
INCY,INCY:UW,BBG000BNQ132,4 Biotech Stocks That Could Be Rocked and Rolled This Month,2017-05-04 23:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A_fDod2CHMQ/4-biotech-stocks-that-could-be-rocked-and-rolled-this-month-cm784671,InvestorPlace Stock Market News Stock Advice amp Trading Tips The month of May isn t usually a good one for the overall market Though a handful of familiar names somehow muster bullishness in the month the S amp P 500 s average performance for the May is a loss of 0 2
INCY,INCY:UW,BBG000BNQ132,Cramer: How to play anticipation ahead of the jobs report,2017-05-04 22:41:00 +0000,http://finance.yahoo.com/video/cramer-play-anticipation-ahead-jobs-224100628.html?.tsrc=rss,Jim Cramer shares his take on how homegamers can play a confused market ahead of a key report.
INCY,INCY:UW,BBG000BNQ132,What to do when your biotechnology stock gets hit by takeover rumors,2017-05-04 16:31:18 +0000,http://finance.yahoo.com/r/56ba24cf-8e51-3469-94d1-160752331ef1/Story.aspx?guid=0CB86EB2-301A-11E7-98BF-F86B6FF9DD6C&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Also, 10 biotech companies that might be targets. By Michael Brush."
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks Projected to Grow Their EPS by at Least 415% in 2018,2017-05-04 13:08:00 +0000,http://finance.yahoo.com/r/9834c0e0-afba-3c1e-98de-79778b2a945e/3-biotech-stocks-projected-to-grow-their-eps-by-at.aspx?yptr=yahoo&.tsrc=rss,You&apos;ll struggle to find quicker year-over-year earnings growth.
INCY,INCY:UW,BBG000BNQ132,Investor Network: Incyte Corporation to Host Earnings Call,2017-05-04 11:50:00 +0000,http://finance.yahoo.com/news/investor-network-incyte-corporation-host-115000111.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Incyte Corporation (NASDAQ: INCY ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 10:00 AM Eastern Time. To listen ..."
INCY,INCY:UW,BBG000BNQ132,Incyte reports 1Q loss,2017-05-04 11:23:36 +0000,http://finance.yahoo.com/news/incyte-reports-1q-loss-112336904.html?.tsrc=rss,"The Wilmington, Delaware-based company said it had a loss of 96 cents per share. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ..."
INCY,INCY:UW,BBG000BNQ132,Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs,2017-05-04 11:00:00 +0000,http://finance.yahoo.com/news/incyte-reports-2017-first-quarter-110000824.html?.tsrc=rss,"Incyte Corporation today reports 2017 first-quarter financial results, highlighting strong revenue growth driven by increased sales of Jakafi® in the U.S."
INCY,INCY:UW,BBG000BNQ132,Incyte Q1 17 Earnings Conference Call At 10:00 AM ET,2017-05-04 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1BJWBWepayM/incyte-q1-17-earnings-conference-call-at-1000-am-et-20170504-01120,Incyte Q1 17 Earnings Conference Call At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Incyte Posts Q1 Loss On Higher R&D Expenses; Jakafi Revenues Up 37%,2017-05-04 08:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CPLU5t-mO2E/incyte-posts-q1-loss-on-higher-rd-expenses-jakafi-revenues-up-37-20170504-01022,Incyte Posts Q1 Loss On Higher R&D Expenses; Jakafi Revenues Up 37%
INCY,INCY:UW,BBG000BNQ132,Did Gilead Just Provide Some &apos;Incyte&apos; Into A Potential Deal?,2017-05-03 20:24:10 +0000,http://finance.yahoo.com/r/3bf342f7-1fdf-38c9-a3a9-63c17382fd40/did-gilead-just-provide-some-incyte-into-a-potential-deal?src=A00220&yptr=yahoo&.tsrc=rss,"Gilead Sciences, on Tuesday, hinted it could be prepping to make an acquisition in oncology after reporting sales from its hepatitis C drug franchise toppled."
INCY,INCY:UW,BBG000BNQ132,"Pre-Market Earnings Report for May 4, 2017 :  D, OXY, REGN, CNQ, ZTS, PPL, K, INCY, APA, CCE, WLTW, ABC",2017-05-03 20:13:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zieXg137274/pre-market-earnings-report-for-may-4-2017-d-oxy-regn-cnq-zts-ppl-k-incy-apa-cce-wltw-abc-cm783750,The following companies are expected to report earnings prior to market open on 05 04 2017 Visit our Earnings Calendar for a full list of expected earnings releases Dominion Resources Inc D is reporting for the quarter ending March 31 2017 The
INCY,INCY:UW,BBG000BNQ132,CORRECTING and REPLACING -- Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments,2017-05-03 20:06:02 +0000,http://finance.yahoo.com/news/correcting-replacing-merus-announces-fourth-200602353.html?.tsrc=rss,"In a release issued April 28, 2017 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made such that the figures for the three months ended December 31, 2016 in the ""Consolidated Statement ..."
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Covanta Holding, PTC, Etsy, KCG Holdings and Incyte",2017-05-03 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-covanta-133001703.html?.tsrc=rss,"Zacks.com featured highlights: Covanta Holding, PTC, Etsy, KCG Holdings and Incyte"
INCY,INCY:UW,BBG000BNQ132,"Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More",2017-05-03 13:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i9-fy5tld40/drug-stock-q1-earnings-releases-on-may-4-zts-regn-more-cm783421,The Q1 earnings season is past the halfway mark Overall earnings and revenue growth has been better than investors expectations We believe this quarter is on track to see the highest growth in many years According to the Earnings Preview report 288 S amp P 500 members accounting for 63
INCY,INCY:UW,BBG000BNQ132,"Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More",2017-05-03 12:22:12 +0000,http://finance.yahoo.com/news/drug-stock-q1-earnings-releases-122212911.html?.tsrc=rss,Here we have four pharma companies that are set to report first-quarter results on May 4. Let&apos;s see how things are shaping up for them.
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dispose of or Play Short for Profit,2017-05-02 13:29:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ghkd4ojxDIA/5-toxic-stocks-to-dispose-of-or-play-short-for-profit-cm782601,Successful investing is largely dependent on the correct identification of overpriced stocks However the overblown toxic stocks and the fairly priced stocks are intermixed in the marketplace in such a way that it becomes very difficult to identify them Investors who can spot the
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dispose of or Play Short for Profit,2017-05-02 12:12:12 +0000,http://finance.yahoo.com/news/5-toxic-stocks-dispose-play-121212645.html?.tsrc=rss,"Just like picking stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to shield your portfolio from big losses or make profits by short selling them."
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation (INCY) Leads 11 Activist Investor Filings,2017-05-01 19:27:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qaiHZP7Kj9I/incyte-corporation-incy-leads-11-activist-investor-filings-cm782258,InvestorPlace Stock Market News Stock Advice amp Trading Tips When a person or group of persons acquires beneficial ownership of more than 5 of a company s equity securities they are required to file a Schedule 13D or 13G with the SEC If these groups intend
INCY,INCY:UW,BBG000BNQ132,5 Things Bristol-Myers Squibb's Management Wants You to Know,2017-04-29 12:26:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DuXc4S3g2rc/5-things-bristol-myers-squibbs-management-wants-you-to-know-cm781597,Bristol Myers Squibb NYSE BMY blew past all expectations when it reported first quarter results on Thursday Wall Street estimated earnings of 0 74 per share on revenue of 4 72 billion The drugmaker delivered first quarter adjusted earnings of 0 84 per share with revenue of 4
INCY,INCY:UW,BBG000BNQ132,"Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.",2017-04-28 23:17:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-llp-announces-investigation-231700102.html?.tsrc=rss,"NEW YORK, April 28, 2017 /PRNewswire/ -- Amyris, Inc. (AMRS) Lifshitz & Miller announces investigation on behalf of AMRS investors after AMRS reported a $10 million decrease in revenue from March 2, 2017 ..."
INCY,INCY:UW,BBG000BNQ132,Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments,2017-04-28 21:14:02 +0000,http://finance.yahoo.com/news/merus-announces-fourth-quarter-full-211402360.html?.tsrc=rss,"UTRECHT, The Netherlands, April 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial ..."
INCY,INCY:UW,BBG000BNQ132,Merus Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Developments,2017-04-28 20:48:11 +0000,http://finance.yahoo.com/news/merus-announces-fourth-quarter-full-204811658.html?.tsrc=rss,"UTRECHT, The Netherlands, April 28, 2017-- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the fourth ..."
INCY,INCY:UW,BBG000BNQ132,Should You Get Rid of Incyte Corporation (INCY) Now?,2017-04-26 15:10:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SBbmt1IHfYg/should-you-get-rid-of-incyte-corporation-incy-now-cm779437,Similar to wise buying decisions exiting certain underperformers at the right time helps maximize portfolio returns Selling off losers can be difficult but if both the share price and estimates are falling it could be time to get rid of the security before more losses hit your portfolio
INCY,INCY:UW,BBG000BNQ132,Should You Get Rid of Incyte Corporation (INCY) Now?,2017-04-26 12:58:12 +0000,http://finance.yahoo.com/news/rid-incyte-corporation-incy-now-125812480.html?.tsrc=rss,"Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year."
INCY,INCY:UW,BBG000BNQ132,"Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down",2017-04-25 17:09:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YP7nF9VrEV8/lilly-lly-tops-q1-earnings-misses-sales-shares-down-cm778822,Eli Lilly and Company LLY reported first quarter 2017 adjusted earnings per share of 98 cents which beat the Zacks Consensus Estimate of 96 cents by 2 1 Earnings rose 18 from the year ago quarter backed by volume driven pharma sales growth and higher profits Including a
INCY,INCY:UW,BBG000BNQ132,Chill Pill: Eli Lilly Cuts Guidance with Earnings,2017-04-25 17:00:00 +0000,http://finance.yahoo.com/r/ce30bef7-115c-3462-9d78-b9c57915a070/chill-pill-eli-lilly-cuts-guidance-earnings?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Lilly trimmed its full-year GAAP EPS guidance, dragging shares lower today."
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2017-04-25 12:00:00 +0000,http://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-120000717.html?.tsrc=rss,Incyte Corporation announced today that it will present at the following investor conferences during the month of May:
INCY,INCY:UW,BBG000BNQ132,Biotech M&A Plunges as Trump Attacks Drug Companies,2017-04-24 10:00:00 +0000,http://finance.yahoo.com/r/36c0c78b-f409-3b03-9601-3f8a62e5a04c/biotech-ma-plunges-trump-attacks-drug-companies?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biotech M&A activity has fallen.
INCY,INCY:UW,BBG000BNQ132,Read This Before You Buy Biotech Stocks,2017-04-23 18:03:00 +0000,http://finance.yahoo.com/r/a11bb068-dc97-3408-93c2-eaf0f3556202/read-this-before-you-buy-biotech-stocks.aspx?yptr=yahoo&.tsrc=rss,Looking to buy biotech stocks? Here are 7 important things to know.
INCY,INCY:UW,BBG000BNQ132,Should Gilead Sciences Acquire NewLink Genetics?,2017-04-21 18:04:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F9T5W5jm1QM/should-gilead-sciences-acquire-newlink-genetics-cm777229,Gilead Sciences NASDAQ GILD sales and its share price are nose diving because of stiff competition for its top selling hepatitis C drugs and that s got everyone wondering if management will uncork its cash flow and make some acquisitions to rekindle growth 160 It s anyone
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: MAT, INCY",2017-04-21 16:05:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z8IYGEH-V3I/nasdaq-100-movers-mat-incy-cm777110,In early trading on Friday shares of Incyte Corporation INCY topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 4 Year to date Incyte Corporation registers a 24 5 gain And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,Is Bristol-Myers Prepping To Outdo Itself In Immuno-Oncology?,2017-04-20 20:32:36 +0000,http://finance.yahoo.com/r/2248dc5a-0423-390a-acc1-b75df6347ca6/is-bristol-myers-prepping-to-outdo-itself-in-immuno-oncology?src=A00220&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb and Cytomx could be working on a less potent version of Yervoy and have data as early as 2018, an analyst said Thursday."
INCY,INCY:UW,BBG000BNQ132,This $26 Billion Company Is the Market's Most Overpriced Biotech Stock,2017-04-20 19:04:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mtjxa2yq-5c/this-26-billion-company-is-the-markets-most-overpriced-biotech-stock-cm776599,Despite learning on Monday that the FDA rejected baricitinib 160 shares of biotech behemoth Incyte NASDAQ INCY have been on a roll Over the past year Incyte s stock is up 64 over five years it s up 450 and since March of 2009 160 its shares are up nearly 5 300 Not
INCY,INCY:UW,BBG000BNQ132,Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting,2017-04-20 17:13:00 +0000,http://finance.yahoo.com/news/incytes-immuno-oncology-targeted-therapy-171300691.html?.tsrc=rss,"Incyte Corporation announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society of Clinical Oncology annual meeting in Chicago, Illinois from June 2-6, 2017."
INCY,INCY:UW,BBG000BNQ132,This $26 Billion Company Is the Market&apos;s Most Overpriced Biotech Stock,2017-04-20 17:06:00 +0000,http://finance.yahoo.com/r/656ced5d-7ff2-3ba4-81a4-3e66343f6fd6/this-26-billion-company-is-the-markets-most-overpr.aspx?yptr=yahoo&.tsrc=rss,Nearly 90% of this biotech&apos;s sales could be at risk within the next two years.
INCY,INCY:UW,BBG000BNQ132,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)",2017-04-20 14:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-140000936.html?.tsrc=rss,"NEW YORK, April 20, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Incyte Corporation (""Incyte"" or ..."
INCY,INCY:UW,BBG000BNQ132,"Cramer Remix: Thanks to Apple & Samsung, this group just ...",2017-04-19 23:13:00 +0000,http://finance.yahoo.com/video/cramer-remix-thanks-apple-samsung-231300918.html?.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
INCY,INCY:UW,BBG000BNQ132,"Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back",2017-04-19 22:59:56 +0000,http://finance.yahoo.com/r/9eb70f5d-fd83-3b79-b0bc-52b6698adf20/104412808?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104412808&yptr=yahoo&.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
INCY,INCY:UW,BBG000BNQ132,"Cramer Remix: Thanks to Apple and Samsung, this group just got its mojo back",2017-04-19 22:59:56 +0000,http://finance.yahoo.com/news/cramer-remix-thanks-apple-samsung-225956438.html?.tsrc=rss,Jim Cramer uncovers one group that could get a lot juicier in the tech space.
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...",2017-04-19 20:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DYS8iDXcwPk/gainers--losers-of-apr19-sngx-imgn-cbli-ssh-aktx-20170419-01430,"Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX..."
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. – Value Analysis (NASDAQ:INCY) : April 19, 2017",2017-04-19 19:05:28 +0000,http://finance.yahoo.com/r/b3333424-6ce3-3b53-b63d-e2d9c1b1c07e/incyte-corp-value-analysis-nasdaqincy-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Incyte Corp. a score of 75. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Wells Fargo Among 5 Stocks Insiders Are Loading Up On,2017-04-19 17:21:00 +0000,http://finance.yahoo.com/r/8f533b46-ff2c-37cb-a9ed-a35cb654054d/wells-fargo-among-5-stocks-insiders-are-loading-up-on.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Insiders at Wells Fargo & Company, Incyte and three other companies have been scooping up shares of their own stock lately."
INCY,INCY:UW,BBG000BNQ132,"Zacks Market Edge Highlights: Insulet, Incyte, Intuitive Surgical and Edwards Lifesciences",2017-04-19 17:05:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i25DfJAvmxA/zacks-market-edge-highlights-insulet-incyte-intuitive-surgical-and-edwards-lifesciences-cm775938,For Immediate Release Chicago IL April 19 2017 Zacks Market Edge is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec Every week Tracey will be joined by guests to discuss the hottest investing topics in stocks bonds and ETFs and how it impacts your life To listen to
INCY,INCY:UW,BBG000BNQ132,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY,2017-04-19 15:37:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-153700121.html?.tsrc=rss,"NEW YORK, April 19, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation (""Incyte"" or the ""Company"") (NASDAQ: INCY).   Such investors ..."
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 14:06:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ElHVpLVTn4U/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-on-oncomed-cm775728,The FDA s complete response letter CRL for Incyte INCY and Lilly s experimental rheumatoid arthritis RA treatment was the big news in the biotech sector while OncoMed OMED continued to be hit by more pipeline setbacks Recap of the Week s Most Important Stories CRL for Incyte s
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 11:57:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-crl-115711490.html?.tsrc=rss,Incyte&apos;s (INCY) shares were hit by the FDA&apos;s complete response letter (CRL) for the company&apos;s rheumatoid arthritis drug.
INCY,INCY:UW,BBG000BNQ132,[$$] Investors bet on Incyte drug success,2017-04-19 11:00:08 +0000,"http://finance.yahoo.com/r/d5bdbc9b-45f6-3207-b5c4-634e5064750d/c71b04d6-23c2-11e7-a34a-538b4cb30025,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The huge escalator running through the headquarters of Incyte, the US biotech company, harks backs to the building's former life as a department store. Where smartly dressed shop assistants once sold ladieswear ..."
INCY,INCY:UW,BBG000BNQ132,Should You Make a Bet on the Healthcare Stocks?,2017-04-19 00:03:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4rAQHcY-lU/should-you-make-a-bet-on-the-healthcare-stocks-cm775583,0 25 A Wide Focused Outlook On The Healthcare Market 3 45 Hidden Gems In the Healthcare Sector 6 40 Immunotherapy Robotic Surgery and Investment Ideas 14 00 Where To Invest In The Healthcare Market 19 10 Neurocrine
INCY,INCY:UW,BBG000BNQ132,"FDA Rejects Eli Lilly, Incyte's Commercialization Application",2017-04-18 20:33:48 +0000,http://finance.yahoo.com/news/fda-rejects-eli-lilly-incytes-203348034.html?.tsrc=rss,Shares tumbled after agency did not approve the companies' rheumatoid arthritis treatment
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals",2017-04-18 15:06:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8-o62rlcW5Q/zackscom-featured-highlights-ptc-covanta-holding-live-nation-entertainment-incyte-and-vertex-pharmaceuticals-cm775270,For Immediate Release Chicago IL April 18 2017 Stocks in this week s article include 160 PTC Inc NASDAQ PTC Free Report Covanta Holding Corporation NYSE CVA Free Report Live Nation Entertainment Inc NYSE LYV Free Report Incyte Corporation
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals",2017-04-18 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-ptc-133001850.html?.tsrc=rss,"Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals"
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : April 18, 2017",2017-04-18 12:53:46 +0000,http://finance.yahoo.com/r/d9443fee-7758-3a2c-b45b-b25937257ad1/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-april-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
INCY,INCY:UW,BBG000BNQ132,Incyte to Report First Quarter Financial Results,2017-04-18 12:00:00 +0000,http://finance.yahoo.com/news/incyte-report-first-quarter-financial-120000471.html?.tsrc=rss,"Incyte Corporation announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.m. ET on Thursday, May 4, 2017."
INCY,INCY:UW,BBG000BNQ132,Today's Research Reports on Biotech Stocks to Watch: Cara Therapeutics and Incyte,2017-04-18 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-113000917.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 18, 2017 / The volatile Biotech Industry has continued to be home to some of the largest gainers on the market in 2017. President Trump's pledge for a faster FDA approval ..."
INCY,INCY:UW,BBG000BNQ132,"Why Snyder's-Lance, Incyte, and Tenet Healthcare Slumped Today",2017-04-17 22:55:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jw5u0CBLGYM/why-snyders-lance-incyte-and-tenet-healthcare-slumped-today-cm774904,The stock market did very well on Monday and the Dow and other major indexes climbed almost 1 on the day Investors seemed ready to embrace the new earnings season which many believe could be a lot stronger than previously anticipated and could spur another leg up in the bull
INCY,INCY:UW,BBG000BNQ132,Billion dollar drug bust,2017-04-17 21:43:00 +0000,http://finance.yahoo.com/video/billion-dollar-drug-bust-214300736.html?.tsrc=rss,CNBC's Meg Tirrell takes a look at the next potential blockbuster drugs. With the &quot;Fast Money&quot; traders.
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY...",2017-04-17 21:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMfSMx6z5us/gainers--losers-of-apr17-cbli-infi-pbyi-omed-incy-20170417-00923,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY..."
INCY,INCY:UW,BBG000BNQ132,The Biggest Loser: Eli Lilly Drops 4.1%,2017-04-17 21:22:00 +0000,http://finance.yahoo.com/r/9e5e6f7f-baf8-3310-a465-ca9953b20d6b/the-biggest-loser-eli-lilly-drops-4-1?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly and partner Incyte Corp. (  INCY  ) both fell today, on news that approval for its rheumatoid arthritis treatment baricitinib will be delayed at best, according to the complete response letter issued by the FDA.  Things looked different earlier this month when Incyte was the best performer in the S&P 500."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,856.79 up 51.64 points",2017-04-17 20:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RtRkacL9DO8/market-close-report-nasdaq-composite-index-closes-at-585679-up-5164-points-cm774868,Monday s session closes with the NASDAQ Composite Index at 5 856 79 The total shares traded for the NASDAQ was over 1 58 billion Monday s session closes with the NASDAQ Composite Index at 5 856 79 The total shares traded for the NASDAQ was over 1 58 billion Advancers stocks led declining by 2
INCY,INCY:UW,BBG000BNQ132,"Why Snyder&apos;s-Lance, Incyte, and Tenet Healthcare Slumped Today",2017-04-17 20:47:12 +0000,http://finance.yahoo.com/r/69952bcb-e6f4-32cd-9972-8ce2813642c4/why-snyders-lance-incyte-and-tenet-healthcare-slum.aspx?yptr=yahoo&.tsrc=rss,"Despite a climbing market, these stocks fell. Find out why."
INCY,INCY:UW,BBG000BNQ132,"Eli Lilly, Incyte Stocks Break Key Levels After FDA Drug Setback",2017-04-17 20:30:46 +0000,http://finance.yahoo.com/r/e6515a94-6dbf-3249-91f7-d9aaab9f7ee2/eli-lilly-incyte-dive-after-fda-doesnt-ok-rheumatoid-arthritis-drug?src=A00220A&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte shares plunged Monday morning after the FDA failed to approve their rheumatoid arthritis drug.
INCY,INCY:UW,BBG000BNQ132,"Apple, Facebook Get Price-Target Hikes; McDonald&apos;s A Buy",2017-04-17 20:23:35 +0000,http://finance.yahoo.com/r/c9151e15-f91a-3288-bc2e-461a2e3ce8ae/apple-facebook-get-price-target-hikes-mcdonalds-a-buy?src=A00220A&yptr=yahoo&.tsrc=rss,"Analyst actions on Monday included price-target hikes for Apple and Facebook, an upgrade for McDonald&apos;s and a downgrade for Eli Lilly."
INCY,INCY:UW,BBG000BNQ132,Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug?,2017-04-17 20:13:20 +0000,http://finance.yahoo.com/r/6d0ff6dd-72cc-3676-a973-21a9370d3686/can-lilly-survive-rheumatoid-arthritis-flop-on-breast-cancer-diabetes?src=A00220A&yptr=yahoo&.tsrc=rss,AbbVie will get some breathing room in rheumatoid arthritis after Eli Lilly and Incyte&apos;s drug caught an FDA delay.
INCY,INCY:UW,BBG000BNQ132,Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher,2017-04-17 20:09:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xfjNwwoDfvU/mid-afternoon-market-update-crude-oil-down-1-mocon-shares-spike-higher-cm774863,Toward the end of trading Monday the Dow traded up 0 64 percent to 20 583 90 while the NASDAQ rose 0 59 percent to 5 839 36 The S amp P also rose gaining 0 60 percent to 2 342 95 Leading and Lagging Sectors Monday afternoon the financial sector proved to be a source of
INCY,INCY:UW,BBG000BNQ132,"Monday Sector Laggards: Energy, Healthcare",2017-04-17 19:55:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BDtQP8UuZSg/monday-sector-laggards-energy-healthcare-cm774817,In afternoon trading on Monday Energy stocks are the worst performing sector higher by 0 1 Within that group Chesapeake Energy Corp Symbol CHK and Tesoro Corporation Symbol TSO are two large stocks that are lagging showing a loss of 3 6 and 0 8 respectively Among energy ETFs
INCY,INCY:UW,BBG000BNQ132,Eli Lilly and Co (LLY) Stock Holders Choke on FDA Letter for Barictinib,2017-04-17 18:56:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sMKPbkwdJ9s/eli-lilly-and-co-lly-stock-holders-choke-on-fda-letter-for-barictinib-cm774828,InvestorPlace Stock Market News Stock Advice amp Trading Tips Eli Lilly and Co 160 NYSE LLY was the disaster of the day Monday falling about 4 on early trade after what was called a rejection of its anti arthritis drug barictinib 160 The morning s fall in LLY stock
INCY,INCY:UW,BBG000BNQ132,Why Incyte Corporation Stock Is Plunging Today,2017-04-17 18:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zui4mUT0bRY/why-incyte-corporation-stock-is-plunging-today-cm774788,What happened Shares of Incyte Corporation NASDAQ INCY fell by as much as 11 9 on Monday as a result of the FDA rejecting its once daily 160 rheumatoid arthritis pill baricitinib for safety and dosing reasons Although Eli Lilly NYSE LLY 160 stood the most to
INCY,INCY:UW,BBG000BNQ132,"Incyte, Eli Lilly Tumble As FDA Delays Arthritis Drug Approval",2017-04-17 17:55:00 +0000,http://finance.yahoo.com/r/55af2705-1e5c-389a-b28a-d57b39f77cd5/incyte-eli-lilly-tumble-as-fda-delays-arthritis-drug-approval?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte Corp. (  INCY  ) and Eli Lilly (  LLY  ) are both falling Monday, on news that the FDA issued a complete response letter concerning its rheumatoid arthritis treatment baricitinib, delaying approval.  The FDA didn't kill the drug, but it didn’t approve it either, saying that more clinical trials would be needed to determine the correct dosage.  Of course, more trials will increase the time and money that the companies will have to spend on baricitinib before its approval.  Incyte and Lilly both said they are committed to working with the agency to get approval."
INCY,INCY:UW,BBG000BNQ132,Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide,2017-04-17 17:39:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E_UsFCC5cqk/mid-day-market-update-dow-surges-over-100-points-oncomed-shares-slide-cm774771,Midway through trading Monday the Dow traded up 0 57 percent to 20 570 30 while the NASDAQ rose 0 62 percent to 5 841 01 The S amp P also rose gaining 0 55 percent to 2 341 73 Leading and Lagging Sectors On Monday the non cyclical consumer goods amp services sector proved to be
INCY,INCY:UW,BBG000BNQ132,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 16:55:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BlP7p0mhnE0/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly-cm774697,Exchange traded funds tracking major stock indexes rose on Monday despite a stunning 160 setback to the health sector 160 as the FDA rejected 160 an Eli Lilly LLY drug to treat rheumatoid arthritis SPDR S amp P 500 SPY added 0 3 shortly after the opening bell
INCY,INCY:UW,BBG000BNQ132,Why Incyte Corporation Stock Is Plunging Today,2017-04-17 16:47:00 +0000,http://finance.yahoo.com/r/40dc06f3-2b78-358a-8787-7a551c52af80/why-incyte-corporation-stock-is-plunging-today.aspx?yptr=yahoo&.tsrc=rss,Shares of Incyte and Eli Lilly are reeling following the FDA&apos;s rejection of their once-daily rheumatoid arthritis pill.
INCY,INCY:UW,BBG000BNQ132,FDA rejects Eli Lilly's arthritis drug,2017-04-17 16:11:04 +0000,https://www.yahoo.com/news/fda-rejects-eli-lillys-arthritis-161104646.html?.tsrc=rss,Shares of Eli Lilly and partner Incyte drop after the U.S. Food and Drug Administration declines to approve a new drug for rheumatoid arthritis. Roselle Chen reports.
INCY,INCY:UW,BBG000BNQ132,"Today&apos;s charts: Netflix, United Airlines earnings on tap; Eli Lilly shares drop; Wells Fargo&apos;s bullish call on McDonald&apos;s",2017-04-17 16:02:46 +0000,http://finance.yahoo.com/news/todays-charts-netflix-united-airlines-earnings-tap-eli-lilly-shares-drop-wells-fargos-bullish-call-mcdonalds-160246437.html?.tsrc=rss,"Yahoo Finance is tracking Netflix, United Airlines, Eli Lilly and McDonald’s in intraday trading on Monday. Netflix and United Airlines are set to report earnings after the bell Monday."
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: INCY, ARNC",2017-04-17 15:57:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BFfG1zqwL8A/sp-500-movers-incy-arnc-cm774649,In early trading on Monday shares of Arconic ARNC topped the list of the day s best performing components of the S amp P 500 index trading up 7 8 Year to date Arconic registers a 50 6 gain And the worst performing S amp P 500 component thus far on the day is Incyte
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, NVDA",2017-04-17 15:57:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7h3OjG94aUQ/nasdaq-100-movers-incy-nvda-cm774646,In early trading on Monday shares of NVIDIA NVDA topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 2 Year to date NVIDIA has lost about 8 5 of its value And the worst performing Nasdaq 100 component thus far on the day is Incyte
INCY,INCY:UW,BBG000BNQ132,Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.,2017-04-17 15:57:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BGZ6MlHNNDs/eli-lillys-rheumatoid-arthritis-drug-gets-crl-in-the-us-cm774628,Eli Lilly and Company LLY and its partner Incyte Corporation INCY recently announced that they have received a Complete Response Letter CRL from the FDA regarding the new drug application NDA for baricitinib Lilly was seeking approval of baricitinib for the treatment of moderate to
INCY,INCY:UW,BBG000BNQ132,[$$] FDA arthritis drug rejection hits Eli Lilly shares,2017-04-17 15:20:52 +0000,"http://finance.yahoo.com/r/7dd0deea-00b5-3a9c-bd20-6744a5d38bdf/abc4818c-237a-11e7-a34a-538b4cb30025,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Investors wiped a combined $6bn from the market value of Eli Lilly and its biotech partner Incyte on Monday after the US medicines regulator rejected their new arthritis medicine. In a letter to the companies, ..."
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Shun or Play Short Right Now,2017-04-17 14:58:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bB9mz-COcVY/5-toxic-stocks-to-shun-or-play-short-right-now-cm774537,Successful investing calls for the appropriate identification of overpriced stocks and correctly priced stocks However in practice the overhyped toxic stocks and the fairly priced stocks are intermixed in the marketplace in such a way that it becomes difficult to distinguish between
INCY,INCY:UW,BBG000BNQ132,Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain,2017-04-17 14:57:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O_eYzlcYKhM/lilly-and-incytes-loss-is-abbvie-and-regenerons-gain-cm774566,The FDA has decided not to grant marketing approval for Eli Lilly amp Co s and Incyte s NASDAQ INCY rheumatoid arthritis drug baricitinib and that setback is potentially good news for AbbVie NYSE ABBV and Regeneron NASDAQ REGN A massive market
INCY,INCY:UW,BBG000BNQ132,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 14:52:59 +0000,http://finance.yahoo.com/r/01e6b672-8992-3020-b187-eaf701a0f6c3/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly?src=A00220A&yptr=yahoo&.tsrc=rss,The arthritis treatment was expected to generate more than $1 billion in sales by 2020.
INCY,INCY:UW,BBG000BNQ132,Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly,2017-04-17 14:52:59 +0000,http://finance.yahoo.com/r/01e6b672-8992-3020-b187-eaf701a0f6c3/health-etfs-wobble-as-fda-spurns-arthritis-drug-in-blow-to-eli-lilly?src=A00220&yptr=yahoo&.tsrc=rss,The arthritis treatment was expected to generate more than $1 billion in sales by 2020.
INCY,INCY:UW,BBG000BNQ132,FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte,2017-04-17 14:20:54 +0000,http://finance.yahoo.com/news/fda-delivers-big-rheumatoid-athritis-142054127.html?.tsrc=rss,"When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment."
INCY,INCY:UW,BBG000BNQ132,Incyte Continues To Post Steep Loss After Initial Sell-Off,2017-04-17 13:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CuKxaNDtKvY/incyte-continues-to-post-steep-loss-after-initial-selloff-20170417-00613,Incyte Continues To Post Steep Loss After Initial Sell-Off
INCY,INCY:UW,BBG000BNQ132,Eli Lilly&apos;s Rheumatoid Arthritis Drug Gets CRL in the U.S.,2017-04-17 13:47:01 +0000,http://finance.yahoo.com/news/eli-lilly-apos-rheumatoid-arthritis-134701278.html?.tsrc=rss,Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.
INCY,INCY:UW,BBG000BNQ132,Lilly and Incyte&apos;s Loss Is AbbVie and Regeneron&apos;s Gain,2017-04-17 13:40:00 +0000,http://finance.yahoo.com/r/0b3708c7-2ac3-3fd3-9623-bcc484b45d72/lilly-and-incytes-loss-is-abbvie-and-regenerons-ga.aspx?yptr=yahoo&.tsrc=rss,The FDA has rejected Eli Lilly and Incyte&apos;s application for approval of a potential blockbuster rheumatoid arthritis drug.
INCY,INCY:UW,BBG000BNQ132,"Biotech Movers: OncoMed, Incyte, Omeros",2017-04-17 13:28:00 +0000,http://finance.yahoo.com/r/c5adf711-4efa-3b91-a0f2-c2d941f017c6/biotech-movers-oncomed-incyte-omeros.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday."
INCY,INCY:UW,BBG000BNQ132,Eli Lilly Stock Falls Premarket After FDA Rejects Arthritis Drug Due to Safety Concerns,2017-04-17 13:14:00 +0000,http://finance.yahoo.com/r/c4d3f90c-8ae0-3752-8782-decb5a993823/eli-lilly-stock-falls-premarket-after-fda-rejects-arthritis-drug-due-to-safety-concerns.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The drug was expected to bring in more than $1 billion in sales by 2020.
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Shun or Play Short Right Now,2017-04-17 13:03:01 +0000,http://finance.yahoo.com/news/5-toxic-stocks-shun-play-130301056.html?.tsrc=rss,"Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them."
INCY,INCY:UW,BBG000BNQ132,US STOCKS-Wall Street looks set to open slightly higher,2017-04-17 12:59:47 +0000,http://finance.yahoo.com/news/us-stocks-wall-street-looks-125947604.html?.tsrc=rss,"Wall Street was on track to open  slightly higher on Monday as oil prices trimmed losses, but  gains may be limited by geopolitical tensions and soft U.S.  data.  Wall Street was closed for the Good Friday holiday."
INCY,INCY:UW,BBG000BNQ132,"FDA Complete Response Smacks LLY & INCY, What Now?",2017-04-17 12:57:00 +0000,http://finance.yahoo.com/r/a778fc67-cb2f-36ca-a54f-069c4864cf98/fda-complete-response-smacks-lly-incy-what-now?partner=YahooSA&yptr=yahoo&.tsrc=rss,The FDA's complete response letter has beaten the stuffing out of Incyte and Eli Lilly this morning. We examine the implications for the firm.
INCY,INCY:UW,BBG000BNQ132,"Pre-Market Most Active for Apr 17, 2017 :  ALR, SWC, MGI, BAC, XIV, LLY, XXIA, INCY, QQQ, TLT, F, KEP",2017-04-17 12:54:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMQoFVs57Ug/pre-market-most-active-for-apr-17-2017-alr-swc-mgi-bac-xiv-lly-xxia-incy-qqq-tlt-f-kep-cm774467,The NASDAQ 100 Pre Market Indicator is up 5 57 to 5 359 16 The total Pre Market volume is currently 2 311 062 shares traded The following are the most active stocks for the pre market session Alere Inc ALR is 7 13 at 49 44 with 3 141 855 shares traded As reported
INCY,INCY:UW,BBG000BNQ132,The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling,2017-04-17 12:49:00 +0000,http://finance.yahoo.com/news/fda-shot-down-rheumatoid-arthritis-124900725.html?.tsrc=rss,The FDA just rejected a new daily pill to treat rheumatoid arthritis. Pharmaceutical...
INCY,INCY:UW,BBG000BNQ132,FDA rejects LLY's rheumatoid arthritis drug,2017-04-17 11:45:00 +0000,http://finance.yahoo.com/video/fda-rejects-llys-rheumatoid-arthritis-114500798.html?.tsrc=rss,CNBC's Meg Tirrell takes a look at what the FDA's rejection of the drug means for Eli Lilly and partner Incyte.
INCY,INCY:UW,BBG000BNQ132,Eli Lilly and Incyte stock drops after FDA fails to approve rheumatoid arthritis drug,2017-04-17 11:38:42 +0000,http://finance.yahoo.com/r/c6e08b7e-9131-3f50-8433-24ff7734195e/Story.aspx?guid=CEA8A0BC-EA23-4B48-BA33-4C9DC1AA62D9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Eli Lilly & Co. shares dropped 5.5% and Incyte Corp. shares dropped 12.7% in premarket trade Monday after the companies said that the Food and Drug Administration failed to approve their drug for moderate-to-severe ...
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) And Eli Lilly (LLY) Are Sinking After FDA Rejection,2017-04-17 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xg-7R6uxDEw/incyte-incy-and-eli-lilly-lly-are-sinking-after-fda-rejection-20170417-00429,Incyte (INCY) And Eli Lilly (LLY) Are Sinking After FDA Rejection
INCY,INCY:UW,BBG000BNQ132,Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis,2017-04-17 01:33:00 +0000,http://finance.yahoo.com/r/93e8e82a-0218-3aa6-b019-9d60cdbb8caa/gilead-pfizer-abbvie-stand-to-gain-from-lilly-incyte-rheumatoid-arthritis-pill-setback.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback."
INCY,INCY:UW,BBG000BNQ132,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move",2017-04-17 00:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o5ZlrIoIdS8/fda-says-no-to-incy-zts-snaps-up-nvet-mdxg-on-the-move-20170417-00004,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move"
INCY,INCY:UW,BBG000BNQ132,[$$] Surprise FDA Rejection Will Sting This Biotech,2017-04-15 04:33:37 +0000,http://finance.yahoo.com/r/eb138240-078b-359d-bbe1-5a6ec540a38c/surprise-fda-rejection-will-sting-this-biotech-1492185721?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.
INCY,INCY:UW,BBG000BNQ132,[$$] FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug,2017-04-15 04:33:11 +0000,http://finance.yahoo.com/r/0274b1eb-d465-3a8b-8e6f-929342d834c1/fda-rejects-eli-lilly-and-incyte-rheumatoid-arthritis-drug-1492183825?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion ...
INCY,INCY:UW,BBG000BNQ132,The FDA just shot down a new rheumatoid arthritis drug,2017-04-14 23:38:00 +0000,http://finance.yahoo.com/news/fda-just-shot-down-rheumatoid-135940534.html?.tsrc=rss,The FDA just rejected a new daily pill to treat rheumatoid arthritis. Pharmaceutical...
INCY,INCY:UW,BBG000BNQ132,Company Spotlight: Incyte,2017-04-14 21:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Al1JAVq5xSQ/company-spotlight-incyte-20170414-00197,Company Spotlight: Incyte
INCY,INCY:UW,BBG000BNQ132,Lilly's rheumatoid arthritis pill rejected by regulators,2017-04-14 16:34:46 +0000,http://finance.yahoo.com/r/15864ea8-68a3-35fe-b821-a16f4d9665fd/lillys-rheumatoid-arthritis-pill-rejected-152727599.html?.tsrc=rss,"Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November."
INCY,INCY:UW,BBG000BNQ132,[$$] FDA Rejects Eli Lilly and Incyte Drug,2017-04-14 16:20:45 +0000,http://finance.yahoo.com/r/0274b1eb-d465-3a8b-8e6f-929342d834c1/fda-rejects-eli-lilly-and-incyte-rheumatoid-arthritis-drug-1492183825?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Eli Lilly and Incyte said the U.S. Food and Drug Administration didn’t approve their new drug application for a rheumatoid arthritis treatment that some analysts estimate could generate more than $2 billion ...
INCY,INCY:UW,BBG000BNQ132,InPlay from Briefing.com,2017-04-14 16:19:02 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
INCY,INCY:UW,BBG000BNQ132,[$$] Surprise FDA Rejection Will Sting This Biotech,2017-04-14 16:02:04 +0000,http://finance.yahoo.com/r/eb138240-078b-359d-bbe1-5a6ec540a38c/surprise-fda-rejection-will-sting-this-biotech-1492185721?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,A Lilly-Incyte rheumatoid arthritis drug won’t come to market any time soon after the FDA’s surprise rejection of the treatment.
INCY,INCY:UW,BBG000BNQ132,U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant,2017-04-14 15:00:18 +0000,http://finance.yahoo.com/news/u-fda-declines-approve-eli-150018238.html?.tsrc=rss,"The U.S. Food and Drug  Administration on Friday declined to approve a new drug for  rheumatoid arthritis made by Eli Lilly and Co and  partner Incyte Corp, the companies said on Friday.  The U.S. FDA indicated that additional clinical data was  needed to determine the most appropriate doses of the drug,  Olumiant, known also as baricitinib, and to further characterize  safety concerns across treatment arms.  The FDA's request for additional data possibly means more  than a year's delay for this important product for both  companies, and represents a break for other drugmakers who were  expected to face tough competition from Olumiant."
INCY,INCY:UW,BBG000BNQ132,U.S. FDA Issues Complete Response Letter for Baricitinib,2017-04-14 13:00:00 +0000,http://finance.yahoo.com/news/u-fda-issues-complete-response-130000860.html?.tsrc=rss,"Eli Lilly and Company and Incyte Corporation announced today that the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis ."
INCY,INCY:UW,BBG000BNQ132,U.S. FDA Issues Complete Response Letter for Baricitinib,2017-04-14 13:00:00 +0000,http://finance.yahoo.com/news/u-fda-issues-complete-response-130000039.html?.tsrc=rss,"INDIANAPOLIS, April 14, 2017 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA).  The letter indicates that the FDA is unable to approve the application in its current form.  Specifically, the FDA indicated that additional clinical data are needed to determine the most appropriate doses."
INCY,INCY:UW,BBG000BNQ132,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib,2017-04-14 09:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EoxDsTJostg/eli-lilly-and-incyte-say-fda-issues-crl-for-baricitinib-20170414-00091,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib
INCY,INCY:UW,BBG000BNQ132,Incyte Stock Rises Following Morgan Stanley Upgrade,2017-04-13 16:26:00 +0000,http://finance.yahoo.com/r/51e4d4d9-e62b-3f6f-9c57-26991fe5a5c4/incyte-stock-rises-following-morgan-stanley-upgrade.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Morgan Stanley raised Incyte's price target to $150.
INCY,INCY:UW,BBG000BNQ132,Morgan Stanley Ups Incyte Target to $150,2017-04-13 16:01:00 +0000,http://finance.yahoo.com/r/edc4754b-0466-3f53-9c98-03527e062784/morgan-stanley-ups-incyte-target-to-150?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Analystand his team reiterated an Overweight rating on the stock and raised their price target by $20, to $150.  Berens writes that he sees the company’s cancer drug epacadostat is a best-in-class treatment, and could be expanded to more tumor uses over time.  More detail from the note:   Following data presented last week at the American Association for Cancer Research (AACR) conference in Washington DC, we increasingly believe epacadostat possesses superior efficacy and safety relative to other IDO competitors, resulting in a best-in-class profile."
INCY,INCY:UW,BBG000BNQ132,The IDO-Inhibitor Race Is On to Improve Cancer Treatment,2017-04-13 15:57:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bC550GMI8dE/the-ido-inhibitor-race-is-on-to-improve-cancer-treatment-cm773836,NewLink Genetics NASDAQ NLNK and Incyte Corporation NASDAQ INCY are racing a new class of drugs through clinical trials and if these trials are successful these new drugs may change how doctors treat cancer including melanoma IDO what Indoleamine 2 3 dioxygenase
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: LILA, ALXN",2017-04-13 15:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rEBq02D84JE/nasdaq-100-movers-lila-alxn-cm773825,In early trading on Thursday shares of Alexion Pharmaceuticals topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 0 Year to date Alexion Pharmaceuticals has lost about 4 5 of its value And the worst performing Nasdaq 100 component thus far
INCY,INCY:UW,BBG000BNQ132,The IDO-Inhibitor Race Is On to Improve Cancer Treatment,2017-04-13 14:41:00 +0000,http://finance.yahoo.com/r/ad94a590-1044-38cd-8e00-b4e18a8b9d46/the-ido-inhibitor-race-is-on-to-improve-cancer-tre.aspx?yptr=yahoo&.tsrc=rss,NewLink Genetics and Incyte Corporation&apos;s IDO-inhibitors could be the next big advance in cancer treatment.
INCY,INCY:UW,BBG000BNQ132,Company Spotlight: Incyte,2017-04-13 10:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/thqKkyD3yu8/company-spotlight-incyte-20170413-00737,Company Spotlight: Incyte
INCY,INCY:UW,BBG000BNQ132,Incytes: Cramer's Top Takeaways,2017-04-13 10:30:00 +0000,http://finance.yahoo.com/r/f3521b8c-8428-3abf-b3fa-88c03af34f48/incytes-cramer-s-top-takeaways.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Jim Cramer cites Incyte's solid fundamentals.
INCY,INCY:UW,BBG000BNQ132,Bank Earnings Are at a Critical Turning Point: Cramer's 'Mad Money' Recap (Wednesday 4/12/17),2017-04-13 10:14:00 +0000,http://finance.yahoo.com/r/90ec0f3a-b65c-38b0-9cc0-b13fb8bededd/bank-earnings-are-at-a-critical-turning-point-cramer-s-mad-money-recap-wednesday-4-12-17.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Loss of bank leadership and the recent pullback are major factors in what's ailing the markets, says Jim Cramer."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,836.16 down -30.61 points",2017-04-12 20:48:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8s_uxvrpHq8/market-close-report-nasdaq-composite-index-closes-at-583616-down-3061-points-cm773492,Wednesday s session closes with the NASDAQ Composite Index at 5 836 16 The total shares traded for the NASDAQ was over 1 65 billion Declining stocks led advancers by 2 19 to 1 ratio There were 902 advancers and 1971 decliners for the day On the NASDAQ Stock Exchange 26 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Wednesday 4/12 Insider Buying Report: INCY, CBK",2017-04-12 15:56:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4fWgvMozfRk/wednesday-412-insider-buying-report-incy-cbk-cm773226,Bargain hunters are wise to pay careful attention to insider buying because although there are many various reasons for an insider to sell a stock presumably the only reason they would use their hard earned dollars to make a purchase is that they expect to make money Today we look at
INCY,INCY:UW,BBG000BNQ132,[$$] Incyte: Why This Biotech Beauty Can Stay Hot,2017-04-12 12:08:00 +0000,http://finance.yahoo.com/r/24f062fb-7bfd-372d-ad50-944ccbefa50a/incyte-why-this-biotech-beauty-can-stay-hot-1491998918?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"In the burgeoning market for drugs that use the body’s immune system to fight cancer, Incyte is the belle of the ball. Shares of Incyte (ticker: INCY) have jumped 76% in the past year. And with revenue ..."
INCY,INCY:UW,BBG000BNQ132,3 Big Drugmakers Most Likely to Buy Incyte,2017-04-11 19:03:00 +0000,http://finance.yahoo.com/r/5a0eeaab-7a39-3ad2-ae55-194954159cb3/3-big-drugmakers-most-likely-to-buy-incyte.aspx?yptr=yahoo&.tsrc=rss,"Incyte could find itself in the crosshairs of Gilead Sciences, Amgen, and/or Bristol-Myers Squibb."
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: AMD, HES",2017-04-10 15:54:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N88d712CmhE/sp-500-movers-amd-hes-cm772119,In early trading on Monday shares of Hess topped the list of the day s best performing components of the S amp P 500 index trading up 3 5 Year to date Hess has lost about 20 2 of its value And the worst performing S amp P 500 component thus far on the day is Advanced Micro
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, TSLA",2017-04-10 15:54:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TrPi8MxVg20/nasdaq-100-movers-incy-tsla-cm772115,In early trading on Monday shares of Tesla topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 2 Year to date Tesla registers a 46 2 gain And the worst performing Nasdaq 100 component thus far on the day is Incyte trading down 1 8 Incyte
INCY,INCY:UW,BBG000BNQ132,INCY Crosses Above Average Analyst Target,2017-04-10 14:54:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rFnsqewO9I8/incy-crosses-above-average-analyst-target-cm772061,In recent trading shares of Incyte Corporation Symbol INCY have crossed above the average analyst 12 month target price of 139 90 changing hands for 140 11 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
INCY,INCY:UW,BBG000BNQ132,Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?,2017-04-10 14:53:00 +0000,http://finance.yahoo.com/r/8f0dcf64-ea53-3eac-bf42-428403db2100/does-incyte-have-the-best-cancer-portfolio-among-mid-cap-biotechs?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"(INCY) is lower Monday, but doesn’t think the stock will be down for long.  Analyst initiated coverage of the biotech stock with a Buy recommendation and a $185 price target. She writes that Incyte has ..."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,877.81 down -1.14 points",2017-04-07 20:49:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Gq7wuEA8IY/market-close-report-nasdaq-composite-index-closes-at-587781-down-114-points-cm771609,Friday s session closes with the NASDAQ Composite Index at 5 877 81 The total shares traded for the NASDAQ was over 2 33 billion Declining stocks led advancers by 1 02 to 1 ratio There were 1411 advancers and 1444 decliners for the day On the NASDAQ Stock Exchange 34 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Leaders: Healthcare, Financial",2017-04-07 19:54:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FL1fQ0M-eJY/friday-sector-leaders-healthcare-financial-cm771571,In afternoon trading on Friday Healthcare stocks are the best performing sector up 0 4 Within the sector Incyte Corporation Symbol INCY and Vertex Pharmaceuticals Inc Symbol VRTX are two large stocks leading the way showing a gain of 3 0 and 2 8 respectively Among healthcare
INCY,INCY:UW,BBG000BNQ132,Would Gilead Sciences Make This Staggeringly Audacious Move?,2017-04-07 19:54:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AcdRkGG62Mc/would-gilead-sciences-make-this-staggeringly-audacious-move-cm771565,Everyone and their brother wants Gilead Sciences NASDAQ GILD to make an acquisition Gilead s CEO John Milligan has indicated a preference for buying another biotech to bolster his company s oncology portfolio However Milligan has also stated that inflammation and non
INCY,INCY:UW,BBG000BNQ132,Would Gilead Sciences Make This Staggeringly Audacious Move?,2017-04-07 18:43:00 +0000,http://finance.yahoo.com/r/dbd9df65-04ae-3042-b9a1-cab47d5d55a7/would-gilead-sciences-make-this-staggeringly-audac.aspx?yptr=yahoo&.tsrc=rss,Many expect Gilead Sciences to buy Incyte. But what if the biotech instead went big -- really big?
INCY,INCY:UW,BBG000BNQ132,Eli Lilly: More Catalysts Ahead,2017-04-07 18:24:00 +0000,http://finance.yahoo.com/r/a0af9cf7-9330-3d3c-9a4b-1f636f2e0c30/eli-lilly-more-catalysts-ahead?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Eli Lilly & Co. (LLY) is fractionally lower Friday, but Barclays sees the shares, up 16% so far this year, gaining more. Analyst Geoff Meacham and Paul Choi reiterated an Overweight rating on the stock ..."
INCY,INCY:UW,BBG000BNQ132,Barclays Ups Incyte Target On Upbeat Data,2017-04-07 17:59:00 +0000,http://finance.yahoo.com/r/9ad2e25b-ec0e-3330-be51-319c5d9cfdc1/barclays-ups-incyte-target-on-upbeat-data?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte Corp. (INCY) is higher Friday, after Barclays raised its price target on the biotech firm.  Analysts Geoff Meacham and Paul Choi reiterated an Overweight rating on the stock and boosted their target by $50, to $135, citing the data the firm presented at the American Association for  Cancer Research’s meeting earlier this week.  More from their note:  Incyte and Merck had already advanced epacadostat plus Keytruda into phase 3 for melanoma and they recently added lung, (MRK) bladder, renal, and H&N, while the collaboration with Bristol moved into phase 3 for lung and H&N this week."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: JD, ESRX",2017-04-07 15:57:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/51InOjMzTqQ/nasdaq-100-movers-jd-esrx-cm771396,In early trading on Friday shares of Express Scripts Holding ESRX topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 3 Year to date Express Scripts Holding has lost about 3 1 of its value And the worst performing Nasdaq 100 component
INCY,INCY:UW,BBG000BNQ132,"Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout",2017-04-07 14:26:00 +0000,http://finance.yahoo.com/r/049311e5-782a-3562-b87e-7141ff3827ed/jim-cramer-incyte-is-red-hot-worth-more-than-200-in-a-takeout.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said."
INCY,INCY:UW,BBG000BNQ132,Stock Exchange: Finding Trading Ideas In A Low Volatility Market,2017-04-07 13:56:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QO-zq84OuFg/stock-exchange-finding-trading-ideas-in-a-low-volatility-market-cm771197,By Jeff Miller ByJeff Miller Ted Williams was a terrific ball player but he had one tactic that many found questionable He almost never swung at the first pitch Ted Williams was a terrific ball player but he had one tactic that many found questionable He almost never swung at
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 5,878.95",2017-04-06 20:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dKFforoXS3w/market-close-report-nasdaq-trading-volume-joins-the-top-ten-ranking-for-the-year-nasdaq-composite-index-closes-at-587895-cm771056,Today s session closes with the NASDAQ Composite Index volume reaching the 10th place in the top ten list for this year The last time the index closed above 2 46 billion shares was on Feb 16 2017 The total shares traded for the NASDAQ was over 2 49 billion Today s session closes with the
INCY,INCY:UW,BBG000BNQ132,"Thursday Sector Laggards: Utilities, Healthcare",2017-04-06 19:53:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OoMDEgPJ-uk/thursday-sector-laggards-utilities-healthcare-cm770990,In afternoon trading on Thursday Utilities stocks are the worst performing sector showing a 0 1 loss Within that group NextEra Energy Inc Symbol NEE and Ameren Corp Symbol AEE are two of the day s laggards showing a loss of 0 8 and 0 7 respectively Among utilities ETFs one
INCY,INCY:UW,BBG000BNQ132,"Step Aside, Merck And Bristol: These Are Your Future Rivals In Cancer Drugs",2017-04-05 18:38:01 +0000,http://finance.yahoo.com/r/499021d3-5c5e-3e2a-8f82-4b807a24e7ad/step-aside-merck-and-bristol-these-are-your-future-rivals-in-cancer?src=A00220A&yptr=yahoo&.tsrc=rss,"Bristol, Roche and Merck tend to grab immuno-oncology headlines, but a conference highlighted competitors waiting in the wings."
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Sharpens Focus on Drug Development Programs,2017-04-05 16:56:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hVbE6u5LQuI/agenus-agen-sharpens-focus-on-drug-development-programs-cm770262,We issued an updated report on Agenus Inc AGEN on Apr 4 Agenus is an immuno oncology company focused on the discovery and development of checkpoint modulators vaccines and adjuvants for the treatment of cancer Agneus share price shows that the company has underperformed the
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Sharpens Focus on Drug Development Programs,2017-04-05 14:57:02 +0000,http://finance.yahoo.com/news/agenus-agen-sharpens-focus-drug-145702065.html?.tsrc=rss,We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
INCY,INCY:UW,BBG000BNQ132,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz",2017-04-05 02:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VS2wOGG0bXo/innl-to-be-acquired-elgx-seeks-funds-opdivo-at-fda-altar-again-nlnk-abuzz-20170405-00066,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz"
INCY,INCY:UW,BBG000BNQ132,Why NewLink Genetics Shares Fell 10.3% Today,2017-04-04 22:24:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WQIMD3ebxd8/why-newlink-genetics-shares-fell-103-today-cm769875,What happened After reporting that a mid stage clinical trial stumbled NewLink Genetics Corporation NASDAQ NLNK 160 shares lost 10 3 of their value today So what Last year attention shifted to NewLink s IDO inhibiting cancer drug pipeline after its once
INCY,INCY:UW,BBG000BNQ132,"Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst",2017-04-04 20:48:13 +0000,http://finance.yahoo.com/r/5c840af5-5302-3881-be6c-0f66572001fb/bristol-keeps-up-with-merck-in-cancer-but-incyte-is-true-winner-analyst?src=A00220A&yptr=yahoo&.tsrc=rss,Bristol is keeping pace with Merck after announcing a partnership with Incyte.
INCY,INCY:UW,BBG000BNQ132,Incyte Is Smart to Date Around,2017-04-04 15:17:39 +0000,http://finance.yahoo.com/r/bd606f81-bd46-3d7d-9050-610f393f0693/incyte-immune-oncology-approach-smartly-dating-around?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,It's leveraging a competitive market to get the most for its IO drug.
INCY,INCY:UW,BBG000BNQ132,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 23:35:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N882ucFp4Ps/bristol-myers-bmy-incyte-to-advance-clinical-program-cm769303,Bristol Myers Squibb Company BMY and Incyte Corporation INCY recently announced that the companies will advance their clinical development program The clinical development program evaluates the combination of Incyte s investigational oral selective IDO1 enzyme inhibitor epacadostat with
INCY,INCY:UW,BBG000BNQ132,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 21:05:09 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-incyte-advance-210509124.html?.tsrc=rss,Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
INCY,INCY:UW,BBG000BNQ132,"Bristol-Myers (BMY), Incyte to Advance Clinical Program",2017-04-03 21:05:09 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-incyte-advance-210509124.html,"Bristol-Myers (BMY), Incyte to Advance Clinical Program"
INCY,INCY:UW,BBG000BNQ132,The Hot Stock: Incyte Jumps 3.6%,2017-04-03 21:02:00 +0000,http://finance.yahoo.com/r/4286a40f-b904-3b84-85ac-fb885ada1f4d/the-hot-stock-incyte-jumps-3-6?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"One trading day after tumbling to the bottom of the S&P 500 following an expanded partnership with Merck (MRK), Incyte (INCY) soared to the top of the popular benchmark after announcing that its cancer ..."
INCY,INCY:UW,BBG000BNQ132,The Hot Stock: Incyte Jumps 3.6%,2017-04-03 21:02:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/04/03/the-hot-stock-incyte-jumps-3-6/?mod=yahoobarrons&ru=yahoo,The Hot Stock: Incyte Jumps 3.6%
INCY,INCY:UW,BBG000BNQ132,"Monday Sector Leaders: Healthcare, Utilities",2017-04-03 20:35:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fNBGZ03TGcw/monday-sector-leaders-healthcare-utilities-cm769227,Looking at the sectors faring best as of midday Monday shares of Healthcare companies are outperforming other sectors losing just 0 2 Within that group Incyte Corporation Symbol INCY and Thermo Fisher Scientific Inc Symbol TMO are two of the day s stand outs showing a gain of 4 7
INCY,INCY:UW,BBG000BNQ132,"Cramer: Stay the Course, but Keep Cash Handy",2017-04-03 20:04:00 +0000,http://finance.yahoo.com/r/b7bb634a-c325-3d0d-a77c-610c787ec77d/cramer-stay-course-keep-cash-handy?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,It's pretty normal to have profit-taking after such a strong first quarter.
INCY,INCY:UW,BBG000BNQ132,"Cramer: Stay the Course, but Keep Cash Handy",2017-04-03 20:04:00 +0000,http://realmoney.thestreet.com/articles/04/03/2017/cramer-stay-course-keep-cash-handy?puc=yahoo&cm_ven=YAHOO,"Cramer: Stay the Course, but Keep Cash Handy"
INCY,INCY:UW,BBG000BNQ132,[$$] Bristol-Myers May Be Hedging on IO,2017-04-03 19:33:00 +0000,http://www.barrons.com/articles/bristol-myers-may-be-hedging-on-io-1491248030?mod=yahoobarrons&ru=yahoo,[$$] Bristol-Myers May Be Hedging on IO
INCY,INCY:UW,BBG000BNQ132,[$$] Bristol-Myers May Be Hedging on IO,2017-04-03 19:33:00 +0000,http://finance.yahoo.com/r/813e6d0a-7d33-30e6-8a78-d9a0faf3a7f7/bristol-myers-may-be-hedging-on-io-1491248030?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Guggenheim Securities Bristol-Myers Squibb and Incyte announced plans to initiate Phase 3 registrational trials with Incyte’s IDO inhibitor, epacadostat, and Bristol-Myers’ Opdivo (anti-PD-1) in first-line ..."
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: HPE, INCY",2017-04-03 16:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i8dUN1yZamY/sp-500-movers-hpe-incy-cm769087,In early trading on Monday shares of Incyte topped the list of the day s best performing components of the S amp P 500 index trading up 4 8 Year to date Incyte registers a 39 7 gain And the worst performing S amp P 500 component thus far on the day is Hewlett Packard
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: ORLY, TSLA",2017-04-03 16:38:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qTl35eYokPA/nasdaq-100-movers-orly-tsla-cm769082,In early trading on Monday shares of Tesla topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 8 Year to date Tesla registers a 36 5 gain And the worst performing Nasdaq 100 component thus far on the day is O Reilly Automotive trading
INCY,INCY:UW,BBG000BNQ132,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 13:38:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/72iKZWmPenc/4-fda-decisions-to-watch-out-for-in-apr-2017-cm768879,The FDA which approved 22 treatments last year has given its approval to 12 drugs so far in 2017 including 7 in March Key approvals this year include Roche s RHHBY multiple sclerosis treatment Ocrevus Regeneron REGN and Sanofi s eczema treatment Dupixent Tesaro s TSRO PARP
INCY,INCY:UW,BBG000BNQ132,Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals,2017-04-03 11:42:00 +0000,http://finance.yahoo.com/r/d1b2bb2d-6d1c-3b8a-b13a-88a4607a670b/incyte-cancer-immunotherapy-drug-is-object-of-desire-for-two-big-pharma-rivals.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.
INCY,INCY:UW,BBG000BNQ132,Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals,2017-04-03 11:42:00 +0000,https://www.thestreet.com/story/14069527/1/incyte-cancer-immunotherapy-drug-is-object-of-desire-for-two-big-pharma-rivals.html?puc=yahoo&cm_ven=YAHOO,Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals
INCY,INCY:UW,BBG000BNQ132,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html,4 FDA Decisions to Watch Out for in Apr 2017
INCY,INCY:UW,BBG000BNQ132,4 FDA Decisions to Watch Out for in Apr 2017,2017-04-03 11:41:11 +0000,http://finance.yahoo.com/news/4-fda-decisions-watch-apr-114111333.html?.tsrc=rss,"Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month."
INCY,INCY:UW,BBG000BNQ132,3:09 am Bristol-Myers and Incyte agree to advance clinical development program initiate Phase 3 registrational trials with Opdivo and PD-1 immune checkpoint inhibitor,2017-04-03 07:09:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#incy,3:09 am Bristol-Myers and Incyte agree to advance clinical development program initiate Phase 3 registrational trials with Opdivo and PD-1 immune checkpoint inhibitor
INCY,INCY:UW,BBG000BNQ132,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise",2017-04-03 00:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5jI90mHkdz0/setback-for-acor-in-ampyra-suit-ears-put-on-notice-stdy-on-steady-rise-20170403-00002,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise"
INCY,INCY:UW,BBG000BNQ132,4 Drug Stocks With Big News Coming in April,2017-04-02 17:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2_bq9BTaeoA/4-drug-stocks-with-big-news-coming-in-april-cm768806,Fill in the blank April brings Some might say that April brings April showers Others eyeing the calendar with dread might say that April brings tax day But for four drugmakers April brings big news that could be catalysts for their stocks Here s what s coming up this month
INCY,INCY:UW,BBG000BNQ132,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,http://finance.yahoo.com/r/706729f1-72a5-3e3c-a956-8d7dbde1451c/4-drug-stocks-with-big-news-coming-in-april.aspx?yptr=yahoo&.tsrc=rss,"Major FDA decisions are on the way this month for Neurocrine, Incyte, Lilly, and BioMarin."
INCY,INCY:UW,BBG000BNQ132,4 Drug Stocks With Big News Coming in April,2017-04-02 15:41:00 +0000,https://www.fool.com/investing/2017/04/02/4-drug-stocks-with-big-news-coming-in-april.aspx,4 Drug Stocks With Big News Coming in April
INCY,INCY:UW,BBG000BNQ132,3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest,2017-04-02 13:36:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xMTfLAR3uI4/3-big-healthcare-stocks-that-wall-street-predicts-will-grow-the-fastest-cm768773,Rapid earnings growth typically translates to higher stock prices But can big healthcare stocks grow earnings and presumably share prices at impressive levels 160 Wall Street thinks so Analysts ranked Vertex Pharmaceuticals NASDAQ VRTX Incyte NASDAQ INCY
INCY,INCY:UW,BBG000BNQ132,3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest,2017-04-02 11:41:00 +0000,https://www.fool.com/investing/2017/04/02/3-big-healthcare-stocks-that-wall-street-predicts.aspx,3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest
INCY,INCY:UW,BBG000BNQ132,3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest,2017-04-02 11:41:00 +0000,http://finance.yahoo.com/r/9ff0e68c-2cbc-3615-91f1-ef72b98e3e44/3-big-healthcare-stocks-that-wall-street-predicts.aspx?yptr=yahoo&.tsrc=rss,"Vertex Pharmaceuticals, Incyte, and Celgene could be headed for tremendous growth if Wall Street's projections are on target."
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials,2017-04-02 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-incyte-advance-105900259.html?.tsrc=rss,"Bristol-Myers Squibb Company and Incyte Corporation today announced the companies have agreed to advance their clinical development program evaluating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Opdivo , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, into phase 3 registrational studies in first-line non-small cell lung cancer across ..."
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials,2017-04-02 10:59:00 +0000,http://finance.yahoo.com/news/bristol-myers-squibb-incyte-advance-105900259.html,"[Business Wire] - Bristol-Myers Squibb Company and Incyte Corporation today announced the companies have agreed to advance their clinical development program evaluating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Opdivo , Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, into phase 3 registrational studies in first-line non-small cell lung cancer across ..."
INCY,INCY:UW,BBG000BNQ132,The 5 Best Performing S&P 500 Stocks for Q1,2017-04-01 13:15:03 +0000,http://finance.yahoo.com/news/5-best-performing-p-500-131503996.html,The 5 Best Performing S&P 500 Stocks for Q1
INCY,INCY:UW,BBG000BNQ132,Here Are Some of the Top Health Care Stocks in the First Quarter,2017-04-01 00:30:00 +0000,http://finance.yahoo.com/r/7d21793f-8b25-3fbd-bd51-a4e2b0b3f386/here-are-some-of-the-top-healthcare-stocks-in-the-first-quarter.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Illumina, Centene, Community Health, Incyte and Vertex were among the healthcare stocks that did well in the first quarter."
INCY,INCY:UW,BBG000BNQ132,Here Are Some of the Top Health Care Stocks in the First Quarter,2017-04-01 00:30:00 +0000,https://www.thestreet.com/story/14068306/1/here-are-some-of-the-top-healthcare-stocks-in-the-first-quarter.html?puc=yahoo&cm_ven=YAHOO,Here Are Some of the Top Health Care Stocks in the First Quarter
INCY,INCY:UW,BBG000BNQ132,The Biggest Loser: Incyte Tumbles 3%,2017-03-31 21:56:00 +0000,http://finance.yahoo.com/r/d6910a7f-99d0-32ca-8ea5-b200482def61/the-biggest-loser-incyte-tumbles-3?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Incyte dropped 3% to $133.67 today, while the S&P 500 declined 0.2% to 2,362.72.  The drop, however, didn't prevent Incyte from becoming one of the 10-best performing stocks in the S&P 500 this quarter.  Merck ticked up 0.1% to $63.54."
INCY,INCY:UW,BBG000BNQ132,The Biggest Loser: Incyte Tumbles 3%,2017-03-31 21:56:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/31/the-biggest-loser-incyte-tumbles-3/?mod=yahoobarrons&ru=yahoo,The Biggest Loser: Incyte Tumbles 3%
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,911.74 down -2.60 points",2017-03-31 20:48:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGlxoLyssYw/market-close-report-nasdaq-composite-index-closes-at-591174-down-260-points-cm768554,Friday s session closes with the NASDAQ Composite Index at 5 911 74 The total shares traded for the NASDAQ was over 2 18 billion Friday s session closes with the NASDAQ Composite Index at 5 911 74 The total shares traded for the NASDAQ was over 2 18 billion Advancers stocks led declining by 1
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Laggards: Healthcare, Services",2017-03-31 19:59:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-W3EKNcLK5U/friday-sector-laggards-healthcare-services-cm768514,In afternoon trading on Friday Healthcare stocks are the worst performing sector showing a 0 3 loss Within that group Incyte Corporation Symbol INCY and Bristol Myers Squibb Co Symbol BMY are two large stocks that are lagging showing a loss of 3 0 and 2 1 respectively
INCY,INCY:UW,BBG000BNQ132,"Merck, Incyte Expand Cancer Collaboration",2017-03-31 16:48:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/31/merck-incyte-expand-cancer-collaboration/?mod=yahoobarrons&ru=yahoo,"Merck, Incyte Expand Cancer Collaboration"
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals",2017-03-31 16:03:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hRxzb_TwcXU/zackscom-featured-highlights-ptc-covanta-holding-etsy-incyte-and-amag-pharmaceuticals-cm768345,For Immediate Release Chicago IL March 31 2017 Stocks in this week s article include 160 PTC Inc NASDAQ PTC Free Report Covanta Holding Corporation NYSE CVA Free Report Etsy Inc NASDAQ ETSY Free Report Incyte Corporation NASDAQ INCY Free
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals",2017-03-31 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-ptc-133001834.html,"Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals"
INCY,INCY:UW,BBG000BNQ132,Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab),2017-03-31 11:00:00 +0000,http://finance.yahoo.com/news/incyte-merck-additional-details-previously-110000450.html,"[Business Wire] - Incyte Corporation and Merck , known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® , Merck’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer , bladder ..."
INCY,INCY:UW,BBG000BNQ132,"Incyte, Merck Give Further Details On Epacadostat - KEYTRUDA Clinical Program",2017-03-31 07:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLJPBLLk2Kk/incyte-merck-give-further-details-on-epacadostat--keytruda-clinical-program-20170331-00324,"Incyte, Merck Give Further Details On Epacadostat - KEYTRUDA Clinical Program"
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Get Rid Of or Play Short to Make Gains,2017-03-30 16:01:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vjqdfRvRZyg/5-toxic-stocks-to-get-rid-of-or-play-short-to-make-gains-cm767715,Accurate identification of overpriced stocks and correctly priced stocks is the key to investing success But this is a tough task as the overhyped stocks and the fairly priced stocks are intermingled in the market place in a very deceptive way Investors who can spot the over bubble toxic
INCY,INCY:UW,BBG000BNQ132,"VO, FISV, APH, INCY: Large Inflows Detected at ETF",2017-03-30 15:58:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U_E7grkIq-8/vo-fisv-aph-incy-large-inflows-detected-at-etf-cm767721,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Mid Cap ETF Symbol VO where we have detected an approximate 59 8 million dollar inflow that s a 0 3 increase week over week in outstanding units
INCY,INCY:UW,BBG000BNQ132,Strange: Bullish INCY Analysts Actually See -6.01% Downside,2017-03-30 14:09:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aYR8vZOam7E/strange-bullish-incy-analysts-actually-see-601-downside-cm767606,Analyst ratings can sometimes be complicated and we here at ETF Channel have noticed a bit of a paradox with Incyte Corporation Symbol INCY The average 12 month price target for INCY averaging the work of 12 analysts reveals an average price target of 130 92 share That s a
INCY,INCY:UW,BBG000BNQ132,"The Best-Case Scenario for Gilead Sciences, Inc.",2017-03-24 14:02:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hl7Zh9FwYjM/the-best-case-scenario-for-gilead-sciences-inc-cm765134,Throw in the towel Cry uncle Give up Gilead Sciences NASDAQ GILD is toast Really With revenue and earnings falling the sentiment about Gilead is largely negative these days However the biotech s future might be brighter than some think Here s a best case scenario
INCY,INCY:UW,BBG000BNQ132,"The Best-Case Scenario for Gilead Sciences, Inc.",2017-03-24 12:04:00 +0000,https://www.fool.com/investing/2017/03/24/the-best-case-scenario-for-gilead-sciences-inc.aspx,"The Best-Case Scenario for Gilead Sciences, Inc."
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks Facing FDA Decision In April,2017-03-24 06:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/70ZD2H6sCX8/biotech-stocks-facing-fda-decision-in-april-20170324-00160,Biotech Stocks Facing FDA Decision In April
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,817.69 down -3.95 points",2017-03-23 20:48:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p1lhyzpD5xY/market-close-report-nasdaq-composite-index-closes-at-581769-down-395-points-cm764907,Thursday s session closes with the NASDAQ Composite Index at 5 817 69 The total shares traded for the NASDAQ was over 1 73 billion Thursday s session closes with the NASDAQ Composite Index at 5 817 69 The total shares traded for the NASDAQ was over 1 73 billion Advancers stocks led declining
INCY,INCY:UW,BBG000BNQ132,"Thursday Sector Laggards: Healthcare, Energy",2017-03-23 19:58:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x1AIeZA5y-k/thursday-sector-laggards-healthcare-energy-cm764871,The worst performing sector as of midday Thursday is the Healthcare sector higher by 0 1 Within that group Centene Corp Symbol CNC and Incyte Corporation Symbol INCY are two of the day s laggards showing a loss of 4 0 and 0 8 respectively Among healthcare ETFs one ETF
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,793.83 down -107.70 points",2017-03-21 20:48:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_lAv_Ajgqa4/market-close-report-nasdaq-composite-index-closes-at-579383-down-10770-points-cm763793,Tuesday s session closes with the NASDAQ Composite Index at 5 793 83 The total shares traded for the NASDAQ was over 2 23 billion Declining stocks led advancers by 5 15 to 1 ratio There were 478 advancers and 2461 decliners for the day On the NASDAQ Stock Exchange 19 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: CSX, MAR",2017-03-21 16:08:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F9J0dLNkM7Y/nasdaq-100-movers-csx-mar-cm763461,In early trading on Tuesday shares of Marriott International MAR topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 0 Year to date Marriott International registers a 9 4 gain And the worst performing Nasdaq 100 component thus far on
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal,2017-03-20 16:45:13 +0000,http://www.investors.com/news/technology/bristol-myers-partner-rockets-to-18-month-high-on-immuno-oncology-deal/?src=A00220A,Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
INCY,INCY:UW,BBG000BNQ132,Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs,2017-03-17 18:06:00 +0000,http://www.forbes.com/sites/kenkam/2017/03/17/take-advantage-of-donald-trumps-tweets-to-buy-top-biotechs/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Take Advantage Of Donald Trump's Tweets To Buy Top Biotechs
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?,2017-03-17 13:09:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3ndF7mqAH7s/incyte-incy-up-262-since-earnings-report-can-it-continue-cm762039,A month has gone by since the last earnings report for Incyte Corporation INCY Shares have added about 26 2 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before we dive
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?,2017-03-17 11:15:11 +0000,http://finance.yahoo.com/news/incyte-incy-26-2-since-111511557.html,Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?
INCY,INCY:UW,BBG000BNQ132,"Noteworthy ETF Outflows: IBB, BIIB, REGN, INCY",2017-03-16 16:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sOzP9EyINyQ/noteworthy-etf-outflows-ibb-biib-regn-incy-cm761661,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 45 1 million dollar outflow that s a 0 5 decrease week over week
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data",2017-03-16 15:10:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F2CbTLWVnAI/biotech-stock-roundup-amgens-data-on-repatha-catalyst-soars-on-firdapse-data-cm761602,The biotech sector reacted favorably to President Donald Trump s selection of Dr Scott Gottlieb to head the FDA His nomination is being viewed as a positive with expectations that the drug approval process will be streamlined during his tenure Recap of the Week s Most Important
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Covanta Holding,  Etsy, PTC, Incyte and Vertex Pharmaceuticals",2017-03-16 15:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dttIvgMFOtE/zackscom-featured-highlights-covanta-holding-etsy-ptc-incyte-and-vertex-pharmaceuticals-cm761720,For Immediate Release Chicago IL March 16 2017 Stocks in this week s article include Covanta Holding Corporation NYSE CVA Free Report Etsy Inc NASDAQ ETSY Free Report PTC Inc NASDAQ PTC Free Report Incyte Corporation NASDAQ INCY
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals",2017-03-16 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-covanta-133001813.html,"Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals"
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data",2017-03-16 12:46:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-amgens-data-124612953.html,"Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data"
INCY,INCY:UW,BBG000BNQ132,Merck Could Be Nearing This Rival With Another Keytruda Approval,2017-03-15 20:25:08 +0000,http://www.investors.com/news/technology/merck-could-be-nearing-this-rival-with-another-keytruda-approval/?src=A00220A,Merck Could Be Nearing This Rival With Another Keytruda Approval
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dump or Play Short to Make Gains,2017-03-15 16:09:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vG9wgFU41aU/5-toxic-stocks-to-dump-or-play-short-to-make-gains-cm761111,One of the important aspects of successful investing is the accurate identification of overpriced and fairly priced stocks However it is not easy to distinguish between overvalued stocks and the correctly priced ones as they are all intermingled in the marketplace Investors who can identify
INCY,INCY:UW,BBG000BNQ132,"After Soaring to $150, Can Incyte Stir Up More Upside?",2017-03-15 15:35:00 +0000,https://www.thestreet.com/story/14043639/1/after-soaring-to-150-can-incyte-stir-up-more-upside.html?puc=yahoo&cm_ven=YAHOO,"After Soaring to $150, Can Incyte Stir Up More Upside?"
INCY,INCY:UW,BBG000BNQ132,3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't,2017-03-15 14:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s39ylCHeaTg/3-reasons-why-gilead-sciences-will-buy-incyte-and-1-reason-why-it-wont-cm760950,Gilead Sciences NASDAQ GILD CEO John Milligan made the audience laugh at the Barclays healthcare conference on Tuesday Barclays analyst Geoff Meacham referenced a letter he had sent to Gilead s management team urging the company to take steps to increase its valuation
INCY,INCY:UW,BBG000BNQ132,"Wait, Gilead Might Actually Hit Its 1st Quarter Numbers?!?!",2017-03-15 13:54:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/15/wait-gilead-might-actually-hit-its-1st-quarter-numbers/?mod=yahoobarrons&ru=yahoo,"Wait, Gilead Might Actually Hit Its 1st Quarter Numbers?!?!"
INCY,INCY:UW,BBG000BNQ132,3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't,2017-03-15 12:03:00 +0000,http://www.fool.com/investing/2017/03/15/3-reasons-why-gilead-sciences-will-buy-incyte-and.aspx,3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't
INCY,INCY:UW,BBG000BNQ132,Gilead Looking To Buy Incyte? It Makes Sense,2017-03-14 14:55:29 +0000,http://finance.yahoo.com/news/gilead-looking-buy-incyte-makes-145529751.html,Gilead Looking To Buy Incyte? It Makes Sense
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of Mar.13: ALIM, AEMD, VSTM, ARLZ, OSIR...",2017-03-13 22:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PeYsLLm3RJw/gainers--losers-of-mar13-alim-aemd-vstm-arlz-osir-20170313-01297,"Gainers & Losers Of Mar.13: ALIM, AEMD, VSTM, ARLZ, OSIR..."
INCY,INCY:UW,BBG000BNQ132,Incyte Spikes To Record High On Rumors Gilead Could Acquire It,2017-03-13 20:48:27 +0000,http://www.investors.com/news/technology/incyte-spikes-to-record-high-on-rumors-gilead-could-acquire-it/?src=A00220A,Incyte Spikes To Record High On Rumors Gilead Could Acquire It
INCY,INCY:UW,BBG000BNQ132,Is Incyte For Sale?,2017-03-13 19:42:00 +0000,http://www.investopedia.com/news/incyte-sale-incy-gild/?partner=YahooSA,Is Incyte For Sale?
INCY,INCY:UW,BBG000BNQ132,"S&P 500 Movers: TSCO, DLPH",2017-03-13 16:07:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4PL3sxgpfc/sp-500-movers-tsco-dlph-cm759970,In early trading on Monday shares of Delphi Automotive DLPH topped the list of the day s best performing components of the S amp P 500 index trading up 3 4 Year to date Delphi Automotive registers a 18 4 gain And the worst performing S amp P 500 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences: Is an Incyte Deal 'Reasonable'?,2017-03-13 14:22:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/13/gilead-sciences-is-an-incyte-deal-reasonable/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Is an Incyte Deal 'Reasonable'?
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation Stock Rises on Price Target Increase,2017-03-13 12:17:00 +0000,https://www.thestreet.com/story/14039474/1/incyte-corporation-stock-rises-on-pt-increase.html?puc=yahoo&cm_ven=YAHOO,Incyte Corporation Stock Rises on Price Target Increase
INCY,INCY:UW,BBG000BNQ132,"NASDAQ Composite Index closes up 1.26 points for the week, rising for the 3rd straight day",2017-03-11 00:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o0hcKuOx7ms/nasdaq-composite-index-closes-up-126-points-for-the-week-rising-for-the-3rd-straight-day-cm759310,Friday s session closes with the NASDAQ Composite Index 22 92 This is the 3rd straight day of increase for the index The total shares traded for the NASDAQ was over 2 33 billion Friday s session closes with the NASDAQ Composite Index 22 92 This is the 3rd straight day of increase for the
INCY,INCY:UW,BBG000BNQ132,The Hot Stock: Incyte Soars 8.1% on Gilead Takeover Speculation,2017-03-10 22:01:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/10/the-hot-stock-incyte-soars-8-1-on-gilead-takeover-speculation/?mod=yahoobarrons&ru=yahoo,The Hot Stock: Incyte Soars 8.1% on Gilead Takeover Speculation
INCY,INCY:UW,BBG000BNQ132,Incyte Pops on Continued Gilead Takeout Speculation,2017-03-10 21:30:00 +0000,https://www.thestreet.com/story/14037636/1/incyte-pops-on-continued-gilead-takeout-speculation.html?puc=yahoo&cm_ven=YAHOO,Incyte Pops on Continued Gilead Takeout Speculation
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K/A, Financial Statements and Exhibits",2017-03-10 21:05:20 +0000,http://biz.yahoo.com/e/170310/incy8-k_a.html,"INCYTE CORP Files SEC form 8-K/A, Financial Statements and Exhibits"
INCY,INCY:UW,BBG000BNQ132,Dear Gilead: Buy Something — Anything — Analyst Pleads,2017-03-10 19:13:16 +0000,http://www.investors.com/news/technology/dear-gilead-buy-something-anything-pleads-barclays-analyst/?src=A00220A,Dear Gilead: Buy Something — Anything — Analyst Pleads
INCY,INCY:UW,BBG000BNQ132,Analyst Pleads With Gilead To Buy — And It May Have Worked,2017-03-10 19:13:16 +0000,http://www.investors.com/news/technology/dear-gilead-buy-something-anything-pleads-barclays-analyst-branch/?src=A00220A,Analyst Pleads With Gilead To Buy — And It May Have Worked
INCY,INCY:UW,BBG000BNQ132,How Gilead Is Paying The Price For Actually Curing A Disease,2017-03-10 16:46:23 +0000,http://www.investors.com/news/technology/can-gilead-withstand-hep-c-boom-and-bust-or-will-merck-abbvie-win/?src=A00220A,How Gilead Is Paying The Price For Actually Curing A Disease
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4,2017-03-10 15:12:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KAjukKJ8K8g/agenus-agen-reports-narrower-than-expected-loss-in-q4-cm759239,Agenus Inc AGEN reported fourth quarter 2016 loss of 30 cents per share including non cash expenses narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year ago loss of 18 cents Moreover revenues declined 27 year over year to 5 5 million slightly
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4,2017-03-10 14:21:02 +0000,http://finance.yahoo.com/news/agenus-agen-reports-narrower-expected-142102754.html,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
INCY,INCY:UW,BBG000BNQ132,Incyte Likely to Incite Further Gains,2017-03-10 13:43:00 +0000,http://realmoney.thestreet.com/articles/03/10/2017/incyte-likely-incite-further-gains?puc=yahoo&cm_ven=YAHOO,Incyte Likely to Incite Further Gains
INCY,INCY:UW,BBG000BNQ132,How Incyte Stock Became a Bull Market Star for Biotech Investors,2017-03-10 12:51:12 +0000,http://finance.yahoo.com/news/incyte-stock-became-bull-market-125112909.html,How Incyte Stock Became a Bull Market Star for Biotech Investors
INCY,INCY:UW,BBG000BNQ132,"A Trip to 8-Year Bull Run: What's Up, What's Down",2017-03-10 01:12:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zhunUURrB50/a-trip-to-8-year-bull-run-whats-up-whats-down-cm758939,After endless woes the U S stock market revived over the last eight years and how While all the three major indices S amp P 500 Dow Jones Industrial Average and Nasdaq more than tripled scaling multiple highs in recent months Nasdaq has won the maximum in the eight year bull
INCY,INCY:UW,BBG000BNQ132,The S&P's 10 best performers since Great Recession,2017-03-10 00:36:00 +0000,http://finance.yahoo.com/video/ps-10-best-performers-since-003600531.html,The S&P's 10 best performers since Great Recession
INCY,INCY:UW,BBG000BNQ132,Cramer’s 10 best S&P performers since the Great Recession,2017-03-09 23:38:00 +0000,http://finance.yahoo.com/video/cramer-10-best-p-performers-233800599.html,Cramer’s 10 best S&P performers since the Great Recession
INCY,INCY:UW,BBG000BNQ132,Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy,2017-03-09 21:31:17 +0000,http://www.investors.com/news/technology/momo-price-target-hiked-amgen-started-at-neutral-mercury-a-buy/?src=A00220A,Momo Dives Despite Price Target Hike; UBS Initiates Biotechs; Mercury Is A Buy
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know,2017-03-09 18:15:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/huU1zW3f1yo/incyte-corporation-at-the-cowen-healthcare-conference-4-things-youll-want-to-know-cm758651,Few biotechs have enjoyed as fun a ride as Incyte Corporation NASDAQ INCY in recent years The stock has soared more than 700 since early 2012 thanks primarily to tremendous success for cancer drug Jakafi Incyte s chief medical officer Steven Stein and chief financial
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know,2017-03-09 16:41:00 +0000,http://www.fool.com/investing/2017/03/09/incyte-corporation-at-the-cowen-healthcare-confere.aspx,Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know
INCY,INCY:UW,BBG000BNQ132,Coverage initiated on Incyte by UBS,2017-03-09 14:59:36 +0000,http://finance.yahoo.com/q/ud?s=INCY,Coverage initiated on Incyte by UBS
INCY,INCY:UW,BBG000BNQ132,5 Top Stocks to Buy as Bull Market Turns Eight,2017-03-09 14:23:02 +0000,http://finance.yahoo.com/news/5-top-stocks-buy-bull-142302081.html,5 Top Stocks to Buy as Bull Market Turns Eight
INCY,INCY:UW,BBG000BNQ132,"10 best, 10 worst stocks in the eight-year bull market",2017-03-09 13:21:52 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=BB3BD792-0335-11E7-918D-62B4A59FE2AC&siteid=yhoof2,"10 best, 10 worst stocks in the eight-year bull market"
INCY,INCY:UW,BBG000BNQ132,"Wednesday Sector Leaders: Services, Healthcare",2017-03-08 21:12:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mSZ6smGOYrI/wednesday-sector-leaders-services-healthcare-cm758104,Looking at the sectors faring best as of midday Wednesday shares of Services companies are outperforming other sectors up 0 8 Within that group H amp R Block Inc Symbol HRB and Macy s Inc Symbol M are two large stocks leading the way showing a gain of 16 1 and 3 4
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At Cowen Health Care Conference; Webcast At 10:00 AM ET,2017-03-08 08:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9SWIaHzuTvw/incyte-to-present-at-cowen-health-care-conference-webcast-at-1000-am-et-20170308-00594,Incyte To Present At Cowen Health Care Conference; Webcast At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Race Tightens for Next Wave of Cancer Drugs,2017-03-08 05:32:06 +0000,https://www.wsj.com/articles/race-tightens-for-next-wave-of-cancer-drugs-1488796210?ru=yahoo?mod=yahoo_itp,Race Tightens for Next Wave of Cancer Drugs
INCY,INCY:UW,BBG000BNQ132,These stocks are outrunning the bull market with quadruple-digit gains,2017-03-07 16:21:17 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E1E98B40-0278-11E7-AF0E-6FD7C0D42EFF&siteid=yhoof2,These stocks are outrunning the bull market with quadruple-digit gains
INCY,INCY:UW,BBG000BNQ132,Race Tightens for Next Wave of Cancer Drugs,2017-03-06 17:23:06 +0000,https://www.wsj.com/articles/race-tightens-for-next-wave-of-cancer-drugs-1488796210?mod=yahoo_hs,Race Tightens for Next Wave of Cancer Drugs
INCY,INCY:UW,BBG000BNQ132,"Friday Sector Leaders: Healthcare, Financial",2017-03-03 21:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PL7fg-aKDqo/friday-sector-leaders-healthcare-financial-cm756154,In afternoon trading on Friday Healthcare stocks are the best performing sector up 0 2 Within that group Incyte Corporation Symbol INCY and Envision Healthcare Corp Symbol EVHC are two large stocks leading the way showing a gain of 2 8 and 2 1 respectively Among healthcare
INCY,INCY:UW,BBG000BNQ132,Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017,2017-03-02 12:30:00 +0000,http://finance.yahoo.com/news/incyte-targeted-therapy-immuno-oncology-123000668.html,"[Business Wire] - Incyte Corporation announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research annual meeting in Washington, D.C."
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of Mar.1: DVAX, SKLN, FOLD, IPXL, QASM...",2017-03-01 22:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y9kCsjH6u6c/gainers--losers-of-mar1-dvax-skln-fold-ipxl-qasm-20170301-01997,"Gainers & Losers Of Mar.1: DVAX, SKLN, FOLD, IPXL, QASM..."
INCY,INCY:UW,BBG000BNQ132,Who Is Incyte Collaborating With?,2017-03-01 15:36:44 +0000,http://marketrealist.com/2017/02/who-is-incyte-collaborating-with/?utm_source=yahoo&utm_medium=feed,Who Is Incyte Collaborating With?
INCY,INCY:UW,BBG000BNQ132,A Look at Incyte’s Product Portfolio,2017-03-01 14:06:38 +0000,http://marketrealist.com/2017/02/a-look-at-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,A Look at Incyte’s Product Portfolio
INCY,INCY:UW,BBG000BNQ132,Performance of Incyte’s Jakafi in the United States,2017-03-01 12:37:25 +0000,http://marketrealist.com/2017/02/performance-of-incytes-jakafi-in-the-united-states/?utm_source=yahoo&utm_medium=feed,Performance of Incyte’s Jakafi in the United States
INCY,INCY:UW,BBG000BNQ132,"VXF, TSLA, LBTYA, INCY: ETF Inflow Alert",2017-02-28 19:50:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K17x458Qddk/vxf-tsla-lbtya-incy-etf-inflow-alert-cm754374,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Extended Market ETF Symbol VXF where we have detected an approximate 223 3 million dollar inflow that s a 4 8 increase week over week in
INCY,INCY:UW,BBG000BNQ132,Understanding Incyte’s Revenue Stream for 2016,2017-02-28 19:35:43 +0000,http://marketrealist.com/2017/02/understanding-incytes-revenue-stream-for-2016/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream for 2016
INCY,INCY:UW,BBG000BNQ132,Incyte’s Revenue Trend for 2016,2017-02-28 18:06:32 +0000,http://marketrealist.com/2017/02/incytes-revenue-trend-for-2016/?utm_source=yahoo&utm_medium=feed,Incyte’s Revenue Trend for 2016
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte",2017-02-28 16:52:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ehBoq5T4Y4/zackscom-featured-highlights-abercrombie-fitch-live-nation-entertainment-vertex-pharmaceuticals-etsy-and-incyte-cm754238,For Immediate Release Chicago IL February 28 2017 Stocks in this week s article include 160 Abercrombie amp Fitch Co NYSE ANF Free Report Live Nation Entertainment Inc NYSE LYV Free Report Vertex Pharmaceuticals Inc NASDAQ VRTX Free
INCY,INCY:UW,BBG000BNQ132,Incyte’s Valuation Compared to Its Peers,2017-02-28 16:22:46 +0000,http://marketrealist.com/2017/02/incytes-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Incyte’s Valuation Compared to Its Peers
INCY,INCY:UW,BBG000BNQ132,Will Alexion’s Research Make Gains in the Inhibitor Space?,2017-02-28 15:36:43 +0000,http://marketrealist.com/2017/02/alexion-pharmaceuticals-continues-advance-research-programs-complement-inhibitor-space/?utm_source=yahoo&utm_medium=feed,Will Alexion’s Research Make Gains in the Inhibitor Space?
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte",2017-02-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-abercrombie-143002354.html,"Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte"
INCY,INCY:UW,BBG000BNQ132,Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017,2017-02-28 14:00:00 +0000,http://finance.yahoo.com/news/incyte-raises-awareness-myeloproliferative-neoplasms-140000237.html,"[Business Wire] - Incyte Corporation joins the National Organization for Rare Disorders , the European Organization for Rare Diseases and other rare disease health organizations and advocates in recognizing Rare Disease Day 2017."
INCY,INCY:UW,BBG000BNQ132,"After Hours Most Active for Feb 27, 2017 :  ENB, INCY, MENT, PG, SWN, ORCL, HUN, XRX, YHOO, CSCO, QVCA, TLT",2017-02-27 21:59:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a9EAthQ6xiE/after-hours-most-active-for-feb-27-2017-enb-incy-ment-pg-swn-orcl-hun-xrx-yhoo-csco-qvca-tlt-cm753856,The NASDAQ 100 After Hours Indicator is up 31 to 5 347 86 The total After hours volume is currently 61 084 668 shares traded The following are the most active stocks for the after hours session Enbridge Inc ENB is 0 2 at 41 79 with 23 519 944 shares traded ENB
INCY,INCY:UW,BBG000BNQ132,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team",2017-02-27 21:34:10 +0000,http://www.investors.com/news/technology/exelixis-rockets-on-bristol-roche-i-o-ties-following-merck-incyte-team/,"Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team"
INCY,INCY:UW,BBG000BNQ132,"Delaware biopharm company moves to S&P 500, inks alliance with Penn",2017-02-27 14:00:12 +0000,http://www.bizjournals.com/philadelphia/news/2017/02/27/incyte-biopharma-cancer-immunocology-sp500-trading.html?ana=yahoo,"Delaware biopharm company moves to S&P 500, inks alliance with Penn"
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Abandon or Play Short Right Now,2017-02-27 13:50:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KHEMJEkiKaQ/5-toxic-stocks-to-abandon-or-play-short-right-now-cm753398,Making a proper distinction between fairly priced stocks and overpriced stocks is the key to investing success However the correctly priced and the overhyped toxic stocks are mingled in such a way in the marketplace that it is not easy to separate them Investors who can figure out the
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Abandon or Play Short Right Now,2017-02-27 11:33:11 +0000,http://finance.yahoo.com/news/5-toxic-stocks-abandon-play-113311800.html,5 Toxic Stocks to Abandon or Play Short Right Now
INCY,INCY:UW,BBG000BNQ132,Here's Why Incyte Rose as Much as 8% Today,2017-02-24 22:50:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ofm7CQxD_JE/heres-why-incyte-rose-as-much-as-8-today-cm753098,What happened Shares of oncology biopharma Incyte NASDAQ INCY rose 8 today after it was announced that the stock will be joining the S amp P 500 replacing Spectra Energy which is leaving the index after its acquisition by Enbridge closes next week 160 Of course
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,845.31 up 9.80 points",2017-02-24 21:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mp8diaRxrcg/market-close-report-nasdaq-composite-index-closes-at-584531-up-980-points-cm753070,Friday s session closes with the NASDAQ Composite Index at 5 845 31 The total shares traded for the NASDAQ was over 1 8 billion Declining stocks led advancers by 1 17 to 1 ratio There were 1336 advancers and 1557 decliners for the day On the NASDAQ Stock Exchange 66 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Pharma company Incyte is moving to the S&P 500, and the stock is rallying",2017-02-24 21:37:52 +0000,http://www.cnbc.com/id/104303475?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104303475,"Pharma company Incyte is moving to the S&P 500, and the stock is rallying"
INCY,INCY:UW,BBG000BNQ132,Here's Why Incyte Rose as Much as 8% Today,2017-02-24 20:44:48 +0000,http://www.fool.com/investing/2017/02/24/heres-why-incyte-rose-as-much-as-8-today.aspx,Here's Why Incyte Rose as Much as 8% Today
INCY,INCY:UW,BBG000BNQ132,Vertex Expects Modest Revenue Growth in This,2017-02-24 19:06:02 +0000,http://marketrealist.com/2017/02/vertex-pharmaceuticals-expects-modest-revenue-growth-orkambi-2017/?utm_source=yahoo&utm_medium=feed,Vertex Expects Modest Revenue Growth in This
INCY,INCY:UW,BBG000BNQ132,Better Buy: Juno Therapeutics vs. Incyte,2017-02-24 17:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EW9J4rjmgwU/better-buy-juno-therapeutics-vs-incyte-cm752887,A major fiasco made 2016 a tough year to be a Juno Therapeutics NASDAQ JUNO shareholder Shares of the clinical stage biotech have fallen about 32 over the past 12 months In contrast its well established industry peer Incyte NASDAQ INCY can boast a string of
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: BIDU, INCY",2017-02-24 16:52:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rj1V0ni4DHA/nasdaq-100-movers-bidu-incy-cm752803,In early trading on Friday shares of Incyte Corporation INCY topped the list of the day s best performing components of the Nasdaq 100 index trading up 6 7 Year to date Incyte Corporation registers a 29 8 gain And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,Better Buy: Juno Therapeutics vs. Incyte,2017-02-24 15:46:20 +0000,http://www.fool.com/investing/2017/02/24/better-buy-juno-therapeutics-vs-incyte.aspx,Better Buy: Juno Therapeutics vs. Incyte
INCY,INCY:UW,BBG000BNQ132,"Incyte, University of Pennsylvania In Cancer Deal",2017-02-24 14:45:00 +0000,http://www.investopedia.com/news/incyte-and-upenn-ink-cancer-research-deal-incy/?partner=YahooSA,"Incyte, University of Pennsylvania In Cancer Deal"
INCY,INCY:UW,BBG000BNQ132,Biotech Movers: Cempra Flys High On Phase Three Results,2017-02-24 14:38:00 +0000,https://www.thestreet.com/story/14015290/1/biotech-movers-cempra-flys-high-on-phase-three-results.html?puc=yahoo&cm_ven=YAHOO,Biotech Movers: Cempra Flys High On Phase Three Results
INCY,INCY:UW,BBG000BNQ132,Incyte Corp. (INCY) Has Jumped To A New High After Added To S&P 500,2017-02-24 09:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6OFFU6gg5Pg/incyte-corp-incy-has-jumped-to-a-new-high-after-added-to-sp-500-20170224-00632,Incyte Corp. (INCY) Has Jumped To A New High After Added To S&P 500
INCY,INCY:UW,BBG000BNQ132,"Incyte, CBOE Holdings, Regency Centers Set to Join S&P 500; Others to Join S&P MidCap 400",2017-02-23 22:57:00 +0000,http://finance.yahoo.com/news/incyte-cboe-holdings-regency-centers-225700806.html,"[PR Newswire] - NEW YORK, Feb. 23, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500 and S&P MidCap 400: Incyte Corp. (NASD: INCY) will replace Spectra Energy Corp. (NYSE: SE) in ..."
INCY,INCY:UW,BBG000BNQ132,"Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences",2017-02-23 18:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E8Pl3fl32Tg/andreas-halvorsen-buys-maker-of-first-in-class-cancer-treatments-calithera-biosciences-cm752251,Andreas Halvorsen Trades Portfolio CALA INCY KITE TSRO BIIB Andreas Halvorsen Premium Members This article first appeared on GuruFocus This article first appeared
INCY,INCY:UW,BBG000BNQ132,Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania,2017-02-23 12:58:00 +0000,http://finance.yahoo.com/news/incyte-announces-oncology-research-alliance-125800530.html,"[Business Wire] - Incyte Corporation today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug discovery and development scientists to conduct collaborative research aimed at advancing the understanding of cancer biology and fostering ..."
INCY,INCY:UW,BBG000BNQ132,Troubling Trial Data Weighed on Agenus Inc Stock Today,2017-02-22 22:49:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HgXG2tZy59Y/troubling-trial-data-weighed-on-agenus-inc-stock-today-cm751656,What happened Shares of Agenus Inc NASDAQ AGEN a biopharmaceutical company developing cancer therapies had fallen about 14 5 as of 3 20 p m EST on Wednesday Investors weren t too thrilled about its cancer vaccine s recent clinical trial failure So what The
INCY,INCY:UW,BBG000BNQ132,"Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences",2017-02-22 22:36:47 +0000,http://finance.yahoo.com/news/andreas-halvorsen-buys-maker-first-223647385.html,"Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences"
INCY,INCY:UW,BBG000BNQ132,Lexington's Agenus quietly discloses failure of cancer vaccine trial,2017-02-22 15:00:12 +0000,http://www.bizjournals.com/boston/news/2017/02/22/lexingtons-agenus-quietly-discloses-failure-of.html?ana=yahoo,Lexington's Agenus quietly discloses failure of cancer vaccine trial
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2017-02-21 13:00:00 +0000,http://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-130000949.html,[Business Wire] - Incyte Corporation announced today that it will present at the following investor conferences during the month of March:
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, F",2017-02-21 12:01:47 +0000,http://biz.yahoo.com/e/170221/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, F"
INCY,INCY:UW,BBG000BNQ132,INCYTE CORP Financials,2017-02-18 18:04:09 +0000,http://finance.yahoo.com/q/is?s=incy,INCYTE CORP Financials
INCY,INCY:UW,BBG000BNQ132,"Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market",2017-02-18 00:41:35 +0000,http://www.investors.com/news/technology/merck-bristol-myers-incyte-race-toward-a-cure-in-25-billion-i-o-market/,"Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market"
INCY,INCY:UW,BBG000BNQ132,"NetEase Delivers Nice Option Win; Mobileye, Tesla, InterDigital On Deck",2017-02-17 23:10:02 +0000,http://www.investors.com/research/earnings-preview/netease-delivers-nice-option-win-mobileye-tesla-interdigital-on-deck/,"NetEase Delivers Nice Option Win; Mobileye, Tesla, InterDigital On Deck"
INCY,INCY:UW,BBG000BNQ132,What's Driving Lilly's (LLY) Shares after 2016 Decline?,2017-02-16 16:57:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EmzsWHW3tFw/whats-driving-lillys-lly-shares-after-2016-decline-cm748996,After a rather difficult 2016 share price of pharma giant Eli Lilly amp Company LLY has picked up in 2017 What Hurt Shares in 2016 In 2016 Lilly s shares were hurt due to soft earnings and some negative pipeline updates including the failure of its high profile
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017",2017-02-16 16:57:28 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-incy-us-earnings-analysis-2016-by-the-numbers-february-16-2017/,"Incyte Corp. :INCY-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017"
INCY,INCY:UW,BBG000BNQ132,Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo,2017-02-15 22:56:00 +0000,http://finance.yahoo.com/news/additional-results-pivotal-ra-beam-225600408.html,"[PR Newswire] - INDIANAPOLIS, Feb. 15, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of ..."
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,819.44.",2017-02-15 21:49:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wtlY_uvWYZI/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-581944-cm748587,Wednesday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 5 819 44 up 36 87 for the day The index first reached the 5000 mark on 02 14 2017 The total shares traded for the NASDAQ was over 2 33 billion Wednesday s session closes with the
INCY,INCY:UW,BBG000BNQ132,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook",2017-02-15 20:54:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r1et009E-30/incytes-incy-beats-on-q4-earnings-provides-2017-outlook-cm748510,Incyte Corporation INCY reported fourth quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents Incyte had reported earnings of 29 cents per share in the year ago quarter Quarterly revenues came in at 326 5 million up 33 9 year over year and beat the Zacks
INCY,INCY:UW,BBG000BNQ132,"Softness in Incyte Should Be Short-Lived, if Our Quants Are Right",2017-02-15 19:45:00 +0000,http://realmoney.thestreet.com/articles/02/15/2017/softness-incyte-should-be-short-lived-if-our-quants-are-right?puc=yahoo&cm_ven=YAHOO,"Softness in Incyte Should Be Short-Lived, if Our Quants Are Right"
INCY,INCY:UW,BBG000BNQ132,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook",2017-02-15 19:00:07 +0000,http://finance.yahoo.com/news/incytes-incy-beats-q4-earnings-190007821.html,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, SIRI",2017-02-15 16:55:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xIAqzw6z5-Y/nasdaq-100-movers-incy-siri-cm748318,In early trading on Wednesday shares of Sirius XM Holdings topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 2 Year to date Sirius XM Holdings registers a 8 9 gain And the worst performing Nasdaq 100 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,Banks Loved Yellen's Testimony,2017-02-15 15:57:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UH0xoepgHvY/banks-loved-yellens-testimony-cm748039,Bank stocks really loved what Janet Yellen had to say on this Valentine s Day The Fed Chair said the plan is to gradually increase rates over time or run the risk of having to play catch up down the line with much sharper hikes Banks would be among the biggest beneficiaries of higher rates
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017",2017-02-15 14:52:01 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-incy-us-earnings-analysis-q4-2016-by-the-numbers-february-15-2017/,"Incyte Corp. :INCY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017"
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data",2017-02-15 14:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w_c5VRf-ydo/biotech-stock-roundup-regenerons-praluent-to-remain-on-market-for-now-gild-presents-hiv-data-cm748087,Regeneron REGN got a bit of a boost with the company and its partner being allowed to continue marketing their PCSK9 inhibitor Praluent pending their appeal in a patent infringement lawsuit Meanwhile Gilead GILD which saw its shares being punished for a not so rosy outlook for
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data",2017-02-15 12:04:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-regenerons-praluent-120412057.html,"Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data"
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State",2017-02-14 22:06:59 +0000,http://biz.yahoo.com/e/170214/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State"
INCY,INCY:UW,BBG000BNQ132,"Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss",2017-02-14 21:12:19 +0000,http://www.investors.com/news/technology/incyte-q4-revenue-tops-views-though-jakafi-sales-narrowly-miss/,"Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss"
INCY,INCY:UW,BBG000BNQ132,"Health Care Sector Update for 02/14/2017: INCY,AGEN,CYNO,HOLX,AVIR",2017-02-14 19:18:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/os8n4UF4Rjc/health-care-sector-update-for-02142017-incyagencynoholxavir-cm747820,Top Health Care StocksTop Health Care Stocks JNJ 0 08 JNJ 0 08 PFE 0 15 PFE 0 15 MRK 0 51 MRK 0 51 ABT 1 10 ABT 1 10 AMGN 0 37 AMGN 0 37 Health care stocks were adding to narrow gains from earlier in Tuesday trading with the NYSE Health Care Index this afternoon adding about 0 4
INCY,INCY:UW,BBG000BNQ132,Incyte 4Q Earnings $9 Million or 5 Cents a Share,2017-02-14 17:55:00 +0000,http://www.investopedia.com/news/incyte-4q-net-9-million-or-5-cents-share-incy/?partner=YahooSA,Incyte 4Q Earnings $9 Million or 5 Cents a Share
INCY,INCY:UW,BBG000BNQ132,Why Agenus Stock Is Surging Today,2017-02-14 17:19:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4PAEbEuEnkI/why-agenus-stock-is-surging-today-cm747672,What happened As of 10 30 a m EST shares of the clinical stage biotech Agenus NASDAQ AGEN were up by more than 15 This double digit move northward was triggered by the news that Incyte NASDAQ INCY and Agenus have amended their immuno oncology licensing deal 160 from
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: LOGM, INCY",2017-02-14 17:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DNwy66h5hSg/nasdaq-100-movers-logm-incy-cm747691,In early trading on Tuesday shares of Incyte INCY topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 6 Year to date Incyte registers a 23 9 gain And the worst performing Nasdaq 100 component thus far on the day is LogMeIn
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 14-Feb-17 3:00pm GMT,2017-02-14 17:07:57 +0000,http://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-170757343.html,Edited Transcript of INCY earnings conference call or presentation 14-Feb-17 3:00pm GMT
INCY,INCY:UW,BBG000BNQ132,"​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash",2017-02-14 16:45:08 +0000,http://www.bizjournals.com/boston/news/2017/02/14/lexington-based-agenus-reworks-incyte-pact.html?ana=yahoo,"​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash"
INCY,INCY:UW,BBG000BNQ132,Incyte and Agenus Amend Drug Licensing Deal,2017-02-14 16:35:00 +0000,http://www.investopedia.com/news/incyte-agenus-amend-licensing-deal-incy-agen/?partner=YahooSA,Incyte and Agenus Amend Drug Licensing Deal
INCY,INCY:UW,BBG000BNQ132,"Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss",2017-02-14 16:29:19 +0000,http://www.investors.com/news/technology/incyte-head/,"Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss"
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences",2017-02-14 16:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XArl_odGSIs/the-zacks-analyst-blog-highlights-incyte-prothena-acorda-therapeutics-and-axovant-sciences-cm747612,For Immediate Release Chicago IL February 14 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
INCY,INCY:UW,BBG000BNQ132,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 16:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u1obRM1WQA/lillys-olumiant-gets-marketing-authorization-in-europe-cm747595,Eli Lilly and Company LLY along with its partner Incyte Corporation INCY announced that the European Commission has granted marketing authorization to once daily baricitinib in Europe for the treatment of adults with moderate to severe active rheumatoid arthritis RA 160 The drug will
INCY,INCY:UW,BBG000BNQ132,Why Agenus Stock Is Surging Today,2017-02-14 16:01:42 +0000,http://www.fool.com/investing/2017/02/14/why-agenus-stock-is-surging-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Agenus Stock Is Surging Today
INCY,INCY:UW,BBG000BNQ132,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 14:32:02 +0000,http://finance.yahoo.com/news/lillys-olumiant-gets-marketing-authorization-143202479.html,Lilly's Olumiant Gets Marketing Authorization in Europe
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences",2017-02-14 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-incyte-143002620.html,"The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences"
INCY,INCY:UW,BBG000BNQ132,Incyte tops Street 4Q forecasts,2017-02-14 12:18:33 +0000,http://sg.finance.yahoo.com/news/incyte-tops-street-4q-forecasts-121833263.html,Incyte tops Street 4Q forecasts
INCY,INCY:UW,BBG000BNQ132,Q4 2016 Incyte Corp Earnings Release - 07:00 am ET,2017-02-14 12:07:02 +0000,http://biz.yahoo.com/research/earncal/20170214.html?t=incy,Q4 2016 Incyte Corp Earnings Release - 07:00 am ET
INCY,INCY:UW,BBG000BNQ132,Incyte and Agenus Amend Collaboration Agreement,2017-02-14 12:00:00 +0000,http://finance.yahoo.com/news/incyte-agenus-amend-collaboration-agreement-120000924.html,"[Business Wire] - Incyte Corporation and Agenus Inc. announced today that the companies have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015."
INCY,INCY:UW,BBG000BNQ132,"Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs",2017-02-14 12:00:00 +0000,http://finance.yahoo.com/news/incyte-reports-2016-fourth-quarter-120000742.html,"[Business Wire] - Incyte Corporation today reports 2016 fourth-quarter and year-end financial results, highlighting strong revenue growth driven by increased sales of Jakafi® in the U.S."
INCY,INCY:UW,BBG000BNQ132,5 Things You Must Know Before the Market Opens Tuesday,2017-02-14 11:46:00 +0000,https://www.thestreet.com/story/13999125/1/5-things-you-must-know-before-the-market-opens-tuesday.html?puc=yahoo&cm_ven=YAHOO,5 Things You Must Know Before the Market Opens Tuesday
INCY,INCY:UW,BBG000BNQ132,Incyte Q4 16 Earnings Conference Call At 10:00 AM ET,2017-02-14 09:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GL2h9leWs7A/incyte-q4-16-earnings-conference-call-at-1000-am-et-20170214-00768,Incyte Q4 16 Earnings Conference Call At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation Bottom Line Falls 84% In Q4,2017-02-14 07:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/10oBWX_mgG8/incyte-corporation-bottom-line-falls-84-in-q4-20170214-00369,Incyte Corporation Bottom Line Falls 84% In Q4
INCY,INCY:UW,BBG000BNQ132,European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis,2017-02-13 21:21:00 +0000,http://finance.yahoo.com/news/european-commission-approves-once-daily-212100120.html,[CNW Group] - European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
INCY,INCY:UW,BBG000BNQ132,"Pre-Market Earnings Report for February 14, 2017 :  TMUS, INCY, Q, TAP, DPS, NBL, MLM, BRX, DISCK, TRU, IPGP, LECO",2017-02-13 21:17:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E8cYRrVQcp4/pre-market-earnings-report-for-february-14-2017-tmus-incy-q-tap-dps-nbl-mlm-brx-disck-tru-ipgp-leco-cm747280,The following companies are expected to report earnings prior to market open on 02 14 2017 Visit our Earnings Calendar for a full list of expected earnings releases T Mobile US Inc TMUS is reporting for the quarter ending December 31 2016 The
INCY,INCY:UW,BBG000BNQ132,"Fed's Yellen, Diamondback, Devon, Incyte: Investing Action Plan",2017-02-13 21:17:32 +0000,http://www.investors.com/news/feds-yellen-diamondback-devon-incyte-investing-action-plan/,"Fed's Yellen, Diamondback, Devon, Incyte: Investing Action Plan"
INCY,INCY:UW,BBG000BNQ132,Is Gilead Sciences Getting Ready for a Massive Acquisition?,2017-02-13 17:14:11 +0000,http://www.fool.com/investing/2017/02/12/is-gilead-sciences-getting-ready-for-a-massive-acq.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Gilead Sciences Getting Ready for a Massive Acquisition?
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies",2017-02-13 16:22:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zOSw2zXkxII/zackscom-featured-highlights-ets-incyte-abercrombie-fitch-vertex-pharmaceuticals-and-bottomline-technologies-cm746998,For Immediate Release Chicago IL February 13 2017 Stocks in this week s article include Etsy Inc NASDAQ ETSY Free Report Incyte Corporation NASDAQ INCY Free Report Abercrombie amp Fitch Co NYSE ANF Free
INCY,INCY:UW,BBG000BNQ132,What's in Store for Avis Budget (CAR) this Earnings Season?,2017-02-13 16:21:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tBqEOz-pd7k/whats-in-store-for-avis-budget-car-this-earnings-season-cm746959,Leading global car rental company Avis Budget Group Inc CAR is scheduled to report fourth quarter 2016 results after market closes on Feb 15 Last quarter the company reported a positive surprise of 5 56 Avis Budget has missed earnings estimates twice by a huge margin in the last
INCY,INCY:UW,BBG000BNQ132,Should You Sell Incyte (INCY) Before Earnings?,2017-02-13 15:22:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9AlW3mTGHe8/should-you-sell-incyte-incy-before-earnings-cm747056,Investors are always looking for stocks that are poised to beat at earnings season and Incyte Corporation INCY may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Incyteis seeing favorable
INCY,INCY:UW,BBG000BNQ132,VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?,2017-02-13 15:21:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gHJuCSNkOHA/vasco-vdsi-q4-earnings-whats-in-store-for-the-stock-cm747049,Leading security software firm 160 VASCO Data Security International Inc VDSI is set to report fourth quarter 2016 results after market close on Feb 14 VASCO has a solid earnings surprise history beating estimates in three of the last four quarters with a positive average earnings
INCY,INCY:UW,BBG000BNQ132,Top 5 Earnings to Look For on Tuesday,2017-02-13 14:45:45 +0000,http://finance.yahoo.com/news/top-5-earnings-look-tuesday-144545191.html,Top 5 Earnings to Look For on Tuesday
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies",2017-02-13 14:30:02 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-ets-143002708.html,"Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies"
INCY,INCY:UW,BBG000BNQ132,"Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More",2017-02-13 14:19:02 +0000,http://finance.yahoo.com/news/drug-stocks-earnings-slated-feb-141902186.html,"Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More"
INCY,INCY:UW,BBG000BNQ132,Should You Sell Incyte (INCY) Before Earnings?,2017-02-13 13:45:01 +0000,http://finance.yahoo.com/news/sell-incyte-incy-earnings-134501556.html,Should You Sell Incyte (INCY) Before Earnings?
INCY,INCY:UW,BBG000BNQ132,Is Gilead Sciences Getting Ready for a Massive Acquisition?,2017-02-12 18:17:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_rarwiDRtLg/is-gilead-sciences-getting-ready-for-a-massive-acquisition-cm746773,Gilead Sciences NASDAQ GILD reported enough bad news on Tuesday to inspire a blues song Falling revenue Sinking earnings Horrible outlook for this year Perhaps the big biotech needs to develop an antidepressant just to give to its shareholders On the other hand
INCY,INCY:UW,BBG000BNQ132,Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?,2017-02-11 00:17:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eAgKcVoxXHE/will-zoetis-zts-disappoint-estimates-this-earnings-season-cm746604,Zoetis Inc ZTS is scheduled to report fourth quarter and full year 2016 results on Feb 16 before the market opens The company has consistently beaten earnings expectations In fact Zoetis earnings surpassed expectations in each of the last four quarters with an average positive surprise
INCY,INCY:UW,BBG000BNQ132,Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?,2017-02-11 00:17:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IWb60icUy9A/alexion-alxn-q4-earnings-can-the-stock-pull-a-surprise-cm746602,Alexion Pharmaceuticals Inc ALXN is scheduled to report fourth quarter 2016 results on Feb 16 before the opening bell The company s track record has been mixed While over the last four quarters the company has beaten estimates on two occasions Alexion posted an average positive
INCY,INCY:UW,BBG000BNQ132,4 Stocks Under $4 That Could Double,2017-02-09 17:20:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MDU-yL7EHJs/4-stocks-under-4-that-could-double-cm745554,It s just like the old idiom says Good things come in small packages Stocks with a very low share price usually 5 and under are often cast aside by investors as being far too risky In some instances investment firms and hedge funds will refrain from buying or owning stock in
INCY,INCY:UW,BBG000BNQ132,Strange: Bullish INCY Analysts Actually See -3.72% Downside,2017-02-09 15:18:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/16P1w7aduoQ/strange-bullish-incy-analysts-actually-see-372-downside-cm745381,Analyst ratings can sometimes be complicated and we here at ETF Channel have noticed a bit of a paradox with Incyte Corporation Symbol INCY The average 12 month price target for INCY averaging the work of 12 analysts reveals an average price target of 118 17 share That s a
INCY,INCY:UW,BBG000BNQ132,5 Drug Stocks Poised to Beat Earnings Estimates in Q4,2017-02-09 14:20:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R733SkOwjzs/5-drug-stocks-poised-to-beat-earnings-estimates-in-q4-cm745419,A positive earnings picture continues to emerge from the fourth quarter earnings season with both earnings and revenue growth improving compared to recent quarters As of Feb 8 319 S amp P 500 members or 76 3 of the index s total market capitalization had reported results the numbers show
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dump or Play Short for Gains,2017-02-09 14:19:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K5ddafma94U/5-toxic-stocks-to-dump-or-play-short-for-gains-cm745407,Precise identification of overpriced stocks and rightly priced stocks holds the key to successful investing However it is not easy to do so as the correctly priced stocks and the bubble stocks are deceptively intermixed in the market place Investors who can figure out the overpriced toxic
INCY,INCY:UW,BBG000BNQ132,5 Drug Stocks Poised to Beat Earnings Estimates in Q4,2017-02-09 12:39:12 +0000,http://finance.yahoo.com/news/5-drug-stocks-poised-beat-123912751.html,5 Drug Stocks Poised to Beat Earnings Estimates in Q4
INCY,INCY:UW,BBG000BNQ132,Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?,2017-02-08 23:17:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aQZZXhHJNMA/regeneron-regn-q4-earnings-will-the-stock-disappoint-cm745200,Regeneron Pharmaceuticals Inc REGN is scheduled to release fourth quarter 2016 results on Feb 9 before the opening bell The company s performance has been mixed so far In the last four reported quarters it has surpassed earnings estimates on three occasions and missed the same
INCY,INCY:UW,BBG000BNQ132,Can Prothena (PRTA) Pull a Surprise This Earnings Season?,2017-02-08 23:16:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aaxUnIyFFdQ/can-prothena-prta-pull-a-surprise-this-earnings-season-cm745195,Prothena Corporation plc PRTA is scheduled to report fourth quarter 2016 results on Feb 14 after the market closes Prothena s share price has increased 61 7 in the past one year while the Zacks classified Medical Biomedical and Genetics industry declined 0 4 Last
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?,2017-02-03 17:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_CRTfEMY6Mk/gilead-sciences-gild-q4-earnings-whats-in-the-cards-cm742948,Gilead Sciences Inc GILD is scheduled to report fourth quarter 2016 results on Feb 7 after the market closes Last quarter the company missed expectations by 1 46 Gilead s track record is mixed with the company beating estimates in two of the last four trailing and missing in
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of The Day: BNTC, PULM, CALA, STML, CORI...",2017-02-02 22:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OQ6eU72GgFM/gainers--losers-of-the-day-bntc-pulm-cala-stml-cori-20170202-01821,"Gainers & Losers Of The Day: BNTC, PULM, CALA, STML, CORI..."
INCY,INCY:UW,BBG000BNQ132,GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?,2017-02-02 17:36:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AxTezlDeVkw/gw-pharmaceuticals-gwph-q1-earnings-whats-in-store-cm742352,GW Pharmaceuticals plc GWPH is scheduled to report first quarter fiscal 2017 results on Feb 7 before the opening bell The company has an impressive track record so far In fact in the four trailing quarters GW Pharma has surpassed estimates every time with an average positive surprise
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data",2017-02-02 11:27:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-celgene-biogen-112711812.html,"Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data"
INCY,INCY:UW,BBG000BNQ132,Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?,2017-02-01 21:30:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BlJhQrVQ56E/mallinckrodt-mnk-earnings-this-quarter-stock-to-disappoint-cm741800,Mallinckrodt plc MNK is set to report results for the quarter ended Dec 30 2016 on Feb 7 We note that this quarter is a transition quarter for the company In May 2016 Mallinckrodt announced that its board of directors has approved a change in the company s fiscal year end to the last
INCY,INCY:UW,BBG000BNQ132,Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys,2017-02-01 17:33:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SsTqLg6e0PY/forget-anavex-life-sciences-corp-these-2-biotech-stocks-are-better-buys-cm741643,Investors are right to focus on potential Alzheimer s disease drugs because of the huge market but Anavex Life Sciences Corp NASDAQ AVXL is an awfully long way from from the finish line with its lead candidate Clinical stage biotech stocks are inherently risky but I d like to
INCY,INCY:UW,BBG000BNQ132,"Stocks Battle Back, Trim Losses; Apple Beats",2017-01-31 21:22:53 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-battle-back-trim-losses-apple-to-report/,"Stocks Battle Back, Trim Losses; Apple Beats"
INCY,INCY:UW,BBG000BNQ132,Calithera Biosciences Inc (CALA): What You Need To Know,2017-01-31 18:30:52 +0000,http://www.insidermonkey.com/blog/calithera-biosciences-inc-cala-what-you-need-to-know-529414/,Calithera Biosciences Inc (CALA): What You Need To Know
INCY,INCY:UW,BBG000BNQ132,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 16:34:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TY1o_SUpnAw/incyte-and-calithera-enter-into-deal-for-oncology-candidate-cm740811,Incyte Corporation INCY and Calithera Biosciences Inc CALA entered into a global collaboration and license agreement for research development and commercialization of the latter s arginase inhibitor candidate CB 1158 in the fields of hematology
INCY,INCY:UW,BBG000BNQ132,Incyte Pays $53M for Calithera’s Oncology Drug,2017-01-31 16:26:00 +0000,http://www.investopedia.com/news/incyte-pays-53m-calithera-cancer-drug-incy-cala/?partner=YahooSA,Incyte Pays $53M for Calithera’s Oncology Drug
INCY,INCY:UW,BBG000BNQ132,Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%,2017-01-31 15:36:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ci7qS0Tm98E/calithera-biosciences-cala-in-focus-stock-jumps-467-cm740757,Calithera Biosciences Inc CALA was a big mover last session as its shares rose almost 47 on the day The move came after the company reported a global collaboration and licensing agreement with Incyte Corp INCY This led to far more shares changing hands than in a normal session
INCY,INCY:UW,BBG000BNQ132,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 14:55:02 +0000,http://finance.yahoo.com/news/incyte-calithera-enter-deal-oncology-145502787.html,Incyte and Calithera Enter into Deal for Oncology Candidate
INCY,INCY:UW,BBG000BNQ132,Better Buy: Inovio Pharmaceuticals vs. Incyte Corp.,2017-01-31 11:13:19 +0000,http://www.fool.com/investing/2017/01/30/better-buy-inovio-pharmaceuticals-vs-incyte-corp.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Inovio Pharmaceuticals vs. Incyte Corp.
INCY,INCY:UW,BBG000BNQ132,Close Update: Immigration Ban Unnerves Wall Street; Travel Stocks Pummeled,2017-01-30 22:11:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7NKuLv9_890/close-update-immigration-ban-unnerves-wall-street-travel-stocks-pummeled-cm740498,The major averages all closed significantly lower Monday after the fallout from a ban on immigrants from seven Middle East countries triggered widespread protests and spooked risk averse investors who fear a backlash on U S companies The major averages all closed significantly lower Monday
INCY,INCY:UW,BBG000BNQ132,"Gainers & Losers Of The Day: CALA, EVOK, EYEG, OCRX, TENX...",2017-01-30 21:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HbRYS0jPzc8/gainers--losers-of-the-day-cala-evok-eyeg-ocrx-tenx-20170130-01445,"Gainers & Losers Of The Day: CALA, EVOK, EYEG, OCRX, TENX..."
INCY,INCY:UW,BBG000BNQ132,"I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink",2017-01-30 21:32:30 +0000,http://www.investors.com/news/technology/i-o-players-incyte-roche-squeeze-arrays-melanoma-market-leerink/,"I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink"
INCY,INCY:UW,BBG000BNQ132,"Health Care Sector Update for 01/30/2017: RGLS,CALA,INCY",2017-01-30 21:31:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xXY8MOICDVo/health-care-sector-update-for-01302017-rglscalaincy-cm740465,Top Health Care StocksTop Health Care Stocks JNJ 0 25 JNJ 0 25 PFE 0 35 PFE 0 35 MRK 0 20 MRK 0 20 ABT 0 50 ABT 0 50 AMGN 1 78 AMGN 1 78 Health care stocks were moderately lower late Monday with the NYSE Health Care Index dropping about 0 5 while shares of health care companies
INCY,INCY:UW,BBG000BNQ132,Mid-Afternoon Market Update: Tempur Sealy Drops After Loss Of Mattress Firm Contract; Digital Ally Shares Surge,2017-01-30 20:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fkoSn6ulCIY/mid-afternoon-market-update-tempur-sealy-drops-after-loss-of-mattress-firm-contract-digital-ally-shares-surge-cm740461,Toward the end of trading Monday the Dow traded down 0 92 percent to 19 908 26 while the NASDAQ declined 1 08 percent to 5 599 68 The S amp P also fell dropping 0 96 percent to 2 272 76 Leading and Lagging Sectors Non cyclical consumer goods amp services shares slipped by
INCY,INCY:UW,BBG000BNQ132,Midday Update: Outcry Surrounding Travel Ban Spooks Investors,2017-01-30 18:32:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/daNSEiZEYp0/midday-update-outcry-surrounding-travel-ban-spooks-investors-cm740369,Stocks were sharply lower Monday as the fallout from President Trump s travel ban on individuals from a handful of countries in the Middle East unnerved investors and upstaged upbeat consumer spending and pending home sales data Stocks were sharply lower Monday as the fallout from President Trump
INCY,INCY:UW,BBG000BNQ132,Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher,2017-01-30 18:21:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d86mMgbHv2Q/mid-day-market-update-dow-falls-over-150-points-calithera-biosciences-shares-spike-higher-cm740370,Midway through trading Monday the Dow traded down 0 80 percent to 19 933 85 while the NASDAQ declined 1 06 percent to 5 600 80 The S amp P also fell dropping 0 87 percent to 2 274 72 Leading and Lagging Sectors Non cyclical consumer goods amp services shares slipped by just 0
INCY,INCY:UW,BBG000BNQ132,"Health Care Sector Update for 01/30/2017: JNJ, PFE, ABT, MRK, AMGN, OCRX, CALA, EYEG",2017-01-30 17:33:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Xz4hRsvs9s/health-care-sector-update-for-01302017-jnj-pfe-abt-mrk-amgn-ocrx-cala-eyeg-cm740298,Top Health Care stocks Top Health Care stocks JNJ 0 3 JNJ 0 3 PFE 0 7 PFE 0 7 ABT 0 1 ABT 0 1 MRK 1 MRK 1 AMGN 1 7 AMGN 1 7 Health care shares were lower at mid day Monday Health care shares were lower at mid day Monday In health care stocks news Calithera
INCY,INCY:UW,BBG000BNQ132,$53M deal: Incyte acquires rights to experimental cancer therapy,2017-01-30 16:45:06 +0000,http://www.bizjournals.com/philadelphia/news/2017/01/30/icyte-calithera-biosciences-pharma-cancer-experime.html?ana=yahoo,$53M deal: Incyte acquires rights to experimental cancer therapy
INCY,INCY:UW,BBG000BNQ132,Better Buy: Inovio Pharmaceuticals vs. Incyte Corp.,2017-01-30 16:35:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0XpjB-3xp1U/better-buy-inovio-pharmaceuticals-vs-incyte-corp-cm740185,At one point last year shares of DNA based vaccine specialist Inovio Pharmaceuticals NASDAQ INO had more than doubled but development problems cut the biotech stock s gains back to about 26 5 over the past year Over the same period shares of Incyte Corp NASDAQ INCY
INCY,INCY:UW,BBG000BNQ132,Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates,2017-01-30 16:21:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2G-ou4-VKcM/mid-morning-market-update-markets-open-lower-booz-allen-profit-misses-estimates-cm740194,Following the market opening Monday the Dow traded down 0 64 percent to 19 964 84 while the NASDAQ declined 1 18 percent to 5 594 25 The S amp P also fell dropping 0 79 percent to 2 276 45 Leading and Lagging Sectors Utilities shares slipped by just 0 1 percent in trading
INCY,INCY:UW,BBG000BNQ132,Why This Collaboration Is So Important for Calithera,2017-01-30 15:50:18 +0000,http://finance.yahoo.com/news/why-collaboration-important-calithera-155018672.html,Why This Collaboration Is So Important for Calithera
INCY,INCY:UW,BBG000BNQ132,Blog Coverage Aurinia Chooses Worldwide Clinical Trials as CRO for AURORA Phase-3 Study of Voclosporin,2017-01-30 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-aurinia-chooses-worldwide-131500087.html,"[Accesswire] - Upcoming AWS Coverage on Incyte Post-Earnings Results LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. blog coverage looks at the headline from Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) ..."
INCY,INCY:UW,BBG000BNQ132,"Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor",2017-01-30 11:45:00 +0000,http://finance.yahoo.com/news/incyte-calithera-biosciences-announce-global-114500291.html,[GlobeNewswire] - Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund ...
INCY,INCY:UW,BBG000BNQ132,Incyte And Calithera Collaborate To Develop And Commercialize CB-1158,2017-01-30 06:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kNhm_Ljjv_4/incyte-and-calithera-collaborate-to-develop-and-commercialize-cb1158-20170130-00239,Incyte And Calithera Collaborate To Develop And Commercialize CB-1158
INCY,INCY:UW,BBG000BNQ132,"Will Merck Let Incyte Go After AstraZeneca, Bristol, Roche Team-Ups Too?",2017-01-27 21:37:43 +0000,http://www.investors.com/news/technology/will-merck-let-incyte-go-after-astrazeneca-bristol-roche-team-ups-too/,"Will Merck Let Incyte Go After AstraZeneca, Bristol, Roche Team-Ups Too?"
INCY,INCY:UW,BBG000BNQ132,What Recent Developments Could Drive Eli Lilly’s Growth?,2017-01-27 15:36:00 +0000,http://marketrealist.com/2017/01/what-recent-developments-could-drive-eli-lillys-growth/?utm_source=yahoo&utm_medium=feed,What Recent Developments Could Drive Eli Lilly’s Growth?
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Live Nation Entertainment, Conns, ConocoPhillips, Etsy and Incyte",2017-01-26 16:35:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bCaF5a1ah80/zackscom-featured-highlights-live-nation-entertainment-conns-conocophillips-etsy-and-incyte-cm738703,For Immediate Release Chicago IL January 26 2017 Stocks in this week s article include Live Nation Entertainment Inc NYSE LYV Free Report Conns Inc NASDAQ CONN Free Report ConocoPhillips NYSE COP Free
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Live Nation Entertainment, Conns, ConocoPhillips, Etsy and Incyte",2017-01-26 14:30:02 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-live-143002053.html,"Zacks.com featured highlights: Live Nation Entertainment, Conns, ConocoPhillips, Etsy and Incyte"
INCY,INCY:UW,BBG000BNQ132,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company,2017-01-26 14:13:16 +0000,http://www.fool.com/investing/2017/01/25/forget-incyte-gilead-sciences-would-be-better-off.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company
INCY,INCY:UW,BBG000BNQ132,Incyte Gets $112 Million Boost On Novartis Jakavi Royalties: RBC,2017-01-25 21:21:25 +0000,http://www.investors.com/news/technology/incyte-gets-112-million-boost-on-novartis-jakavi-royalties-rbc/,Incyte Gets $112 Million Boost On Novartis Jakavi Royalties: RBC
INCY,INCY:UW,BBG000BNQ132,Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company,2017-01-25 15:32:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d7pH8_vl71c/forget-incyte-gilead-sciences-would-be-better-off-buying-this-company-cm737858,Image source Getty Images After successfully commercializing what became the world s most successful drug by annual sales numbers Gilead Sciences NASDAQ GILD has been forced to live with endless investor anxiety What will it do with all of that cash generated from its
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dump or Play Short Now,2017-01-25 13:32:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q7fiJ1F_leM/5-toxic-stocks-to-dump-or-play-short-now-cm737819,Distinguishing between overpriced stocks and fairly priced stocks is the key to successful investing But the task is not easy as the correctly priced and the overvalued stocks are mingled in a very deceptive way in the marketplace However investors who can pinpoint the overhyped toxic stocks
INCY,INCY:UW,BBG000BNQ132,5 Toxic Stocks to Dump or Play Short Now,2017-01-25 12:28:12 +0000,http://finance.yahoo.com/news/5-toxic-stocks-dump-play-122812686.html,5 Toxic Stocks to Dump or Play Short Now
INCY,INCY:UW,BBG000BNQ132,"J&J HCV Dips To 'Virtually Zero,' Mirroring Gilead; 2017 Views Lag",2017-01-24 21:36:13 +0000,http://www.investors.com/news/technology/johnson-hcv-dips-to-virtually-zero-mirroring-gilead-2017-views-lag/,"J&J HCV Dips To 'Virtually Zero,' Mirroring Gilead; 2017 Views Lag"
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Fourth Quarter and Year-End Financial Results,2017-01-24 13:00:00 +0000,http://finance.yahoo.com/news/incyte-report-fourth-quarter-end-130000693.html,"[Business Wire] - Incyte Corporation announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017."
INCY,INCY:UW,BBG000BNQ132,Incyte Has Insight Into Market With Potential Blockbuster Drugs,2017-01-23 22:31:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aNJsNL6Dqnc/incyte-has-insight-into-market-with-potential-blockbuster-drugs-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
INCY,INCY:UW,BBG000BNQ132,Incyte Has Insight Into Market With Potential Blockbuster Drugs,2017-01-23 21:20:07 +0000,http://www.investors.com/research/the-new-america/incyte-poised-to-outperform-biotech-industry-on-strong-pipeline/,Incyte Has Insight Into Market With Potential Blockbuster Drugs
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Other Events",2017-01-23 21:10:00 +0000,http://biz.yahoo.com/e/170123/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Other Events"
INCY,INCY:UW,BBG000BNQ132,Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies,2017-01-23 21:06:02 +0000,http://finance.yahoo.com/news/merus-announces-closing-global-strategic-210602034.html,"[GlobeNewswire] - UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the ..."
INCY,INCY:UW,BBG000BNQ132,"We’re in the year of the biotech buyout, and here are five prime targets",2017-01-23 20:21:48 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=017E3E92-E0DC-11E6-A68E-C10141C44E92&siteid=yhoof2,"We’re in the year of the biotech buyout, and here are five prime targets"
INCY,INCY:UW,BBG000BNQ132,Incyte Poised To Outperform Biotech Industry On Strong Pipeline,2017-01-20 22:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y-pPosM2-7s/incyte-poised-to-outperform-biotech-industry-on-strong-pipeline-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: CSX, SWKS",2017-01-20 16:39:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VIOzG2G9Pds/nasdaq-100-movers-csx-swks-cm735991,In early trading on Friday shares of Skyworks Solutions SWKS topped the list of the day s best performing components of the Nasdaq 100 index trading up 12 4 Year to date Skyworks Solutions registers a 18 1 gain And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,"Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017",2017-01-20 12:00:47 +0000,http://www.investors.com/news/technology/biotech-stocks-might-catalyze-or-plunge-on-4-key-sectors-in-2017/,"Biotech Stocks Might Catalyze, Or Plunge, On 4 Key Sectors In 2017"
INCY,INCY:UW,BBG000BNQ132,Incyte Corp. (INCY) Has Broken Out To A New High For The Year,2017-01-20 09:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZZ9ijW5gW-g/incyte-corp-incy-has-broken-out-to-a-new-high-for-the-year-20170120-00493,Incyte Corp. (INCY) Has Broken Out To A New High For The Year
INCY,INCY:UW,BBG000BNQ132,"Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst",2017-01-19 21:41:07 +0000,http://www.investors.com/news/technology/gilead-merck-alexion-2017-views-hazy-biogen-likely-to-surge-analyst/,"Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst"
INCY,INCY:UW,BBG000BNQ132,Leading Stocks That Are Driving A Hot Mutual Fund's Rally,2017-01-19 16:22:38 +0000,http://www.investors.com/etfs-and-funds/mutual-funds/leading-stocks-that-are-driving-a-hot-mutual-funds-rally/,Leading Stocks That Are Driving A Hot Mutual Fund's Rally
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, DLTR",2017-01-17 16:37:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-RfoOdvBjnY/nasdaq-100-movers-incy-dltr-cm734201,In early trading on Tuesday shares of Dollar Tree DLTR topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 6 Year to date Dollar Tree registers a 3 6 gain And the worst performing Nasdaq 100 component thus far on the day is Incyte
INCY,INCY:UW,BBG000BNQ132,Is LLY's Arthritis Drug Delay a Minor Setback?,2017-01-17 14:27:00 +0000,http://www.investopedia.com/news/lilly-arthritis-drug-delayed-fda-lly-incy/?partner=YahooSA,Is LLY's Arthritis Drug Delay a Minor Setback?
INCY,INCY:UW,BBG000BNQ132,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",2017-01-17 14:14:23 +0000,http://finance.yahoo.com/news/barictinib-fda-delay-only-short-141423422.html,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse"
INCY,INCY:UW,BBG000BNQ132,FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate,2017-01-17 04:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gBqQD44MMTU/fda-delays-decision-on-lillys-rheumatoid-arthritis-drug-candidate-20170117-00139,FDA Delays Decision On Lilly's Rheumatoid Arthritis Drug Candidate
INCY,INCY:UW,BBG000BNQ132,FDA Delays Decision On Lilly''s Rheumatoid Arthritis Drug Candidate,2017-01-16 22:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJeemo0hDNI/fda-delays-decision-on-lillys-rheumatoid-arthritis-drug-candidate-20170116-00741,FDA Delays Decision On Lilly''s Rheumatoid Arthritis Drug Candidate
INCY,INCY:UW,BBG000BNQ132,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended,2017-01-16 14:39:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J0q2VXUFt7o/lilly-incyte-rheumatoid-arthritis-drug-pdufa-date-extended-cm733817,Eli Lilly and Company LLY and partner Incyte Corporation INCY announced that the FDA has extended the time to review the company s New Drug Application NDA seeking approval of its pipeline candidate baricitinib for the treatment of rheumatoid arthritis RA Previously the FDA was
INCY,INCY:UW,BBG000BNQ132,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended,2017-01-16 12:39:12 +0000,http://finance.yahoo.com/news/lilly-incyte-rheumatoid-arthritis-drug-123912305.html,Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
INCY,INCY:UW,BBG000BNQ132,"U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment",2017-01-13 21:51:00 +0000,http://finance.yahoo.com/news/u-fda-extends-review-period-215100650.html,"[PR Newswire] - INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review ..."
INCY,INCY:UW,BBG000BNQ132,Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink,2017-01-13 21:29:51 +0000,http://www.investors.com/news/technology/merck-carries-incyte-on-keytruda-coattails-in-4-hot-tumors-leerink/,Merck Carries Incyte On Keytruda Coattails In 4 'Hot' Tumors: Leerink
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: SWKS, INCY",2017-01-12 16:59:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BLqO-_SF7sc/nasdaq-100-movers-swks-incy-cm732786,In early trading on Thursday shares of Incyte Corporation INCY topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 3 Year to date Incyte Corporation registers a 16 5 gain And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,"Small Caps Soar, Dow Off; Which Tech Stocks Beat Apple In Gains Today?",2017-01-11 00:00:02 +0000,http://www.investors.com/market-trend/stock-market-today/small-caps-soar-dow-off-which-tech-stocks-beat-apple-in-gains-today/,"Small Caps Soar, Dow Off; Which Tech Stocks Beat Apple In Gains Today?"
INCY,INCY:UW,BBG000BNQ132,"Notable ETF Inflow Detected - IBB, REGN, ALXN, INCY",2017-01-10 17:50:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xDETBod0o8I/notable-etf-inflow-detected-ibb-regn-alxn-incy-cm731725,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 140 1 million dollar inflow that s a 1 7 increase week over week
INCY,INCY:UW,BBG000BNQ132,4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal,2017-01-10 16:55:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FtgRdTy4lhk/4-stocks-in-focus-as-biotech-ma-hopes-surge-on-takeda-ariad-deal-cm731695,Quite a few deals and licensing agreements were announced yesterday by pharma and biotech stocks but the one that stood out is the Takeda Pharmaceutical Company Limited TKPYY ARIAD Pharmaceuticals Inc ARIA announcement Japanese firm Takeda will be acquiring cancer focused ARIAD for
INCY,INCY:UW,BBG000BNQ132,Incyte's Prospects Get Even Brighter With Merck Announcement,2017-01-10 16:40:04 +0000,http://www.fool.com/investing/2017/01/10/incytes-prospects-get-even-brighter-with-merck-ann.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Incyte's Prospects Get Even Brighter With Merck Announcement
INCY,INCY:UW,BBG000BNQ132,Incyte/Merck to Start More Epacadostat-Keytruda Studies,2017-01-10 15:54:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kGro67ivpso/incytemerck-to-start-more-epacadostat-keytruda-studies-cm731570,Incyte Corporation INCY along with its partner Merck amp Co Inc MRK announced that they have decided to initiate additional pivotal studies on epacadostat in combination with Merck s anti PD 1 therapy Keytruda Shares of Incyte gained 9 4 on the news while Merck s shares inched
INCY,INCY:UW,BBG000BNQ132,Incyte/Merck to Start More Epacadostat-Keytruda Studies,2017-01-10 13:58:01 +0000,http://finance.yahoo.com/news/incyte-merck-start-more-epacadostat-135801452.html,Incyte/Merck to Start More Epacadostat-Keytruda Studies
INCY,INCY:UW,BBG000BNQ132,Incyte's Prospects Get Even Brighter With Merck Announcement,2017-01-10 13:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1EzlbKd4K00/incytes-prospects-get-even-brighter-with-merck-announcement-cm731412,Incyte NASDAQ INCY didn t have to wait for its presentation at the J P Morgan Healthcare Conference on Monday to make investors happy Merck NYSE MRK and Incyte announced earlier in the day that a combination of 160 epacadostat and Keytruda would advance to pivotal
INCY,INCY:UW,BBG000BNQ132,Jefferies Has 5 Top Biotech Stocks to Buy for 2017,2017-01-10 13:35:34 +0000,http://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html,Jefferies Has 5 Top Biotech Stocks to Buy for 2017
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,531.82.",2017-01-09 21:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3VkFjnxeaGE/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-553182-cm731323,Monday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 5 531 82 up 10 76 for the day The index first reached the 5000 mark on 01 06 2017 The total shares traded for the NASDAQ was over 2 06 billion Declining stocks led advancers by 1 43 to 1
INCY,INCY:UW,BBG000BNQ132,"Incyte Stock Breaks Out, It And Partner Merck Will Advance Key Trial",2017-01-09 21:13:51 +0000,http://www.investors.com/news/technology/incyte-stock-breaks-out-it-and-partner-merck-will-advance-key-trial/,"Incyte Stock Breaks Out, It And Partner Merck Will Advance Key Trial"
INCY,INCY:UW,BBG000BNQ132,"Biotech, Chip Stocks Lift Nasdaq To Fresh Closing High",2017-01-09 21:08:34 +0000,http://www.investors.com/market-trend/stock-market-today/biotech-chip-stocks-lift-nasdaq-to-fresh-all-time-high/,"Biotech, Chip Stocks Lift Nasdaq To Fresh Closing High"
INCY,INCY:UW,BBG000BNQ132,Nasdaq hits all-time high,2017-01-09 21:01:00 +0000,http://finance.yahoo.com/video/nasdaq-hits-time-high-210100570.html,Nasdaq hits all-time high
INCY,INCY:UW,BBG000BNQ132,"Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next Amgen?",2017-01-09 19:59:41 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-still-mixed-medicals-lead-upside-is-incyte-the-next-amgen/,"Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next Amgen?"
INCY,INCY:UW,BBG000BNQ132,Chips Stocks Post Solid Gains As Nasdaq Hits New High,2017-01-09 19:22:45 +0000,http://finance.yahoo.com/video/chips-stocks-post-solid-gains-192245976.html,Chips Stocks Post Solid Gains As Nasdaq Hits New High
INCY,INCY:UW,BBG000BNQ132,Merck Cancer Drug Test Sends Incyte Shares Higher,2017-01-09 18:57:00 +0000,https://www.thestreet.com/story/13947186/1/merck-cancer-drug-test-sends-incyte-shares-higher.html?puc=yahoo&cm_ven=YAHOO,Merck Cancer Drug Test Sends Incyte Shares Higher
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: VOD, INCY",2017-01-09 17:51:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e1QzaC-bob8/nasdaq-100-movers-vod-incy-cm731122,In early trading on Monday shares of Incyte topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 7 Year to date Incyte registers a 13 1 gain And the worst performing Nasdaq 100 component thus far on the day is Vodafone Group trading down 2
INCY,INCY:UW,BBG000BNQ132,Incyte Reaches Analyst Target Price,2017-01-09 15:48:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7mI8BPhxD-g/incyte-reaches-analyst-target-price-cm730957,In recent trading shares of Incyte Corporation Symbol INCY have crossed above the average analyst 12 month target price of 107 33 changing hands for 108 31 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
INCY,INCY:UW,BBG000BNQ132,Why These Collaborations Are Important to Incyte,2017-01-09 15:36:34 +0000,http://marketrealist.com/2017/01/why-these-collaborations-are-important-to-incyte/?utm_source=yahoo&utm_medium=feed,Why These Collaborations Are Important to Incyte
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation To Present At J.P. Morgan Conference; Webcast At 4:30 PM ET,2017-01-09 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WKfGfNFfxEg/incyte-corporation-to-present-at-jp-morgan-conference-webcast-at-430-pm-et-20170109-00871,Incyte Corporation To Present At J.P. Morgan Conference; Webcast At 4:30 PM ET
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks Surge Monday Amid Flurry of Deal Activity,2017-01-09 14:59:00 +0000,https://www.thestreet.com/story/13946782/1/biotech-stocks-surge-monday-amid-flurry-of-deal-activity.html?puc=yahoo&cm_ven=YAHOO,Biotech Stocks Surge Monday Amid Flurry of Deal Activity
INCY,INCY:UW,BBG000BNQ132,How Was Incyte’s Profitability in 3Q16?,2017-01-09 14:06:29 +0000,http://marketrealist.com/2017/01/how-was-incytes-profitability-in-3q16/?utm_source=yahoo&utm_medium=feed,How Was Incyte’s Profitability in 3Q16?
INCY,INCY:UW,BBG000BNQ132,Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab),2017-01-09 13:00:00 +0000,http://finance.yahoo.com/news/incyte-merck-advance-clinical-development-130000608.html,"[Business Wire] - Incyte Corporation and Merck , known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® , Merck’s anti-PD-1 therapy."
INCY,INCY:UW,BBG000BNQ132,What’s in Incyte’s Product Portfolio?,2017-01-09 12:36:21 +0000,http://marketrealist.com/2017/01/whats-in-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,What’s in Incyte’s Product Portfolio?
INCY,INCY:UW,BBG000BNQ132,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-09 12:25:11 +0000,http://www.fool.com/investing/2017/01/08/3-stocks-expected-to-more-than-double-their-earnin.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks Expected to More Than Double Their Earnings in 2017
INCY,INCY:UW,BBG000BNQ132,Incyte & Merck Expand Clinical Trial On Combination Of Epacadostat With KEYTRUDA,2017-01-09 08:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hFl_TUMAtLM/incyte--merck-expand-clinical-trial-on-combination-of-epacadostat-with-keytruda-20170109-00464,Incyte & Merck Expand Clinical Trial On Combination Of Epacadostat With KEYTRUDA
INCY,INCY:UW,BBG000BNQ132,3 Stocks Expected to More Than Double Their Earnings in 2017,2017-01-08 13:49:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmYAYq0nPTo/3-stocks-expected-to-more-than-double-their-earnings-in-2017-cm730785,Most investors idea of impressive earnings growth is say 20 or more per year So what does that say about companies that grow their earnings by more than 100 in a year That s what Wall Street expects three biotechs to achieve over the next year Here s how Corcept
INCY,INCY:UW,BBG000BNQ132,"Noteworthy Friday Option Activity: CBRL, INCY, BWLD",2017-01-06 21:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zP70E1McwAI/noteworthy-friday-option-activity-cbrl-incy-bwld-cm730590,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Cracker Barrel Old Country Store Inc Symbol CBRL where a total volume of 2 952 contracts has been traded thus far today a contract volume which is representative
INCY,INCY:UW,BBG000BNQ132,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 15:55:41 +0000,http://www.fool.com/investing/2017/01/06/biotech-investing-3-bold-predictions-for-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Investing: 3 Bold Predictions for 2017
INCY,INCY:UW,BBG000BNQ132,How Did Incyte’s Jakafi Perform in the US?,2017-01-06 15:36:59 +0000,http://marketrealist.com/2017/01/how-did-incytes-jakafi-perform-in-the-us/?utm_source=yahoo&utm_medium=feed,How Did Incyte’s Jakafi Perform in the US?
INCY,INCY:UW,BBG000BNQ132,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 14:40:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75sL-Uy4MWA/biotech-investing-3-bold-predictions-for-2017-cm730229,Making bold predictions actually isn t too hard to do Having them come true is another story altogether Nevertheless a new year is now upon us and I can t resist the urge to make a few bold predictions about the world of biotech investing in 2017 A handful of biotechs showed up in
INCY,INCY:UW,BBG000BNQ132,What Were Incyte’s Revenue Streams in 3Q16?,2017-01-06 14:07:07 +0000,http://marketrealist.com/2017/01/what-were-incytes-revenue-streams-in-3q16/?utm_source=yahoo&utm_medium=feed,What Were Incyte’s Revenue Streams in 3Q16?
INCY,INCY:UW,BBG000BNQ132,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017,2017-01-06 13:35:11 +0000,http://finance.yahoo.com/news/5-biotech-stocks-could-big-133511110.html,These 5 Biotech Stocks Could Be Big Takeover Targets in 2017
INCY,INCY:UW,BBG000BNQ132,How Are Incyte’s Revenues Trending?,2017-01-06 12:36:31 +0000,http://marketrealist.com/2017/01/how-are-incytes-revenues-trending/?utm_source=yahoo&utm_medium=feed,How Are Incyte’s Revenues Trending?
INCY,INCY:UW,BBG000BNQ132,How Does Incyte’s Valuation Compare to Peers?,2017-01-05 21:52:21 +0000,http://marketrealist.com/2017/01/how-does-incytes-valuation-compare-to-peers/?utm_source=yahoo&utm_medium=feed,How Does Incyte’s Valuation Compare to Peers?
INCY,INCY:UW,BBG000BNQ132,3 Reasons Geron Corporation Plunged 57% in 2016,2017-01-05 15:39:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6iCa5gnrq7I/3-reasons-geron-corporation-plunged-57-in-2016-cm729765,Image source Getty Images What happened Shares of Geron Corporation NASDAQ GERN a clinical stage biotechnology company focused on development treatments to fight cancer plunged a whopping 57 in 2016 according to data from S amp P Global Market Intelligence
INCY,INCY:UW,BBG000BNQ132,3 Reasons Geron Corporation Plunged 57% in 2016,2017-01-05 13:27:08 +0000,http://www.fool.com/investing/2017/01/05/3-reasons-geron-corporation-plunged-57-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons Geron Corporation Plunged 57% in 2016
INCY,INCY:UW,BBG000BNQ132,"Lilly Nears FDA Nod On Arthritis Drug, But Chemo Med Stuck In Court",2017-01-04 21:15:19 +0000,http://www.investors.com/news/technology/lilly-nears-fda-nod-on-arthritis-drug-but-chemo-med-stuck-in-court/,"Lilly Nears FDA Nod On Arthritis Drug, But Chemo Med Stuck In Court"
INCY,INCY:UW,BBG000BNQ132,"Gilead Sciences: With New Hire, M&A Might Be on the Way",2017-01-04 15:00:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/04/gilead-sciences-with-new-hire-ma-might-be-on-the-way/?mod=yahoobarrons&ru=yahoo,"Gilead Sciences: With New Hire, M&A Might Be on the Way"
INCY,INCY:UW,BBG000BNQ132,"Commit To Buy Incyte Corporation At $70, Earn 10.7% Using Options",2017-01-03 17:59:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IEPl-okI8OA/commit-to-buy-incyte-corporation-at-70-earn-107-using-options-cm728765,Investors considering a purchase of Incyte Corporation Symbol INCY stock but tentative about paying the going market price of 101 53 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
INCY,INCY:UW,BBG000BNQ132,"Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day",2017-01-03 17:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4p6XQrVvMvY/bluerock-residential-growth-reit-cal-maine-foods-incyte-eli-lilly-and-synergy-pharmaceuticals-highlighted-as-zacks-bull-and-bear-of-the-day-cm728713,For Immediate Release Chicago IL January 03 2017 Zacks Equity Research highlights Bluerock Residential Growth REIT AMEX BRG Free Report as the Bull of the Day and Cal Maine Foods Nasdaq CALM Free Report as the Bear of the Day In addition Zacks Equity
INCY,INCY:UW,BBG000BNQ132,"Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day",2017-01-03 14:30:02 +0000,http://finance.yahoo.com/news/bluerock-residential-growth-reit-cal-143002136.html,"Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day"
INCY,INCY:UW,BBG000BNQ132,Incyte Treats First Patient in Phase II GVHD Study on Jakafi,2017-01-02 16:56:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uloPo7wSt-o/incyte-treats-first-patient-in-phase-ii-gvhd-study-on-jakafi-cm728377,Incyte Corporation INCY announced that the first patient has been treated in the pivotal phase II REACH 1 study assessing its marketed drug Jakafi in combination with corticosteroids for the treatment of steroid refractory acute graft versus host disease GVHD Incyte s share price has
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks: What to Watch in 2017,2017-01-02 16:54:17 +0000,http://www.fool.com/investing/2017/01/01/biotech-stocks-what-to-watch-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Stocks: What to Watch in 2017
INCY,INCY:UW,BBG000BNQ132,Two Key FDA Decisions to Watch Out for in January 2017,2017-01-02 15:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FFiQ2xLzIXg/two-key-fda-decisions-to-watch-out-for-in-january-2017-cm728367,The drug development process is often lengthy and time consuming and requires the utilization of a lot of funds and resources It may well take a drug anything between 10 12 years to be successfully developed and reach the market In such a scenario key pipeline events including data readouts
INCY,INCY:UW,BBG000BNQ132,Incyte Treats First Patient in Phase II GVHD Study on Jakafi,2017-01-02 14:50:02 +0000,http://finance.yahoo.com/news/incyte-treats-first-patient-phase-145002871.html,Incyte Treats First Patient in Phase II GVHD Study on Jakafi
INCY,INCY:UW,BBG000BNQ132,Two Key FDA Decisions to Watch Out for in January 2017,2017-01-02 13:41:01 +0000,http://finance.yahoo.com/news/two-key-fda-decisions-watch-134101183.html,Two Key FDA Decisions to Watch Out for in January 2017
INCY,INCY:UW,BBG000BNQ132,"3 Biotech Stocks That Turned $10,000 Into Over $100,000",2017-01-01 12:22:32 +0000,http://www.fool.com/investing/2016/12/31/3-biotech-stocks-that-turned-10000-into-over-10000.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Biotech Stocks That Turned $10,000 Into Over $100,000"
INCY,INCY:UW,BBG000BNQ132,"3 Biotech Stocks That Turned $10,000 Into Over $100,000",2016-12-31 18:57:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iMoAzknRkGY/3-biotech-stocks-that-turned-10000-into-over-100000-cm728235,Some biotech stocks have made shareholders a lot of money over the last decade Few though have performed as well as Opko Health NASDAQ OPK Incyte NASDAQ INCY and China Biologic Products NASDAQ CBPO These three biotech stocks turned an initial investment
INCY,INCY:UW,BBG000BNQ132,Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease,2016-12-30 21:22:07 +0000,http://www.publicnow.com/view/F57C599CF52586196A2441DC58E6047F076F1629,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 30, 2016-- Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi) ..."
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks Facing FDA Decision In January,2016-12-29 05:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0PaWkzXTG0o/biotech-stocks-facing-fda-decision-in-january-20161229-00031,Biotech Stocks Facing FDA Decision In January
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech",2016-12-28 17:02:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LHXNZZdyNGs/the-zacks-analyst-blog-highlights-alexion-pharmaceuticals-celgene-incyte-eli-lilly-regeneron-pharmaceuticals-and-ophthotech-cm726995,For Immediate Release Chicago IL December 28 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech",2016-12-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-alexion-143002668.html,"The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech"
INCY,INCY:UW,BBG000BNQ132,Unusual activity: Incyte & Apple,2016-12-27 17:44:00 +0000,http://finance.yahoo.com/video/unusual-activity-incyte-apple-174400224.html,Unusual activity: Incyte & Apple
INCY,INCY:UW,BBG000BNQ132,"Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead",2016-12-27 16:02:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7vFwp3s2r4/forget-alexion-alxn-buy-these-3-biotech-stocks-instead-cm726406,New Haven CT based Alexion Pharmaceuticals Inc ALXN has had a tough year with shares falling 33 3 year to date YTD The company which is known for its focus on developing treatments for rare disorders has underperformed the Zacks categorized Medical Biomed Genetics industry which
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences: Time to Act Like Incyte?,2016-12-27 14:41:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/27/gilead-sciences-time-to-act-like-incyte/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Time to Act Like Incyte?
INCY,INCY:UW,BBG000BNQ132,"Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead",2016-12-27 13:53:01 +0000,http://finance.yahoo.com/news/forget-alexion-alxn-buy-3-135301037.html,"Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead"
INCY,INCY:UW,BBG000BNQ132,The Most Likely Incyte Acquisition Deal for 2017?,2016-12-24 13:06:56 +0000,http://www.fool.com/investing/2016/12/23/is-this-the-most-likely-incyte-acquisition-deal-fo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Most Likely Incyte Acquisition Deal for 2017?
INCY,INCY:UW,BBG000BNQ132,Stocks Trade Quietly Ahead Of Long Weekend; Biotechs Lead,2016-12-23 20:07:15 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-trade-quietly-ahead-of-long-weekend-biotechs-lead/,Stocks Trade Quietly Ahead Of Long Weekend; Biotechs Lead
INCY,INCY:UW,BBG000BNQ132,Merus NV Executives Discuss Products And Plans Going Into 2017: 'We Have Milestones Coming Up',2016-12-23 15:19:14 +0000,http://finance.yahoo.com/news/merus-nv-executives-discuss-products-151914384.html,Merus NV Executives Discuss Products And Plans Going Into 2017: 'We Have Milestones Coming Up'
INCY,INCY:UW,BBG000BNQ132,Merus CEO Explains The Incyte Agreement: 'This Deal Is Strategic For Both',2016-12-22 17:26:35 +0000,http://finance.yahoo.com/news/merus-ceo-explains-incyte-agreement-172635782.html,Merus CEO Explains The Incyte Agreement: 'This Deal Is Strategic For Both'
INCY,INCY:UW,BBG000BNQ132,Incyte/Merus Ink Collaboration for Bispecific Antibodies,2016-12-22 15:00:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3qEZZ0d48rA/incytemerus-ink-collaboration-for-bispecific-antibodies-cm725006,Incyte Corporation INCY announced that it has entered into a global strategic collaboration agreement with Merus N V MRUS to discover and develop bispecific antibodies using the latter s proprietary Biclonics technology platform Although Incyte s shares were down 2 4 on the news
INCY,INCY:UW,BBG000BNQ132,Blog Coverage Merus Announced a Multibillion Dollar Collaboration Agreement with Incyte,2016-12-22 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-merus-announced-multibillion-131500838.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / December 22, 2016 / Active Wall St. blog coverage looks at the headline from Dutch biopharmaceutical company Merus N.V. (NASDAQ: MRUS ) and Incyte Corp. (NASDAQ: INCY ) as both ..."
INCY,INCY:UW,BBG000BNQ132,Incyte/Merus Ink Collaboration for Bispecific Antibodies,2016-12-22 12:59:12 +0000,http://finance.yahoo.com/news/incyte-merus-ink-collaboration-bispecific-125912233.html,Incyte/Merus Ink Collaboration for Bispecific Antibodies
INCY,INCY:UW,BBG000BNQ132,Christmas Came Early for These Biotech Stocks,2016-12-22 12:21:25 +0000,http://www.fool.com/investing/2016/12/21/christmas-came-early-for-these-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Christmas Came Early for These Biotech Stocks
INCY,INCY:UW,BBG000BNQ132,"CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study",2016-12-21 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LivsjpkbrEE/cala-surges-on-bmy-deal-ovas-hands-pink-slips-mack-halts-breast-cancer-study-20161221-00953,"CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study"
INCY,INCY:UW,BBG000BNQ132,Christmas Came Early for These Biotech Stocks,2016-12-21 22:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kEGir9Jg4IQ/christmas-came-early-for-these-biotech-stocks-cm724840,The week before Christmas is typically a slow time of the year for news releases a staple of biotech valuation changes But Clovis Oncology NASDAQ CLVS Akebia Therapeutics NASDAQ AKBA Merus NASDAQ MRUS and Ionis Pharmaceuticals NASDAQ IONS all had news
INCY,INCY:UW,BBG000BNQ132,"Close Update: Wall Street Retreats From Record Highs Leaving Dow 20,000 For Another Day",2016-12-21 21:57:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tWtQComwl5Q/close-update-wall-street-retreats-from-record-highs-leaving-dow-20000-for-another-day-cm724823,The benchmark averages traded marginally lower Wednesday wedged in paper thin ranges for most of the day as light profit taking across most sectors tugged the Dow Jones Industrial Average and Nasdaq away from Tuesday s record highs and prevented the Dow from touching 20 000 for a
INCY,INCY:UW,BBG000BNQ132,"Health Care Sector Update for 12/21/2016: ALXN,GILD,MRUS,INCY,MACK",2016-12-21 21:36:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yLz6DSRAPsI/health-care-sector-update-for-12212016-alxngildmrusincymack-cm724822,Top Health Care StocksTop Health Care Stocks JNJ 0 13 JNJ 0 13 PFE 1 34 PFE 1 34 MRK 0 13 MRK 0 13 ABT 1 62 ABT 1 62 AMGN 0 59 AMGN 0 59 Health care stocks weighed on the broader U S markets Wednesday with the NYSE Health Care Index retreating about 0 4 while shares of health
INCY,INCY:UW,BBG000BNQ132,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher,2016-12-21 21:17:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZxMikSBvFPw/mid-afternoon-market-update-crude-oil-down-15-merus-shares-spike-higher-cm724821,Toward the end of trading Wednesday the Dow traded down 0 05 percent to 19 963 94 while the NASDAQ declined 0 08 percent to 5 479 51 The S amp P also fell dropping 0 10 percent to 2 268 60 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State",2016-12-21 21:07:11 +0000,http://biz.yahoo.com/e/161221/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State"
INCY,INCY:UW,BBG000BNQ132,"Health Care Sector Update for 12/21/2016: CALA,BMY,MRUS,INCY,MACK",2016-12-21 19:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nnc5PN0cchk/health-care-sector-update-for-12212016-calabmymrusincymack-cm724760,Top Health Care StocksTop Health Care Stocks JNJ 0 28 JNJ 0 28 PFE 1 42 PFE 1 42 MRK 0 42 MRK 0 42 ABT 1 38 ABT 1 38 AMGN 0 82 AMGN 0 82 Health care stocks continued to weigh on the broader U S markets today but pared some of their earlier declines with the NYSE Health Care
INCY,INCY:UW,BBG000BNQ132,Incyte invests $200M in Dutch company's antibody technology,2016-12-21 18:25:06 +0000,http://www.bizjournals.com/philadelphia/news/2016/12/21/incyte-merus-netherlands-antibody-bispecific-tech.html?ana=yahoo,Incyte invests $200M in Dutch company's antibody technology
INCY,INCY:UW,BBG000BNQ132,Midday Update: Wall Street Retreats From Record Highs,2016-12-21 18:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IB9WOC-V1mY/midday-update-wall-street-retreats-from-record-highs-cm724723,The benchmark averages were slightly underwater midday on Wednesday as light profit taking pressure off Tuesday s record levels kept the Dow Jones Industrial Average from hitting the elusive 20 000 level for the seventh consecutive day Gains in the energy and materials sector on a
INCY,INCY:UW,BBG000BNQ132,Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations,2016-12-21 16:17:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dzrNNyMEXgg/mid-morning-market-update-markets-edge-lower-finish-line-misses-q3-expectations-cm724638,Following the market opening Wednesday the Dow traded down 0 07 percent to 19 960 55 while the NASDAQ declined 0 10 percent to 5 478 21 The S amp P also fell dropping 0 11 percent to 2 268 20 Leading and Lagging Sectors Non cyclical consumer goods amp services shares
INCY,INCY:UW,BBG000BNQ132,Futures Mixed After Another Record-Setting Run for Dow and Nasdaq,2016-12-21 14:36:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BlpZO1DWv3I/futures-mixed-after-another-record-setting-run-for-dow-and-nasdaq-cm724467,Stock futures were trading flat to slightly lower with little buying interest for equities after the Dow Jones Industrial Average and Nasdaq both set new record highs on Tuesday and before the Christmas holiday Yesterday the Dow came withinm15 points of the elusive 20 000 level but drifted
INCY,INCY:UW,BBG000BNQ132,Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies,2016-12-21 13:12:09 +0000,http://www.publicnow.com/view/E271A27565BA2E6C2836836B6489F8B368AABEFC,[at noodls] - Collaboration designed to leverage Merus' Biclonics® bispecific antibody technology to expand Incyte's discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million ...
INCY,INCY:UW,BBG000BNQ132,Merus (MRUS) Has Broken Out To A New High On News Of Incyte Collaboration,2016-12-21 09:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ux9gplYHEpg/merus-mrus-has-broken-out-to-a-new-high-on-news-of-incyte-collaboration-20161221-00454,Merus (MRUS) Has Broken Out To A New High On News Of Incyte Collaboration
INCY,INCY:UW,BBG000BNQ132,3 Incredibly Cheap Biotech Stocks,2016-12-20 16:51:18 +0000,http://www.fool.com/investing/2016/12/20/3-incredibly-cheap-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Incredibly Cheap Biotech Stocks
INCY,INCY:UW,BBG000BNQ132,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC,2016-12-19 21:14:27 +0000,http://www.investors.com/news/technology/incyte-could-step-onto-auction-block-with-strong-jakafi-sales-rbc/,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC
INCY,INCY:UW,BBG000BNQ132,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis,2016-12-19 16:01:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wXikCLKndTE/incytelilly-olumiant-wins-chmp-nod-for-rheumatoid-arthritis-cm723233,Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has issued a positive opinion for the approval of Olumiant baricitinib for the treatment of adults with moderate to
INCY,INCY:UW,BBG000BNQ132,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis,2016-12-19 13:36:01 +0000,http://finance.yahoo.com/news/incyte-lilly-olumiant-wins-chmp-133601910.html,Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
INCY,INCY:UW,BBG000BNQ132,3 Biggest Risks for Incyte Corporation,2016-12-17 18:56:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E3ph42Ze8j4/3-biggest-risks-for-incyte-corporation-cm722918,Can anything slow down Incyte NASDAQ INCY The biotech s stock is up 30 in just the last three months A potential rival to the company s Jakafi in treating myelofibrosis underperformed in a late stage clinical study Another possible blockbuster drug for Incyte awaits
INCY,INCY:UW,BBG000BNQ132,3 Biggest Risks for Incyte Corporation,2016-12-17 17:06:17 +0000,http://www.fool.com/investing/2016/12/17/3-biggest-risks-for-incyte-corporation.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biggest Risks for Incyte Corporation
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-12-16 21:17:43 +0000,http://biz.yahoo.com/e/161216/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement"
INCY,INCY:UW,BBG000BNQ132,Eli Lilly & Co. is Higher For Second Day In a Row,2016-12-16 14:29:00 +0000,http://www.investopedia.com/news/lly-positive-european-ad-comm-review/?partner=YahooSA,Eli Lilly & Co. is Higher For Second Day In a Row
INCY,INCY:UW,BBG000BNQ132,CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA),2016-12-16 13:48:13 +0000,http://www.publicnow.com/view/99D5D716033542E4F141C9F55661D2E40B256376,"[at noodls] - INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ..."
INCY,INCY:UW,BBG000BNQ132,CHMP Recommends Approval Of Lilly's Baricitinib For Rheumatoid Arthritis,2016-12-16 08:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nV5bJ8ivgJI/chmp-recommends-approval-of-lillys-baricitinib-for-rheumatoid-arthritis-20161216-00220,CHMP Recommends Approval Of Lilly's Baricitinib For Rheumatoid Arthritis
INCY,INCY:UW,BBG000BNQ132,Could Geron Corporation Be a Millionaire-Maker Stock?,2016-12-13 17:22:03 +0000,http://www.fool.com/investing/2016/12/12/could-geron-corporation-be-a-millionaire-maker-sto.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Could Geron Corporation Be a Millionaire-Maker Stock?
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conference,2016-12-13 13:00:00 +0000,http://finance.yahoo.com/news/incyte-present-upcoming-investor-conference-130000543.html,"[Business Wire] - Incyte Corporation announced today that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 1:30 pm in San Francisco."
INCY,INCY:UW,BBG000BNQ132,Could Geron Corporation Be a Millionaire-Maker Stock?,2016-12-12 17:58:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ev4zYLZ7eG0/could-geron-corporation-be-a-millionaire-maker-stock-cm720227,Image source Getty Images Investors have been on a wild ride with Geron Corporation NASDAQ GERN in the last five years Its lead and only drug imetelstat has enjoyed all the ups and downs of clinical development Promising results in late 2013 for oncology indications
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, COST",2016-12-08 16:59:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sd0v18zZGGI/nasdaq-100-movers-incy-cost-cm718694,In early trading on Thursday shares of Costco Wholesale COST topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 0 Year to date Costco Wholesale has lost about 1 9 of its value And the worst performing Nasdaq 100 component thus far on
INCY,INCY:UW,BBG000BNQ132,"NASDAQ Composite Index closes up 24.11 points for the week, rising for the 4th straight day",2016-12-07 21:49:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oQrywPCM2TU/nasdaq-composite-index-closes-up-2411-points-for-the-week-rising-for-the-4th-straight-day-cm718295,Wednesday s session closes with the NASDAQ Composite Index 60 76 This is the 4th straight day of increase for the index The total shares traded for the NASDAQ was over 2 15 billion Wednesday s session closes with the NASDAQ Composite Index 60 76 This is the 4th straight day of increase for
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences Inc.'s Worst Moves in 2016,2016-12-07 20:48:53 +0000,http://www.fool.com/investing/2016/12/06/gilead-sciences-incs-worst-moves-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Gilead Sciences Inc.'s Worst Moves in 2016
INCY,INCY:UW,BBG000BNQ132,"Stock Indexes Extend Gains, But Big R&D Biotechs Dive",2016-12-07 19:04:22 +0000,http://www.investors.com/market-trend/stock-market-today/stock-indexes-rise-but-big-rd-biomeds-dive/,"Stock Indexes Extend Gains, But Big R&D Biotechs Dive"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, WDC",2016-12-07 16:57:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tjgLo_Ew2So/nasdaq-100-movers-incy-wdc-cm718035,In early trading on Wednesday shares of Western Digital WDC topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 0 Year to date Western Digital registers a 11 6 gain And the worst performing Nasdaq 100 component thus far on the day is
INCY,INCY:UW,BBG000BNQ132,GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started,2016-12-06 21:21:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3TjS2Ne02cw/gw-pharmaceuticals-plc-adr-gwph-stock-is-just-getting-started-cm717443,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips With revenue down 62 on a year over year basis and a loss of 21 8 million booked for the quarter in question one might have expected GW Pharmaceuticals PLC ADR NASDAQ
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences Inc.'s Worst Moves in 2016,2016-12-06 21:16:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bfic-PAwyWA/gilead-sciences-incs-worst-moves-in-2016-cm717289,As 2016 draws to a close we all tend to look back on the good and the bad experienced during another trip around the sun Unfortunately for Gilead Sciences NASDAQ GILD there were plenty of bad things that happened this year Some of the bad news was just the reality of
INCY,INCY:UW,BBG000BNQ132,Hedge Funds Head For Energy Transfer Equity LP (ETE)’s Exits: Spooked by Dakota Pipeline?,2016-12-05 22:58:01 +0000,http://www.insidermonkey.com/blog/hedge-funds-head-for-energy-transfer-equity-lp-etes-exits-spooked-by-dakota-pipeline-496093/,Hedge Funds Head For Energy Transfer Equity LP (ETE)’s Exits: Spooked by Dakota Pipeline?
INCY,INCY:UW,BBG000BNQ132,Incyte CEO: We're building for the long term,2016-12-05 17:47:00 +0000,http://finance.yahoo.com/video/incyte-ceo-were-building-long-174700712.html,Incyte CEO: We're building for the long term
INCY,INCY:UW,BBG000BNQ132,Incyte Jakafi Positive in Pooled Analysis of Five-Year Data,2016-12-05 14:06:02 +0000,http://finance.yahoo.com/news/incyte-jakafi-positive-pooled-analysis-140602510.html,Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
INCY,INCY:UW,BBG000BNQ132,Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib),2016-12-04 18:08:00 +0000,http://finance.yahoo.com/news/pooled-analysis-five-data-two-180800655.html,[Business Wire] - Incyte Corporation today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall survival findings and suggests that earlier treatment with Jakafi® may result in an improved survival advantage for patients with intermediate-2 or high-risk myelofibrosis than best available therapy ...
INCY,INCY:UW,BBG000BNQ132,3 Reasons Why Incyte Corporation Stock Could Soar in 2017,2016-12-04 11:49:31 +0000,http://www.fool.com/investing/2016/12/03/3-reasons-why-incyte-corporation-stock-could-soar.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons Why Incyte Corporation Stock Could Soar in 2017
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks to Buy in December,2016-12-02 14:21:09 +0000,http://www.fool.com/investing/2016/12/01/3-biotech-stocks-to-buy-in-december.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy in December
INCY,INCY:UW,BBG000BNQ132,Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors,2016-12-01 17:21:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XampTwI5Uk/agenus-incagn1876-in-phase-iii-study-for-solid-tumors-cm716406,Lexington MA based immuno oncology company Agenus Inc AGEN announced that it has dosed the first patient in a phase I II study on INCAGN1949 for the treatment of patients with solid tumors The open label dose escalation part of the study will evaluate the safety and tolerability
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks to Buy in December,2016-12-01 15:19:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XNV973yfpJ4/3-biotech-stocks-to-buy-in-december-cm716237,Image source Getty Images It has been a wild year to be a biotech investor Shares of the SPDR S amp P Biotech ETF NYSEMKT XBI a popular ETF that holds several dozen individual biotech companies cratered and recovered multiple times in 2016 based on the political
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks to Buy on Sale,2016-11-29 14:55:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vouM4tNKpkA/3-biotech-stocks-to-buy-on-sale-cm714931,Image source Getty Images You know what makes long term investing even sweeter Buying great companies at great prices when their shares are on sale When the opportunity presents itself moving in at the right starting price can make all the difference for buy and hold
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks to Buy on Sale,2016-11-29 13:32:06 +0000,http://www.fool.com/investing/2016/11/29/3-biotech-stocks-to-buy-on-sale-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotech Stocks to Buy on Sale
INCY,INCY:UW,BBG000BNQ132,Does Incyte Corporation (INCY) Represent a Good Addition to Your Portfolio?,2016-11-28 20:00:25 +0000,http://www.insidermonkey.com/blog/does-incyte-corporation-incy-represent-a-good-addition-to-your-portfolio-490752/,Does Incyte Corporation (INCY) Represent a Good Addition to Your Portfolio?
INCY,INCY:UW,BBG000BNQ132,Intellipharmaceutics Submits NDA for Pain Treatment Rexista,2016-11-28 15:32:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dzfSWetryoU/intellipharmaceutics-submits-nda-for-pain-treatment-rexista-cm714422,Intellipharmaceutics International Inc IPCI announced that it has filed a new drug application NDA with the FDA for Rexista abuse deterrent oxycodone hydrochloride extended release tablets in the 10 mg 15 mg 20 mg 30 mg 40 mg 60 mg and 80 mg strengths The company is looking to
INCY,INCY:UW,BBG000BNQ132,Intellipharmaceutics Submits NDA for Pain Treatment Rexista,2016-11-28 13:42:01 +0000,http://finance.yahoo.com/news/intellipharmaceutics-submits-nda-pain-treatment-134201302.html,Intellipharmaceutics Submits NDA for Pain Treatment Rexista
INCY,INCY:UW,BBG000BNQ132,Is It Time to Invest in American Water Works Company Inc (AWK)?,2016-11-27 23:25:52 +0000,http://www.insidermonkey.com/blog/is-it-time-to-invest-in-american-water-works-company-inc-awk-493080/,Is It Time to Invest in American Water Works Company Inc (AWK)?
INCY,INCY:UW,BBG000BNQ132,Read This Before You Buy Any Marijuana Stocks,2016-11-27 16:47:15 +0000,http://www.fool.com/investing/2016/11/26/read-this-before-you-buy-any-marijuana-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Read This Before You Buy Any Marijuana Stocks
INCY,INCY:UW,BBG000BNQ132,Read This Before You Buy Any Marijuana Stocks,2016-11-26 18:08:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fO6bDWvSg58/read-this-before-you-buy-any-marijuana-stocks-cm714193,Thinking about buying a marijuana stock There s certainly a lot of excitement in the investor community Now that the elections are over 28 states allow use of medical marijuana Another eight states plus the District of Columbia allow recreational use of the drug Before you make
INCY,INCY:UW,BBG000BNQ132,Merck (MRK) Announces 2.2% Increase in Quarterly Dividend,2016-11-24 15:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LJ8tkhlYTjg/merck-mrk-announces-22-increase-in-quarterly-dividend-cm713647,Merck amp Co Inc MRK recently announced a 2 2 hike in its quarterly dividend The company will now pay shareholders a quarterly dividend of 47 cents compared with the previous payout of 46 cents Based on the closing price of 61 64 on Nov 23 the increased payout translates to a yield
INCY,INCY:UW,BBG000BNQ132,Merck (MRK) Announces 2.2% Increase in Quarterly Dividend,2016-11-24 13:30:01 +0000,http://finance.yahoo.com/news/merck-mrk-announces-2-2-133001159.html,Merck (MRK) Announces 2.2% Increase in Quarterly Dividend
INCY,INCY:UW,BBG000BNQ132,When Will Gilead Sciences' Unlucky Streak End?,2016-11-23 18:59:20 +0000,http://www.fool.com/investing/2016/11/23/when-will-gilead-sciences-unlucky-streak-end.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,When Will Gilead Sciences' Unlucky Streak End?
INCY,INCY:UW,BBG000BNQ132,Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod,2016-11-23 16:05:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mlF9rCL_WFo/novo-nordisks-diabetes-combination-drug-gets-fdas-nod-cm713240,Novo Nordisk A S NVO received favorable news with the FDA approving its new drug application for Xultophy 100 3 6 Xultophy 100 3 6 is approved as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus who have inadequately controlled their disease
INCY,INCY:UW,BBG000BNQ132,When Will Gilead Sciences' Unlucky Streak End?,2016-11-23 15:05:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3PEIa52OboA/when-will-gilead-sciences-unlucky-streak-end-cm713165,If it weren t for bad luck Gilead Sciences NASDAQ GILD might not have any luck at all At least it might seem that way lately for the biotech s shareholders There has been plenty of bad news with Gilead s announcements in recent months When will Gilead Sciences unlucky
INCY,INCY:UW,BBG000BNQ132,Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod,2016-11-23 14:13:02 +0000,http://finance.yahoo.com/news/novo-nordisks-diabetes-combination-drug-141302828.html,Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod
INCY,INCY:UW,BBG000BNQ132,AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials,2016-11-23 13:05:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AUYxWCj8xTU/astrazeneca-fda-lifts-hold-on-head-neck-cancer-trials-cm713116,AstraZeneca plc AZN announced that it has resumed enrolment of new patients in head and neck cancer studies of its lead pipeline candidate durvalumab as the FDA has lifted a partial clinical hold that it had imposed in October Late last month durvalumab was placed on partial clinical hold
INCY,INCY:UW,BBG000BNQ132,AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials,2016-11-23 10:42:10 +0000,http://finance.yahoo.com/news/astrazeneca-fda-lifts-hold-head-104210643.html,AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials
INCY,INCY:UW,BBG000BNQ132,Ligand's Partner Retrophin Provides New Data on Sparsentan,2016-11-22 22:20:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xe4Z5Amc_PY/ligands-partner-retrophin-provides-new-data-on-sparsentan-cm712661,Ligand Pharmaceuticals Incorporated s LGND partner Retrophin Inc RTRX announced additional positive data results from the phase II DUET study on sparsentan for the treatment of focal segmental glomerulosclerosis FSGS The data was presented at the American Society of Nephrology Kidney
INCY,INCY:UW,BBG000BNQ132,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults,2016-11-22 18:21:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pBga_NaEpn4/sanofi-sny-soliqua-approved-for-type-2-diabetes-in-adults-cm712687,Sanofi SNY announced that the FDA has approved its once daily injection Soliqua 100 33 a combination of its diabetes drugs Lantus and lixisenatide EU trade name Lyxumia for the treatment of type 2 diabetes in adults who have inadequately controlled their disease with basal insulin
INCY,INCY:UW,BBG000BNQ132,Aduro Reports Partial Hold Lift on LADD Studies in U.S.,2016-11-22 16:21:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dXSzeMC3LLQ/aduro-reports-partial-hold-lift-on-ladd-studies-in-us-cm712679,Aduro Biotech Inc ADRO received encouraging news when the FDA lifted the partial clinical hold on studies evaluating investigational agents based on its LADD live attenuated double deleted immunotherapy platform With the partial hold lift the company has now been able to resume
INCY,INCY:UW,BBG000BNQ132,Ligand's Partner Retrophin Provides New Data on Sparsentan,2016-11-22 14:02:02 +0000,http://finance.yahoo.com/news/ligands-partner-retrophin-provides-data-140202477.html,Ligand's Partner Retrophin Provides New Data on Sparsentan
INCY,INCY:UW,BBG000BNQ132,Aduro Reports Partial Hold Lift on LADD Studies in U.S.,2016-11-22 13:58:01 +0000,http://finance.yahoo.com/news/aduro-reports-partial-hold-lift-135801029.html,Aduro Reports Partial Hold Lift on LADD Studies in U.S.
INCY,INCY:UW,BBG000BNQ132,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults,2016-11-22 13:54:01 +0000,http://finance.yahoo.com/news/sanofi-sny-soliqua-approved-type-135401923.html,Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: HSIC, NFLX",2016-11-21 16:50:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bkHoGQnjZsg/nasdaq-100-movers-hsic-nflx-cm711958,In early trading on Monday shares of Netflix NFLX topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 0 Year to date Netflix registers a 3 8 gain And the worst performing Nasdaq 100 component thus far on the day is Henry Schein
INCY,INCY:UW,BBG000BNQ132,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day",2016-11-18 16:52:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzxZPgB8cwk/new-oriental-education-technology-group-bjs-restaurants-ariad-pharmaceuticals-incyte-and-exelixis-highlighted-as-zacks-bull-and-bear-of-the-day-cm711226,For Immediate Release Chicago IL November 18 2016 Zacks Equity Research highlights 160 New Oriental Education amp Technology Group NYSE EDU Free Report as the Bull of the Day and BJ s Restaurants NASDAQ BJRI Free Report as the Bear of the Day In
INCY,INCY:UW,BBG000BNQ132,[$$] Gilead Now More Likely to Buy Incyte?,2016-11-18 16:01:00 +0000,http://www.barrons.com/articles/gilead-now-more-likely-to-buy-incyte-1479484871?mod=yahoobarrons&ru=yahoo,[$$] Gilead Now More Likely to Buy Incyte?
INCY,INCY:UW,BBG000BNQ132,Endo Reports Positive Cellulite Treatment Data on Xiaflex,2016-11-18 15:51:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HAtr2pSNNEs/endo-reports-positive-cellulite-treatment-data-on-xiaflex-cm711173,Endo International plc ENDP announced positive data from a phase IIb study on Xiaflex collagenase clostridium histolyticum for the treatment of patients suffering from edematous fibrosclerotic panniculopathy also known as cellulite Data showed that patients treated with
INCY,INCY:UW,BBG000BNQ132,Gilead Sciences: Buy 'Regeneron Lite'…Or Just Buy Regeneron?,2016-11-18 15:24:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/18/gilead-sciences-buy-regeneron-lite-or-just-buy-regeneron/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Buy 'Regeneron Lite'…Or Just Buy Regeneron?
INCY,INCY:UW,BBG000BNQ132,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day",2016-11-18 14:30:02 +0000,http://finance.yahoo.com/news/oriental-education-technology-group-bjs-143002240.html,"New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day"
INCY,INCY:UW,BBG000BNQ132,Endo Reports Positive Cellulite Treatment Data on Xiaflex,2016-11-18 13:48:01 +0000,http://finance.yahoo.com/news/endo-reports-positive-cellulite-treatment-134801246.html,Endo Reports Positive Cellulite Treatment Data on Xiaflex
INCY,INCY:UW,BBG000BNQ132,Shire Launches Cuvitru in U.S. for Primary Immunodeficiency,2016-11-18 04:10:04 +0000,http://finance.yahoo.com/news/shire-launches-cuvitru-u-primary-041004794.html,Shire Launches Cuvitru in U.S. for Primary Immunodeficiency
INCY,INCY:UW,BBG000BNQ132,Increased Earnings Estimates Seen for Incyte (INCY): Can It Move Higher?,2016-11-18 00:52:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9x8XTFqpL0g/increased-earnings-estimates-seen-for-incyte-incy-can-it-move-higher-cm710535,Incyte Corporation INCY is an American pharmaceutical companythat could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These positive
INCY,INCY:UW,BBG000BNQ132,Gilead Could Scoop Up Incyte After Cancer Drug Proves 'Not Good Enough',2016-11-17 21:11:46 +0000,http://www.investors.com/news/technology/gilead-could-scoop-up-incyte-after-cancer-drug-proves-not-good-enough/,Gilead Could Scoop Up Incyte After Cancer Drug Proves 'Not Good Enough'
INCY,INCY:UW,BBG000BNQ132,Get Excited About Incyte,2016-11-17 18:37:00 +0000,http://realmoney.thestreet.com/articles/11/17/2016/get-excited-about-incyte?puc=yahoo&cm_ven=YAHOO,Get Excited About Incyte
INCY,INCY:UW,BBG000BNQ132,Bad News for Gilead Sciences Is Good News for Incyte,2016-11-17 18:02:06 +0000,http://www.fool.com/investing/2016/11/17/bad-news-for-gilead-sciences-is-good-news-for-incy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Bad News for Gilead Sciences Is Good News for Incyte
INCY,INCY:UW,BBG000BNQ132,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise,2016-11-17 15:51:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/haGDFsP1dtc/3-stocks-to-add-to-your-portfolio-as-biotech-ma-hopes-rise-cm710528,2016 has not been a great year for mergers and acquisitions M amp As in the pharma and biotech sector although some headline deals like the Pfizer PFE Medivation and the Teva Actavis Generics acquisitions were completed this year While expectations were high that this year too the pharma
INCY,INCY:UW,BBG000BNQ132,"Gilead Sciences: Failure, Failure, Failure…and the Case For Upside",2016-11-17 14:35:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/17/gilead-sciences-failure-failure-failure-and-the-case-for-upside/?mod=yahoobarrons&ru=yahoo,"Gilead Sciences: Failure, Failure, Failure…and the Case For Upside"
INCY,INCY:UW,BBG000BNQ132,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise,2016-11-17 13:56:01 +0000,http://finance.yahoo.com/news/3-stocks-add-portfolio-biotech-135601225.html,3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
INCY,INCY:UW,BBG000BNQ132,Increased Earnings Estimates Seen for Incyte (INCY): Can It Move Higher?,2016-11-17 13:52:01 +0000,http://finance.yahoo.com/news/increased-earnings-estimates-seen-incyte-135201221.html,Increased Earnings Estimates Seen for Incyte (INCY): Can It Move Higher?
INCY,INCY:UW,BBG000BNQ132,Gilead Reports Phase III Myelofibrosis Data on Momelotinib,2016-11-17 13:21:01 +0000,http://finance.yahoo.com/news/gilead-reports-phase-iii-myelofibrosis-132101676.html,Gilead Reports Phase III Myelofibrosis Data on Momelotinib
INCY,INCY:UW,BBG000BNQ132,"Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!",2016-11-17 11:36:00 +0000,https://www.thestreet.com/story/13897080/1/hey-gilead-stop-developing-drugs-and-start-buying-biotech-companies-now.html?puc=yahoo&cm_ven=YAHOO,"Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!"
INCY,INCY:UW,BBG000BNQ132,Ionis (IONS) Offers Positive Interim Data on Lipid Candidate,2016-11-16 15:52:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OOI8xK6V860/ionis-ions-offers-positive-interim-data-on-lipid-candidate-cm710015,Ionis Pharmaceuticals Inc s IONS wholly owned subsidiary Akcea Therapeutics announced positive data from an interim analysis of a phase I IIa study on its pipeline candidate IONIS ANGPTL3 L RX Data were presented at the American Heart Association Meeting In the study patients
INCY,INCY:UW,BBG000BNQ132,Ionis (IONS) Offers Positive Interim Data on Lipid Candidate,2016-11-16 13:25:01 +0000,http://finance.yahoo.com/news/ionis-ions-offers-positive-interim-132501257.html,Ionis (IONS) Offers Positive Interim Data on Lipid Candidate
INCY,INCY:UW,BBG000BNQ132,Blog Coverage Biopharma Company uniQure Undertakes a Companywide Strategic Review Aimed at Increasing Shareholders Value,2016-11-16 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-biopharma-company-uniqure-131500231.html,"[Accesswire] - Upcoming AWS Coverage on Incyte Post-Earnings Results LONDON, UK / ACCESSWIRE / November 16, 2016 / Active Wall St. blog coverage looks at the headline from uniQure N.V. (NASDAQ: QURE ) as the company ..."
INCY,INCY:UW,BBG000BNQ132,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib",2016-11-16 00:49:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zH31T563-Bk/incyte-eli-lilly-offer-positive-phase-iii-data-on-baricitinib-cm709760,Incyte Corporation INCY and Eli Lilly and Company LLY provided updates from two phase III studies RA BEAM and RA BUILD on baricitinib for the treatment of rheumatoid arthritis RA RA BEAM evaluated baricitinib in comparison to AbbVie Inc s ABBV Humira in patients who had
INCY,INCY:UW,BBG000BNQ132,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib",2016-11-15 22:33:10 +0000,http://finance.yahoo.com/news/incyte-eli-lilly-offer-positive-223310457.html,"Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib"
INCY,INCY:UW,BBG000BNQ132,Repros (RPRX) Reports Positive Top-Line Data on Proellex,2016-11-15 14:31:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-vQP28NyJ-g/repros-rprx-reports-positive-top-line-data-on-proellex-cm709172,Repros Therapeutics Inc RPRX reported top line results from two phase II studies on its lead pipeline candidate Proellex when delivered orally and vaginally for the treatment of uterine fibroids The company s shares were up 3 87 on the news The studies enrolled women with
INCY,INCY:UW,BBG000BNQ132,Celldex Stock Up on Positive Data on New Cancer Candidate,2016-11-15 14:30:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OVg81-W7KfQ/celldex-stock-up-on-positive-data-on-new-cancer-candidate-cm709357,Celldex Therapeutics Inc CLDX presented pre clinical data on a new candidate CDX 1140 a fully human antibody that targets CD40 and demonstrated potent agonist activity The data was presented at the Society for Immunotherapy of Cancer Annual Meeting Importantly the company said that
INCY,INCY:UW,BBG000BNQ132,Celldex Stock Up on Positive Data on New Cancer Candidate,2016-11-15 13:03:01 +0000,http://finance.yahoo.com/news/celldex-stock-positive-data-cancer-130301911.html,Celldex Stock Up on Positive Data on New Cancer Candidate
INCY,INCY:UW,BBG000BNQ132,Repros (RPRX) Reports Positive Top-Line Data on Proellex,2016-11-15 12:39:12 +0000,http://finance.yahoo.com/news/repros-rprx-reports-positive-top-123912797.html,Repros (RPRX) Reports Positive Top-Line Data on Proellex
INCY,INCY:UW,BBG000BNQ132,"3 Sectors, 6 Stocks With A Lot To Gain Under President Trump",2016-11-14 18:13:00 +0000,http://www.forbes.com/sites/kenkam/2016/11/14/3-sectors-6-stocks-with-a-lot-to-gain-under-president-trump/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"3 Sectors, 6 Stocks With A Lot To Gain Under President Trump"
INCY,INCY:UW,BBG000BNQ132,Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes,2016-11-14 14:47:17 +0000,http://www.publicnow.com/view/62582315DBEE08A83E0B6892084F2DBEF61F0916,"[at noodls] - - Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3 studies shows ..."
INCY,INCY:UW,BBG000BNQ132,Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/baricitinib-demonstrates-early-response-compared-140000725.html,[CNW Group] - Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
INCY,INCY:UW,BBG000BNQ132,New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/analyses-phase-3-trials-show-140000364.html,"[PR Newswire] - Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDs INDIANAPOLIS, ..."
INCY,INCY:UW,BBG000BNQ132,New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients,2016-11-14 14:00:00 +0000,http://finance.yahoo.com/news/analyses-phase-3-trials-show-140000727.html,[CNW Group] - New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
INCY,INCY:UW,BBG000BNQ132,Lilly Says New Analyses Of Phase 3 Trials Show Improvements In RA Symptom,2016-11-14 09:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SytgpKSJTOw/lilly-says-new-analyses-of-phase-3-trials-show-improvements-in-ra-symptom-20161114-00695,Lilly Says New Analyses Of Phase 3 Trials Show Improvements In RA Symptom
INCY,INCY:UW,BBG000BNQ132,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally,2016-11-13 16:20:00 +0000,https://www.thestreet.com/story/13887750/1/six-thoughts-on-president-trump-and-the-durability-of-the-biotech-stock-rally.html?puc=yahoo&cm_ven=YAHOO,Six Thoughts on President Trump and the Durability of the Biotech Stock Rally
INCY,INCY:UW,BBG000BNQ132,3 Highest Growth Stocks in the Market Today,2016-11-11 17:29:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TDCy-MIRJm0/3-highest-growth-stocks-in-the-market-today-cm707917,Most investors are on the hunt for stocks that promise fast sales and earnings growth in the years ahead That makes sense as companies that can do so for extended periods of time stand a good chance of producing market beating returns With that in mind I ran a simple screen on
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte",2016-11-11 16:15:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iZ4ede6Qxqc/the-zacks-analyst-blog-highlights-enzo-biochem-exelixis-genmab-as-heska-and-incyte-cm707752,For Immediate Release Chicago IL November 11 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
INCY,INCY:UW,BBG000BNQ132,3 Highest Growth Stocks in the Market Today,2016-11-11 14:41:07 +0000,http://www.fool.com/investing/2016/11/11/x-highest-growth-stocks-in-the-market-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Highest Growth Stocks in the Market Today
INCY,INCY:UW,BBG000BNQ132,"The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte",2016-11-11 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-enzo-143002423.html,"The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte"
INCY,INCY:UW,BBG000BNQ132,INCY Crosses Above Average Analyst Target,2016-11-10 16:14:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3GguPf5f1k8/incy-crosses-above-average-analyst-target-cm707153,In recent trading shares of Incyte Corporation Symbol INCY have crossed above the average analyst 12 month target price of 102 46 changing hands for 104 13 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
INCY,INCY:UW,BBG000BNQ132,Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now,2016-11-10 15:56:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e8xd6YkfwdM/drug-stocks-surge-on-trump-win-5-stocks-to-buy-now-cm707089,The Presidential election is finally over and the stock market has reacted favorably to Donald Trump s surprise win with the S amp P 500 rising 1 1 the Dow Jones Industrial Average surging 1 4 and the NASDAQ gaining 1 1 Finance energy pharma biotech financial services
INCY,INCY:UW,BBG000BNQ132,Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now,2016-11-10 13:31:01 +0000,http://finance.yahoo.com/news/drug-stocks-surge-trump-win-133101328.html,Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now
INCY,INCY:UW,BBG000BNQ132,Why Incyte (INCY) Could Be a Potential Winner,2016-11-09 16:56:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A16j3RIp974/why-incyte-incy-could-be-a-potential-winner-cm706525,It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out Before they take the plunge others get to know the hidden potential and enter into these stocks pushing them out of reach So instead of repenting spotting
INCY,INCY:UW,BBG000BNQ132,Why Incyte (INCY) Could Be a Potential Winner,2016-11-09 14:21:02 +0000,http://finance.yahoo.com/news/why-incyte-incy-could-potential-142102315.html,Why Incyte (INCY) Could Be a Potential Winner
INCY,INCY:UW,BBG000BNQ132,ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss,2016-11-08 17:03:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pR3RQEyMSuk/ariad-aria-stock-up-on-narrower-than-expected-q3-loss-cm705654,ARIAD Pharmaceutical Inc ARIA reported third quarter 2016 loss of 14 cents per share narrower than the Zacks Consensus Estimate of a loss of 19 cents and the year ago loss of 29 cents Higher U S Iclusig sales and lower costs led to narrower loss in the quarter Third quarter revenues
INCY,INCY:UW,BBG000BNQ132,ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss,2016-11-08 13:43:01 +0000,http://finance.yahoo.com/news/ariad-aria-stock-narrower-expected-134301476.html,ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss
INCY,INCY:UW,BBG000BNQ132,"3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results",2016-11-07 19:55:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5uojh-xSHWg/3-things-you-really-need-to-know-about-ariad-pharmaceuticals-inc-q3-results-cm705199,Ariad Pharmaceuticals Inc NASDAQ ARIA has given shareholders a lot to like in 2016 The biotech s stock more than doubled by early October although it has given up some of those gains in the last several weeks Ariad announced its third quarter results before the market opened
INCY,INCY:UW,BBG000BNQ132,"3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results",2016-11-07 18:22:08 +0000,http://www.fool.com/investing/2016/11/07/3-things-you-really-need-to-know-about-ariad-pharm.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: LVNTA, BIIB",2016-11-07 17:12:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iufIMiTe5BU/nasdaq-100-movers-lvnta-biib-cm704962,In early trading on Monday shares of Biogen BIIB topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 9 Year to date Biogen has lost about 4 3 of its value And the worst performing Nasdaq 100 component thus far on the day is Liberty
INCY,INCY:UW,BBG000BNQ132,"Gilead Sciences: No M&A, No Pipeline?",2016-11-07 15:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/07/gilead-sciences-no-ma-no-pipeline/?mod=yahoobarrons&ru=yahoo,"Gilead Sciences: No M&A, No Pipeline?"
INCY,INCY:UW,BBG000BNQ132,Incyte Recoups Losses After Price-Fixing Fracas On Strong Chemo Results,2016-11-04 21:18:59 +0000,http://www.investors.com/news/technology/incyte-recoups-losses-after-price-fixing-fracas-on-strong-chemo-results/,Incyte Recoups Losses After Price-Fixing Fracas On Strong Chemo Results
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,046.37 down -12.04 points",2016-11-04 20:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cjrjfs8jDj0/market-close-report-nasdaq-composite-index-closes-at-504637-down-1204-points-cm704398,Friday s session closes with the NASDAQ Composite Index at 5 046 37 The total shares traded for the NASDAQ was over 2 05 billion Friday s session closes with the NASDAQ Composite Index at 5 046 37 The total shares traded for the NASDAQ was over 2 05 billion Advancers stocks led declining by 1
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : November 4, 2016",2016-11-04 12:32:56 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-november-4-2016/,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : November 4, 2016"
INCY,INCY:UW,BBG000BNQ132,"ETF’s with exposure to Incyte Corp. : November 3, 2016",2016-11-03 16:12:08 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-incyte-corp-november-3-2016/,"ETF’s with exposure to Incyte Corp. : November 3, 2016"
INCY,INCY:UW,BBG000BNQ132,More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting,2016-11-03 14:32:00 +0000,http://finance.yahoo.com/news/more-20-abstracts-highlighting-data-143200423.html,"[Business Wire] - Incyte Corporation announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi® and its small molecule development programs targeting JAK1, LSD1 and PI3Kδ will be presented at the upcoming American Society of Hematology Annual Meeting 2016 in San Diego, California from December 3-6, 2016."
INCY,INCY:UW,BBG000BNQ132,New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo,2016-11-02 19:00:04 +0000,http://www.publicnow.com/view/74A4540406794AEC67F44D2086CC0EB317035F87,"[at noodls] - Phase 3 trial results published in Annals of the Rheumatic Diseases demonstrate baricitinib's significant efficacy in patients with inadequate response to conventional and biologic DMARDs INDIANAPOLIS, ..."
INCY,INCY:UW,BBG000BNQ132,"Zoetis (ZTS) Tops Q3 Earnings Estimates, Updates Outlook",2016-11-02 16:12:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jzCJq0cvOic/zoetis-zts-tops-q3-earnings-estimates-updates-outlook-cm702524,Zoetis Inc s ZTS third quarter 2016 earnings of 52 cents per share comfortably surpassed the Zacks Consensus Estimate of 46 cents Earnings were also up 4 from the year ago period FindTheCompany Graphiq Total revenue increased 4 year over year to 1 24 billion in
INCY,INCY:UW,BBG000BNQ132,"Gilead (GILD) Misses Q3 Earnings Estimates, Retains View",2016-11-02 16:11:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bg2Xb8JhRi8/gilead-gild-misses-q3-earnings-estimates-retains-view-cm702472,Gilead Sciences Inc s GILD third quarter 2016 earnings including the impact of stock based compensation expenses of 2 70 per share missed the Zacks Consensus Estimate of 2 74 and were down 15 4 from the year ago quarter figure Moreover total revenue in the reported quarter came in
INCY,INCY:UW,BBG000BNQ132,The Waiting Game Sends Geron Corporation Lower by Another 18% in October,2016-11-02 16:09:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oop8FZKdZls/the-waiting-game-sends-geron-corporation-lower-by-another-18-in-october-cm702500,Image source Getty Images What happened Shares of Geron Corporation NASDAQ GERN a clinical stage small cap biotech focused on the development of treatments for cancer plunged 18 in October based on data from S amp P Global Market Intelligence The reason for the
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y,2016-11-02 15:10:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/beyAAjTnkUw/incyte-incy-stock-up-as-q3-earnings-revenues-rise-yy-cm702365,Incyte Corporation INCY reported third quarter earnings of 11 cents including the impact of a change in fair value of acquisition related contingent consideration and unrealized gain on long term investment The Zacks Consensus Estimate was of breakeven results Incyte had reported a loss of
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016",2016-11-02 13:55:36 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-incy-us-earnings-analysis-q3-2016-by-the-numbers-november-2-2016/,"Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016"
INCY,INCY:UW,BBG000BNQ132,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y,2016-11-02 13:17:01 +0000,http://finance.yahoo.com/news/incyte-incy-stock-q3-earnings-131701972.html,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y
INCY,INCY:UW,BBG000BNQ132,Why Incyte's Shares Could Soon Hit $100,2016-11-02 13:17:00 +0000,https://www.thestreet.com/story/13876670/1/why-incyte-s-shares-could-soon-hit-100.html?puc=yahoo&cm_ven=YAHOO,Why Incyte's Shares Could Soon Hit $100
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conference,2016-11-02 12:20:12 +0000,http://www.publicnow.com/view/749FA7F14A5EA20FB198FBF888A980C9E6B2809F,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 2, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28 Annual Piper Jaffray Healthcare Conference onTuesday, November 29, 2016 ..."
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 1-Nov-16 2:00pm GMT,2016-11-02 01:02:15 +0000,http://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-010215469.html,Edited Transcript of INCY earnings conference call or presentation 1-Nov-16 2:00pm GMT
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,153.58 down -35.56 points",2016-11-01 20:48:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YBNEHTllpQQ/market-close-report-nasdaq-composite-index-closes-at-515358-down-3556-points-cm702061,Tuesday s session closes with the NASDAQ Composite Index at 5 153 58 The total shares traded for the NASDAQ was over 1 89 billion Declining stocks led advancers by 2 25 to 1 ratio There were 872 advancers and 1963 decliners for the day On the NASDAQ Stock Exchange 12 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,"Align, Incyte, GrubHub Among Best R&D Stock Plays: Goldman",2016-11-01 18:23:11 +0000,http://www.investors.com/news/technology/align-incyte-grubhub-palo-alto-among-best-rd-stock-plays/,"Align, Incyte, GrubHub Among Best R&D Stock Plays: Goldman"
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-11-01 11:25:20 +0000,http://biz.yahoo.com/e/161101/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
INCY,INCY:UW,BBG000BNQ132,Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs,2016-11-01 11:13:10 +0000,http://www.publicnow.com/view/8D1255E133F9E3ACA65C8287BCB8CA5427E47024,"[at noodls] - $224 million of 2016 third-quarter net product revenues from Jakafi (ruxolitinib), representing 39 percent growth over the same period last year Jakafi included as a recommended treatment for patients ..."
INCY,INCY:UW,BBG000BNQ132,Q3 2016 Incyte Corp Earnings Release - 07:00 am ET,2016-11-01 11:07:06 +0000,http://biz.yahoo.com/research/earncal/20161101.html?t=incy,Q3 2016 Incyte Corp Earnings Release - 07:00 am ET
INCY,INCY:UW,BBG000BNQ132,There's Still Time to Buy These 5 Breakout Trades,2016-11-01 10:05:00 +0000,https://www.thestreet.com/story/13874333/1/there-s-still-time-to-buy-these-5-breakout-trades.html?puc=yahoo&cm_ven=YAHOO,There's Still Time to Buy These 5 Breakout Trades
INCY,INCY:UW,BBG000BNQ132,Incyte Q3 16 Earnings Conference Call At 10:00 AM ET,2016-11-01 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9GHGU_nfMSQ/incyte-q3-16-earnings-conference-call-at-1000-am-et-20161101-00226,Incyte Q3 16 Earnings Conference Call At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Incyte Corp. Updates 2016 Guidance - Quick Facts,2016-11-01 07:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AzDiOXKb4yg/incyte-corp-updates-2016-guidance--quick-facts-20161101-01514,Incyte Corp. Updates 2016 Guidance - Quick Facts
INCY,INCY:UW,BBG000BNQ132,ARIAD (ARIA): Is a Beat in the Cards this Earnings Season?,2016-10-28 19:34:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L4xyDL6EDxo/ariad-aria-is-a-beat-in-the-cards-this-earnings-season-cm700305,ARIAD Pharmaceuticals Inc ARIA is expected to report third quarter 2016 results on Nov 1 In the last reported quarter the company recorded a positive earnings surprise of 670 Overall ARIAD has posted an average positive earnings surprise of 153 54 in the four trailing quarters Let
INCY,INCY:UW,BBG000BNQ132,"BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus",2016-10-28 16:35:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/74q6bQBXFaY/biomarin-bmrn-q3-loss-narrows-yy-pipeline-in-focus-cm700295,BioMarin Pharmaceutical Inc BMRN reported a loss of 18 cents per share in the third quarter of 2016 including stock based compensation expense narrower than the year ago loss of 44 cents The Zacks Consensus Estimate was of a loss of 39 cents per share Total revenue came in at
INCY,INCY:UW,BBG000BNQ132,"Noteworthy ETF Inflows: XBI, SRPT, TSRO, INCY",2016-10-28 16:32:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2tRE81Bhb0w/noteworthy-etf-inflows-xbi-srpt-tsro-incy-cm700265,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 111 4 million dollar inflow that s a 5 0 increase week over week in outstanding
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN) Reports Wider-than-Expected Loss in Q3,2016-10-28 15:35:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J2YfD1aMdOk/agenus-agen-reports-wider-than-expected-loss-in-q3-cm700168,Agenus Inc AGEN reported third quarter 2016 loss of 47 cents per share including non cash expenses wider than the Zacks Consensus Estimate of a loss of 32 cents as well as the loss of 16 cents in the prior year quarter Lower revenues and higher costs hurt earnings in the
INCY,INCY:UW,BBG000BNQ132,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 17:44:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-eBxuF7vS0k/bristol-myers-bmy-beats-on-q3-earnings-ups-2016-view-cm699608,Bristol Myers Squibb Company s BMY third quarter 2016 earnings of 77 cents per share beat the Zacks Consensus Estimate of 65 cents and surged 97 from the year ago period FindTheCompany Graphiq Total revenue of 4 92 billion was also above the Zacks Consensus Estimate
INCY,INCY:UW,BBG000BNQ132,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 17:42:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NShLezeq-80/celgene-celg-beats-on-q3-earnings-raises-16-outlook-cm699542,Celgene Corporation CELG reported third quarter 2016 earnings of 1 39 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 31 and surging almost 28 from the year ago period Excluding share based compensation expense Celgene
INCY,INCY:UW,BBG000BNQ132,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook",2016-10-27 15:45:03 +0000,http://finance.yahoo.com/news/celgene-celg-beats-q3-earnings-154503140.html,"Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook"
INCY,INCY:UW,BBG000BNQ132,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View",2016-10-27 15:22:03 +0000,http://finance.yahoo.com/news/bristol-myers-bmy-beats-q3-152203873.html,"Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View"
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners",2016-10-26 14:52:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIzcQfX3rcI/zackscom-featured-highlights-incyte-legacytexas-financial-group-exelixis-bayerische-motoren-werke-aktiengesellschaft-and-eqt-midstream-partners-cm698555,For Immediate Release Chicago IL October 26 2016 Stocks in this week s article include Incyte Corporation NASDAQ INCY Free Report LegacyTexas Financial Group Inc NASDAQ LTXB Free Report Exelixis Inc NASDAQ EXEL Free Report Bayerische Motoren
INCY,INCY:UW,BBG000BNQ132,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners",2016-10-26 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-incyte-133001138.html,"Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners"
INCY,INCY:UW,BBG000BNQ132,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte,2016-10-25 20:12:53 +0000,http://www.investors.com/news/technology/novartis-tumbles-on-q3-sales-miss-chemo-sales-may-boost-incyte/,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte
INCY,INCY:UW,BBG000BNQ132,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 16:28:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIXvyQoplXI/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-cm697925,Merck amp Co Inc MRK reported third quarter 2016 earnings of 1 07 per share comfortably surpassing the Zacks Consensus Estimate of 98 cents and increasing approximately 12 from the year ago period FindTheCompany Graphiq Again revenues for the quarter were up 5
INCY,INCY:UW,BBG000BNQ132,5 Profitable Stocks for Outstanding Returns,2016-10-25 15:28:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l3uB9jvLrmg/5-profitable-stocks-for-outstanding-returns-cm697956,One of the most widely used tools to measure the potential of stocks is profitability analysis It helps in evaluating whether a company can generate ample sales revenue not only to meet all its business operations but also to offer stable returns to investors There is no guarantee that the
INCY,INCY:UW,BBG000BNQ132,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates",2016-10-25 14:25:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EdFxmxEHzp8/novartis-nvs-tops-q3-earnings-misses-sales-estimates-cm697809,Novartis AG NVS reported third quarter 2016 core earnings of 1 23 per share above the Zacks Consensus Estimate of 1 18 but below than the year ago figure of 1 27 Moreover revenues declined 1 1 to 12 1 billion and missed below the Zacks Consensus Estimate of 12 3
INCY,INCY:UW,BBG000BNQ132,Aduro Stock Down on Partial Clinical Hold on LADD Studies,2016-10-25 14:25:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fgr6As9rnhM/aduro-stock-down-on-partial-clinical-hold-on-ladd-studies-cm697793,Aduro BioTech Inc s ADRO shares were down 4 5 after the company announced that the FDA has placed a partial clinical hold on studies evaluating investigational agents based on its LADD Listeria based immunotherapy construct platform The partial clinical hold was implemented after a
INCY,INCY:UW,BBG000BNQ132,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View",2016-10-25 14:04:02 +0000,http://finance.yahoo.com/news/merck-mrk-beats-q3-earnings-140402772.html,"Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View"
INCY,INCY:UW,BBG000BNQ132,5 Profitable Stocks for Outstanding Returns,2016-10-25 13:48:01 +0000,http://finance.yahoo.com/news/5-profitable-stocks-outstanding-returns-134801903.html,5 Profitable Stocks for Outstanding Returns
INCY,INCY:UW,BBG000BNQ132,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates",2016-10-25 12:59:12 +0000,http://finance.yahoo.com/news/novartis-nvs-tops-q3-earnings-125912900.html,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates"
INCY,INCY:UW,BBG000BNQ132,Agenus (AGEN): What's Ahead for the Stock in Q3 Earnings?,2016-10-24 16:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/btoXoysV1D4/agenus-agen-whats-ahead-for-the-stock-in-q3-earnings-cm697243,Agenus Inc AGEN is scheduled to report third quarter 2016 results on Oct 27 before the opening bell Last quarter Agenus delivered a positive earnings surprise of 29 41 Let s see how things are shaping up for the company this quarter Factors at Play Agenus is an immuno
INCY,INCY:UW,BBG000BNQ132,Eli Lilly and Co.’s 3Q16: The Major Developments,2016-10-21 14:04:09 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-the-major-developments/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16: The Major Developments
INCY,INCY:UW,BBG000BNQ132,"Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact",2016-10-21 14:02:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o-0m2t6pu3I/roche-rhhby-misses-q3-sales-estimates-2016-view-intact-cm696461,Roche Holding AG RHHBY reported sales of 12 79 billion CHF12 48 billion in the third quarter of 2016 compared to CHF11 94 billion 12 38 billion in the year ago comparable period The reported figure however missed the Zacks Consensus Estimate of 12 88 billion by a whisker
INCY,INCY:UW,BBG000BNQ132,"Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact",2016-10-21 12:57:12 +0000,http://finance.yahoo.com/news/roche-rhhby-misses-q3-sales-125712300.html,"Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact"
INCY,INCY:UW,BBG000BNQ132,SPDR S&P Biotech ETF Experiences Big Outflow,2016-10-20 16:25:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MYrlh9Yd0kM/spdr-sp-biotech-etf-experiences-big-outflow-cm696022,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 70 6 million dollar outflow that s a 3 0 decrease week over week from 40 200 000
INCY,INCY:UW,BBG000BNQ132,"Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View",2016-10-19 19:14:07 +0000,http://finance.yahoo.com/news/abbott-labs-abt-beats-q3-191407306.html,"Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View"
INCY,INCY:UW,BBG000BNQ132,Roche's Tecentriq Wins FDA Nod for Additional Indication,2016-10-19 12:48:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ig-tM9FvOFQ/roches-tecentriq-wins-fda-nod-for-additional-indication-cm695170,Roche Holding AG RHHBY announced that the FDA has approved its immuno oncology drug Tecentriq atezolizumab for an additional indication Tecentriq has been approved for the treatment of metastatic non small cell lung cancer NSCLC in patients whose disease has progressed during or
INCY,INCY:UW,BBG000BNQ132,Roche's Tecentriq Wins FDA Nod for Additional Indication,2016-10-19 10:52:10 +0000,http://finance.yahoo.com/news/roches-tecentriq-wins-fda-nod-105210958.html,Roche's Tecentriq Wins FDA Nod for Additional Indication
INCY,INCY:UW,BBG000BNQ132,Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study,2016-10-18 15:51:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zZCQ0HNnb8c/regeneron-teva-hit-by-clinical-hold-on-chronic-pain-study-cm694765,Both Regeneron Pharmaceuticals Inc REGN and its partner Teva Pharmaceutical Industries Ltd TEVA suffered a setback with the FDA placing a clinical hold on a phase IIb study evaluating their experimental nerve growth factor NGF antibody fasinumab for chronic low back pain While
INCY,INCY:UW,BBG000BNQ132,Shire (SHPG) Updates Vyvanse Label with New Efficacy Data,2016-10-18 13:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lqbVhPHvX-c/shire-shpg-updates-vyvanse-label-with-new-efficacy-data-cm694669,Shire plc SHPG announced that it has updated Vyvanse s label to include data associated with its supplemental New Drug Application sNDA for the treatment of adults with moderate to severe binge eating disorder B E D The updated label includes data from a phase III study SPD489
INCY,INCY:UW,BBG000BNQ132,Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study,2016-10-18 13:25:01 +0000,http://finance.yahoo.com/news/regeneron-teva-hit-clinical-hold-132501243.html,Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study
INCY,INCY:UW,BBG000BNQ132,Celgene to Present Phase Ib Data on Crohn's Disease Drug,2016-10-17 15:44:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YdgsWIca7oI/celgene-to-present-phase-ib-data-on-crohns-disease-drug-cm694152,Celgene Corporation s CELG wholly owned subsidiary Celgene International Sàrl announced encouraging data from a phase Ib study on its pipeline candidate GED 0301 mongersen Data will be presented at the United European Gastroenterology Week The randomized double blind multi
INCY,INCY:UW,BBG000BNQ132,Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC,2016-10-17 15:42:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qml6Lbl8o6I/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-cm694108,Intercept Pharmaceuticals Inc ICPT announced that that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has recommended a conditional approval of Ocaliva obeticholic acid OCA for the treatment of primary biliary cholangitis PBC Note that
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, MAT",2016-10-17 15:40:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fl_ZzoWe-9s/nasdaq-100-movers-incy-mat-cm694098,In early trading on Monday shares of Mattel MAT topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 0 Year to date Mattel registers a 13 0 gain And the worst performing Nasdaq 100 component thus far on the day is Incyte INCY
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion,2016-10-17 13:42:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_D2QW_2IhQ4/bristol-myers-wins-chmp-nod-for-opdivo-label-expansion-cm694051,Bristol Myers Squibb Company BMY announced that the European Medicines Agency s Committee for Medicinal Products for Human Use CHMP has recommended the approval of Opdivo for adults with relapsed or refractory classical Hodgkin lymphoma cHL after autologous stem cell transplant ASCT
INCY,INCY:UW,BBG000BNQ132,Celgene to Present Phase Ib Data on Crohn's Disease Drug,2016-10-17 13:24:01 +0000,http://finance.yahoo.com/news/celgene-present-phase-ib-data-132401704.html,Celgene to Present Phase Ib Data on Crohn's Disease Drug
INCY,INCY:UW,BBG000BNQ132,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion,2016-10-17 12:44:12 +0000,http://finance.yahoo.com/news/bristol-myers-wins-chmp-nod-124412636.html,Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion
INCY,INCY:UW,BBG000BNQ132,Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron,2016-10-14 16:42:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n17cqIkYVZ8/oculars-ocul-stock-jumps-on-collaboration-with-regeneron-cm693506,Regeneron Pharmaceuticals Inc REGN and Ocular Therapeutix Inc OCUL announced a strategic collaboration and option and license agreement for the development of a sustained release formulation of Regeneron s Eylea aflibercept for the treatment of wet age related macular degeneration
INCY,INCY:UW,BBG000BNQ132,Merck KGaA Offers Portfolio Updates at Market Day Event,2016-10-14 15:43:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mv1PBQZkjqY/merck-kgaa-offers-portfolio-updates-at-market-day-event-cm693418,Germany based Merck KGaA MKGAF provided an update on its objectives up to 2018 at the company s 2016 Capital Market Day At the Healthcare business the company aims to obtain approval of one medicine or indication every year starting 2017 Through 2022 Merck expects to generate sales of
INCY,INCY:UW,BBG000BNQ132,BioMarin Issues Encouraging Update on Hemophilia A Drug,2016-10-14 14:23:02 +0000,http://finance.yahoo.com/news/biomarin-issues-encouraging-hemophilia-drug-142302451.html,BioMarin Issues Encouraging Update on Hemophilia A Drug
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Third Quarter Financial Results,2016-10-14 12:20:05 +0000,http://www.publicnow.com/view/868D0ABE077D0A104650A8CDDFFBEDE804EDD1A0,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2016 financial results conference call and webcast for 10:00 ..."
INCY,INCY:UW,BBG000BNQ132,Alnylam (ALNY) to Continue Phase III Study on Patisiran,2016-10-12 14:42:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIjah7JiKzM/alnylam-alny-to-continue-phase-iii-study-on-patisiran-cm692365,Alnylam Pharmaceuticals Inc ALNY announced that the Data Monitoring Committee DMC has recommended the continuation of the phase III APOLLO study on patisiran without any modification However the committee also stated that it will periodically meet to monitor the overall safety of
INCY,INCY:UW,BBG000BNQ132,Horizon (HZNP) Stock Down on Dull Q3 View; Cuts '16 Outlook,2016-10-12 14:41:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T4RBZMv8UlA/horizon-hznp-stock-down-on-dull-q3-view-cuts-16-outlook-cm692351,Horizon Pharma plc s HZNP shares fell 6 5 after the company revealed sales and EBITDA results for the third quarter of 2016 through an 8 K filing It also provided a weak sales and EBITDA outlook for 2016 Including the impact of the 65 million settlement with Express Scripts Holding
INCY,INCY:UW,BBG000BNQ132,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 14:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xRxdEZs_O1o/biotech-stock-roundup-alnylam-slumps-on-revusiran-update-tesaro-impresses-at-esmo-cm692293,Alnylam ALNY focused on developing novel therapeutics based on RNA interference RNAi saw its shares slump on its decision to discontinue the development of a late stage pipeline candidate Meanwhile several biotech companies were present at the congress of the European Society for
INCY,INCY:UW,BBG000BNQ132,Horizon (HZNP) Stock Down on Dull Q3 View; Cuts '16 Outlook,2016-10-12 13:39:01 +0000,http://finance.yahoo.com/news/horizon-hznp-stock-down-dull-133901500.html,Horizon (HZNP) Stock Down on Dull Q3 View; Cuts '16 Outlook
INCY,INCY:UW,BBG000BNQ132,"Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook",2016-10-12 13:20:01 +0000,http://finance.yahoo.com/news/mylan-epipen-medicaid-settlement-cuts-132001214.html,"Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook"
INCY,INCY:UW,BBG000BNQ132,3 Biotechs Most Likely to Be Acquired,2016-10-12 11:28:03 +0000,http://www.fool.com/investing/2016/10/11/3-biotechs-most-likely-to-be-acquired.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs Most Likely to Be Acquired
INCY,INCY:UW,BBG000BNQ132,"XBI, SRPT, IONS, INCY: Large Outflows Detected at ETF",2016-10-11 16:19:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pQG-dTx2-bw/xbi-srpt-ions-incy-large-outflows-detected-at-etf-cm691866,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 39 3 million dollar outflow that s a 1 5 decrease week over week from 39 800 000
INCY,INCY:UW,BBG000BNQ132,New Strong Buy Stocks for October 11th,2016-10-11 11:45:11 +0000,http://finance.yahoo.com/news/strong-buy-stocks-october-11th-114511999.html,New Strong Buy Stocks for October 11th
INCY,INCY:UW,BBG000BNQ132,3 biotech breakouts,2016-10-10 21:42:00 +0000,http://finance.yahoo.com/video/3-biotech-breakouts-214200206.html,3 biotech breakouts
INCY,INCY:UW,BBG000BNQ132,10 Hot Stocks That Made Millionaires in 10 Years,2016-10-10 21:18:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oSZ9BHPwI4E/10-hot-stocks-that-made-millionaires-in-10-years-cm691333,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Do you own any hot stocks that have dished out a 1 000 return in a decade or less 160 Those are the kind of results you only hear about when they happen to someone else and all too often the those
INCY,INCY:UW,BBG000BNQ132,Will Gilead Sciences Inc. Set Its Sights on Incyte?,2016-10-10 16:30:48 +0000,http://www.fool.com/investing/2016/10/10/will-gilead-sciences-inc-set-its-sights-on-incyte.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Will Gilead Sciences Inc. Set Its Sights on Incyte?
INCY,INCY:UW,BBG000BNQ132,Can the Rally in Incyte (INCY) Shares Continue?,2016-10-10 11:49:11 +0000,http://finance.yahoo.com/news/rally-incyte-incy-shares-continue-114911583.html,Can the Rally in Incyte (INCY) Shares Continue?
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,292.41 down -14.44 points",2016-10-07 20:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MC0ay0tm1IM/market-close-report-nasdaq-composite-index-closes-at-529241-down-1444-points-cm690563,Friday s session closes with the NASDAQ Composite Index at 5 292 41 The total shares traded for the NASDAQ was over 1 61 billion Declining stocks led advancers by 1 86 to 1 ratio There were 1003 advancers and 1867 decliners for the day On the NASDAQ Stock Exchange 22 stocks reached a 52
INCY,INCY:UW,BBG000BNQ132,Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results,2016-10-07 20:23:53 +0000,http://www.investors.com/news/technology/incyte-could-stoke-ma-fire-on-deep-and-durable-melanoma-drug-results/,Incyte Could Stoke M&A Fire On 'Deep And Durable' Melanoma Drug Results
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: LBTYK, INCY",2016-10-07 15:45:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4wvn63qJQl0/nasdaq-100-movers-lbtyk-incy-cm690328,In early trading on Friday shares of Incyte topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 8 Year to date Incyte has lost about 11 1 of its value And the worst performing Nasdaq 100 component thus far on the day is Liberty Global Class
INCY,INCY:UW,BBG000BNQ132,These Are the Fastest Growing Profitable Biotech Stocks,2016-10-07 14:12:36 +0000,http://www.fool.com/investing/2016/10/07/these-are-the-fastest-growing-profitable-biotech-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,These Are the Fastest Growing Profitable Biotech Stocks
INCY,INCY:UW,BBG000BNQ132,Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab),2016-10-07 08:19:00 +0000,http://www.publicnow.com/view/8DE669D48AB5AD2E631D7998394D39C2A2C292B4,"[at noodls] - Updated data published at ESMO to be discussed on Incyte investor conference call and webcast today, 7 October, at 14:00 CET / 8:00 a.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 7, 2016-- Incyte Corporation ..."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: TSLA, LRCX",2016-10-06 15:46:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CyDFd17yU20/nasdaq-100-movers-tsla-lrcx-cm689755,In early trading on Thursday shares of Lam Research LRCX topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 4 Year to date Lam Research registers a 24 0 gain And the worst performing Nasdaq 100 component thus far on the day is Tesla
INCY,INCY:UW,BBG000BNQ132,What Will Gilead Try Buying Next? Polls Offer Some 'Incyte',2016-09-30 20:20:31 +0000,http://www.investors.com/news/technology/post-medivation-flop-to-pfizer-what-will-gilead-try-buying-next/,What Will Gilead Try Buying Next? Polls Offer Some 'Incyte'
INCY,INCY:UW,BBG000BNQ132,Biotech stocks have plenty of catalysts around the corner,2016-09-30 17:28:21 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0681569A-8646-11E6-A751-447CDAF369FF&siteid=yhoof2,Biotech stocks have plenty of catalysts around the corner
INCY,INCY:UW,BBG000BNQ132,ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan,2016-09-30 16:24:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kDxR7UD1Fho/ariad-aria-leukemia-drug-iclusig-gets-approval-in-japan-cm687182,ARIAD Pharmaceuticals Inc ARIA announced that its partner Otsuka Pharmaceutical Co Ltd has gained approval from the Japanese Pharmaceuticals and Medical Devices Agency for leukemia drug Iclusig Iclusig is approved for the treatment of patients with chronic myeloid leukemia CML
INCY,INCY:UW,BBG000BNQ132,"Street Talk: INCY, EBAY & more",2016-09-29 17:51:00 +0000,http://finance.yahoo.com/video/street-talk-incy-ebay-more-175100612.html,"Street Talk: INCY, EBAY & more"
INCY,INCY:UW,BBG000BNQ132,"Market Close Report: NASDAQ Composite index closes at 5,318.55 up 12.84 points",2016-09-28 20:48:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N8LyhCJHfio/market-close-report-nasdaq-composite-index-closes-at-531855-up-1284-points-cm686239,Wednesday s session closes with the NASDAQ Composite Index at 5 318 55 The total shares traded for the NASDAQ was over 1 79 billion Wednesday s session closes with the NASDAQ Composite Index at 5 318 55 The total shares traded for the NASDAQ was over 1 79 billion Advancers stocks led
INCY,INCY:UW,BBG000BNQ132,Wednesday's ETF with Unusual Volume: FTC,2016-09-28 20:21:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n2j5QwF_-0k/wednesdays-etf-with-unusual-volume-ftc-cm686182,The First Trust Large Cap Growth AlphaDEX Fund ETF FTC is seeing unusually high volume in afternoon trading Wednesday with over 115 000 shares traded versus three month average volume of about 60 000 Shares of FTC were trading flat on the day Components of that ETF with the
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: PAYX, INCY",2016-09-28 16:21:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rFluA6Evgs0/nasdaq-100-movers-payx-incy-cm685989,In early trading on Wednesday shares of Incyte topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 6 Year to date Incyte has lost about 13 3 of its value And the worst performing Nasdaq 100 component thus far on the day is Paychex trading
INCY,INCY:UW,BBG000BNQ132,Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab),2016-09-28 10:29:08 +0000,http://www.publicnow.com/view/73977C7C36CA6AEA0C03500F9517435CAC5C134A,"[at noodls] - Incyte's IDO1 inhibitor in combination with Merck's anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma WILMINGTON, Del.--(BUSINESS ..."
INCY,INCY:UW,BBG000BNQ132,Incyte Corp. (INCY) Has Risen To Over An 8-Month High On Study Results,2016-09-28 09:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-P6CJ8dN2y4/incyte-corp-incy-has-risen-to-over-an-8month-high-on-study-results-20160928-00533,Incyte Corp. (INCY) Has Risen To Over An 8-Month High On Study Results
INCY,INCY:UW,BBG000BNQ132,"National Research Corporation (NRCIB) Ex-Dividend Date Scheduled for September 28, 2016",2016-09-27 13:14:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ad_Tv8bI3iI/national-research-corporation-nrcib-ex-dividend-date-scheduled-for-september-28-2016-cm685100,National Research Corporation NRCIB will begin trading ex dividend on September 28 2016 A cash dividend payment of 0 48 per share is scheduled to be paid on October 14 2016 Shareholders who purchased NRCIB prior to the ex dividend date are eligible for the cash dividend payment
INCY,INCY:UW,BBG000BNQ132,"National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for September 28, 2016",2016-09-27 13:11:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLjmfs-u5Y0/national-research-corporation-nrcia-ex-dividend-date-scheduled-for-september-28-2016-cm685012,National Research Corporation NRCIA will begin trading ex dividend on September 28 2016 A cash dividend payment of 0 08 per share is scheduled to be paid on October 14 2016 Shareholders who purchased NRCIA prior to the ex dividend date are eligible for the cash dividend payment
INCY,INCY:UW,BBG000BNQ132,NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis,2016-09-27 11:45:00 +0000,http://finance.yahoo.com/news/nccn-guidelines-recommend-jakafi-ruxolitinib-114500468.html,"[Business Wire] - Incyte Corporation today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi® , has been included as a recommended treatment in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for myelofibrosis ."
INCY,INCY:UW,BBG000BNQ132,Incyte : NCCN Guidelines Recommend Jakafi For Treatment Of Myelofibrosis,2016-09-27 07:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OsYomMJmmBs/incyte--nccn-guidelines-recommend-jakafi-for-treatment-of-myelofibrosis-20160927-00982,Incyte : NCCN Guidelines Recommend Jakafi For Treatment Of Myelofibrosis
INCY,INCY:UW,BBG000BNQ132,"Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98",2016-09-26 16:40:08 +0000,http://finance.yahoo.com/news/incyte-could-takeover-target-argus-164008720.html,"Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: NTES, WDC",2016-09-26 16:24:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLMC2Ed3d2A/nasdaq-100-movers-ntes-wdc-cm684511,In early trading on Monday shares of Western Digital WDC topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 4 Year to date Western Digital has lost about 5 5 of its value And the worst performing Nasdaq 100 component thus far on the day
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016",2016-09-21 15:34:56 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-value-analysis-nasdaqincy-september-21-2016/,"Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016"
INCY,INCY:UW,BBG000BNQ132,3 Buyout Targets That Could Get Snatched Up,2016-09-21 13:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GoovjQaqFyo/3-buyout-targets-that-could-get-snatched-up-cm682456,Image source Getty Images Your investment thesis should never hinge completely on a takeover even if rumors are swirling but some stocks have more acquisition potential than others Here are three buyout targets for 2016 or the near
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 20, 2016",2016-09-20 12:14:20 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-breached-its-50-day-moving-average-in-a-bullish-manner-incy-us-september-20-2016/,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 20, 2016"
INCY,INCY:UW,BBG000BNQ132,"After Losing Medivation, Who Is Gilead Going After Next?",2016-09-19 19:00:00 +0000,http://www.forbes.com/sites/kenkam/2016/09/19/who-is-gilead-about-to-buy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"After Losing Medivation, Who Is Gilead Going After Next?"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, SWKS",2016-09-15 16:17:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SVvFM7nQN3A/nasdaq-100-movers-incy-swks-cm680020,In early trading on Thursday shares of Skyworks Solutions SWKS topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 7 Year to date Skyworks Solutions has lost about 2 3 of its value And the worst performing Nasdaq 100 component thus far
INCY,INCY:UW,BBG000BNQ132,The Implied Analyst 12-Month Target For QQEW,2016-09-15 13:17:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WoqTbbh7g-0/the-implied-analyst-12-month-target-for-qqew-cm679817,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
INCY,INCY:UW,BBG000BNQ132,Incyte Morgan Stanley Global Healthcare Conference; Webcast At 11:05 AM ET,2016-09-14 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VEpDLlBjXDk/incyte-morgan-stanley-global-healthcare-conference-webcast-at-1105-am-et-20160914-00624,Incyte Morgan Stanley Global Healthcare Conference; Webcast At 11:05 AM ET
INCY,INCY:UW,BBG000BNQ132,2 Companies Johnson & Johnson Should Consider Buying,2016-09-09 15:34:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w7n5mJJndMc/2-companies-johnson-johnson-should-consider-buying-cm676887,Johnson amp Johnson s straight shooting CEO Alex Gorsky Image source Johnson amp Johnson Healthcare conglomerate Johnson amp Johnson NYSE JNJ is a staple holding for quite a few long term investors and retirees and there s a long list of reasons why 160 The company
INCY,INCY:UW,BBG000BNQ132,"ETF’s with exposure to Incyte Corp. : September 9, 2016",2016-09-09 14:56:20 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-incyte-corp-september-9-2016/,"ETF’s with exposure to Incyte Corp. : September 9, 2016"
INCY,INCY:UW,BBG000BNQ132,2 Companies Johnson & Johnson Should Consider Buying,2016-09-09 13:41:05 +0000,http://www.fool.com/investing/2016/09/09/2-companies-johnson-johnson-should-consider-buying.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Companies Johnson & Johnson Should Consider Buying
INCY,INCY:UW,BBG000BNQ132,"Notable ETF Outflow Detected - PBE, INCY, BMRN, REGN",2016-09-08 16:18:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6_o810aC6k/notable-etf-outflow-detected-pbe-incy-bmrn-regn-cm676274,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the PowerShares Dynamic Biotechnology amp Genome Portfolio Symbol PBE where we have detected an approximate 35 1 million dollar outflow that s a 12 0
INCY,INCY:UW,BBG000BNQ132,Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month,2016-09-08 13:00:00 +0000,http://finance.yahoo.com/news/incyte-supports-those-affected-rare-130000489.html,"[Business Wire] - Incyte Corporation calls for increased awareness and support for those living with myeloproliferative neoplasms today, MPN Awareness Day, and throughout September, Blood Cancer Awareness Month."
INCY,INCY:UW,BBG000BNQ132,CAR-T Isn't the Only Play in Immunotherapy Stocks,2016-09-07 15:18:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NUuA4tX0cf0/car-t-isnt-the-only-play-in-immunotherapy-stocks-cm675573,Image source 160 Getty Images Despite a few recent setbacks the enthusiasm for immunotherapy stocks hasn t dampened all that much Led by an insatiable appetite for therapies based on chimeric antigen receptor T cells or CAR T several biopharmaceutical companies have found
INCY,INCY:UW,BBG000BNQ132,CAR-T Isn't the Only Play in Immunotherapy Stocks,2016-09-07 13:21:38 +0000,http://www.fool.com/investing/2016/09/07/car-t-isnt-the-only-play-in-immunotherapy-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,CAR-T Isn't the Only Play in Immunotherapy Stocks
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 7, 2016",2016-09-07 12:28:49 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-breached-its-50-day-moving-average-in-a-bullish-manner-incy-us-september-7-2016/,"Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 7, 2016"
INCY,INCY:UW,BBG000BNQ132,These Collaborations Could Boost Jakafi Sales,2016-09-06 12:04:20 +0000,http://marketrealist.com/2016/09/collaborations-boost-jakafi-sales/?utm_source=yahoo&utm_medium=feed,These Collaborations Could Boost Jakafi Sales
INCY,INCY:UW,BBG000BNQ132,"Incyte’s Profitability Improves, Allowing for Revised Guidance",2016-09-05 15:04:24 +0000,http://marketrealist.com/2016/09/incytes-profitability-improves-allowing-revised-guidance/?utm_source=yahoo&utm_medium=feed,"Incyte’s Profitability Improves, Allowing for Revised Guidance"
INCY,INCY:UW,BBG000BNQ132,How Is Incyte’s Only FDA-Approved Drug Performing?,2016-09-05 14:04:29 +0000,http://marketrealist.com/2016/09/incytes-fda-approved-drug-performing/?utm_source=yahoo&utm_medium=feed,How Is Incyte’s Only FDA-Approved Drug Performing?
INCY,INCY:UW,BBG000BNQ132,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs,2016-09-05 12:04:36 +0000,http://marketrealist.com/2016/09/incytes-product-portfolio-includes-potentially-lucrative-drugs/?utm_source=yahoo&utm_medium=feed,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
INCY,INCY:UW,BBG000BNQ132,Understanding Incyte’s Revenue Stream in 2Q16,2016-09-02 20:04:05 +0000,http://marketrealist.com/2016/09/understanding-incytes-revenue-stream-2q16/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream in 2Q16
INCY,INCY:UW,BBG000BNQ132,Is Incyte Hurt by Having Only One FDA-Approved Drug?,2016-09-02 18:04:05 +0000,http://marketrealist.com/2016/09/incyte-hurt-one-fda-approved-drug/?utm_source=yahoo&utm_medium=feed,Is Incyte Hurt by Having Only One FDA-Approved Drug?
INCY,INCY:UW,BBG000BNQ132,How Incyte’s Valuation Measures Up to Its Peers,2016-09-02 16:13:48 +0000,http://marketrealist.com/2016/09/incytes-valuation-measures-peers/?utm_source=yahoo&utm_medium=feed,How Incyte’s Valuation Measures Up to Its Peers
INCY,INCY:UW,BBG000BNQ132,'Mad Money' Lightning Round: I'm Staying With Potash,2016-09-01 10:00:00 +0000,https://www.thestreet.com/story/13597457/1/mad-money-lightning-round-i-m-staying-with-potash.html?puc=yahoo&cm_ven=YAHOO,'Mad Money' Lightning Round: I'm Staying With Potash
INCY,INCY:UW,BBG000BNQ132,Cramer: September could be dicey for these stocks,2016-08-31 23:00:00 +0000,http://www.cnbc.com/id/103906376?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103906376,Cramer: September could be dicey for these stocks
INCY,INCY:UW,BBG000BNQ132,3 Biotech Stocks Could Be the Next Big Takeover Targets,2016-08-31 12:20:37 +0000,http://247wallst.com/healthcare-business/2016/08/31/3-biotech-stocks-could-be-the-next-big-takeover-targets/,3 Biotech Stocks Could Be the Next Big Takeover Targets
INCY,INCY:UW,BBG000BNQ132,"CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up",2016-08-30 16:14:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eh9u08xRhCE/cti-biopharma-reports-mixed-pacritinib-study-data-stock-up-cm672282,"CTI BioPharma Corp. 's CTIC shares gained 14.9% after the company announced top line results from a phase III study (PERSIST 2) on pacritinib, wherein the study met one of the co primary endpoints.  The PERSIST"
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2016-08-30 12:23:03 +0000,http://www.publicnow.com/view/5849067558EBC50758CD085834936C279E79DBC6,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 30, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley ..."
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2016-08-30 12:00:00 +0000,http://finance.yahoo.com/news/incyte-present-upcoming-investor-conferences-120000031.html,[Business Wire] - Incyte Corporation announced today that it will present at the following investor conferences during the month of September:
INCY,INCY:UW,BBG000BNQ132,Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year,2016-08-25 11:48:07 +0000,http://www.publicnow.com/view/3F482AECE1B50DC529113B94BBF1F3BDD3C87518,"[at noodls] - Company ranked 4in 2016 and in Top 10 for Second Year Running WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 25, 2016-- Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4thon Forbes magazine's ..."
INCY,INCY:UW,BBG000BNQ132,Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears,2016-08-24 20:50:18 +0000,http://www.investors.com/news/technology/biotech-stocks-seesaw-as-ma-hopes-meet-new-pricing-fears/,Biotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears
INCY,INCY:UW,BBG000BNQ132,Call buyers betting on rebound in Incyte,2016-08-24 18:04:38 +0000,http://finance.yahoo.com/news/call-buyers-bet-rebound-incyte-180300796.html,Call buyers betting on rebound in Incyte
INCY,INCY:UW,BBG000BNQ132,INCY Crosses Above Key Moving Average Level,2016-08-24 16:39:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a796qipU0zg/incy-crosses-above-key-moving-average-level-cm669565,"In trading on Wednesday, shares of Incyte Corporation (Symbol INCY) crossed above their 200 day moving average of $84.56, changing hands as high as $87.98 per share. Incyte Corporation shares are currently trading up about 6.4% on the day."
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INTU, INCY",2016-08-24 15:45:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fH0kDiAx1Hw/nasdaq-100-movers-intu-incy-cm669487,"In early trading on Wednesday, shares of Incyte topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.7%. Year to date, Incyte has lost"
INCY,INCY:UW,BBG000BNQ132,[$$] Smaller Biotech Buyout Targets After Medivation,2016-08-24 15:17:00 +0000,http://www.barrons.com/articles/smaller-biotech-buyout-targets-after-medivation-1472051871?mod=yahoobarrons&ru=yahoo,[$$] Smaller Biotech Buyout Targets After Medivation
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: MYL, AMAT",2016-08-23 15:46:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aISTxGSRoFo/nasdaq-100-movers-myl-amat-cm668947,"In early trading on Tuesday, shares of Applied Materials topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.0%. Year to date, Applied Materials"
INCY,INCY:UW,BBG000BNQ132,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss",2016-08-23 13:44:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/23/4-biotech-buyout-targets-for-gilead-sanofi-after-medivation-miss/?mod=yahoobarrons&ru=yahoo,"4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss"
INCY,INCY:UW,BBG000BNQ132,Biotech's next big deal?,2016-08-22 21:25:00 +0000,http://finance.yahoo.com/video/biotechs-next-big-deal-212500006.html,Biotech's next big deal?
INCY,INCY:UW,BBG000BNQ132,Pfizer-Medivation Deal Reignites Biotech Buyout Speculation,2016-08-22 20:29:12 +0000,http://www.investors.com/news/technology/pfizer-medivation-deal-reignites-biotech-buyout-speculation/,Pfizer-Medivation Deal Reignites Biotech Buyout Speculation
INCY,INCY:UW,BBG000BNQ132,"Stocks Struggle For Direction As Oil Sinks, Biotechs Soar",2016-08-22 17:52:09 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-slide-deeper-into-red-as-oil-sinks-but-biotechs-soar/,"Stocks Struggle For Direction As Oil Sinks, Biotechs Soar"
INCY,INCY:UW,BBG000BNQ132,"Monday's ETF Movers: BBH, SIL",2016-08-22 17:42:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i1pJV6B2HPA/mondays-etf-movers-bbh-sil-cm668577,"In trading on Monday, the Biotech ETF is outperforming other ETFs, up about 2.2% on the day. Components of that ETF showing particular strength include shares of Medivation, up about 19.8% and shares"
INCY,INCY:UW,BBG000BNQ132,Biotechs Rise on Bet Medivation Losers Will Look to Next Deal,2016-08-22 17:14:52 +0000,http://finance.yahoo.com/news/biotechs-rise-bet-medivation-losers-171452706.html,Biotechs Rise on Bet Medivation Losers Will Look to Next Deal
INCY,INCY:UW,BBG000BNQ132,"Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal",2016-08-22 16:07:00 +0000,https://www.thestreet.com/story/13681606/1/incyte-incy-stock-rises-on-takeover-speculation-after-14-billion-pfizer-medivation-deal.html?puc=yahoo&cm_ven=YAHOO,"Incyte (INCY) Stock Rises on Takeover Speculation After $14 Billion Pfizer, Medivation Deal"
INCY,INCY:UW,BBG000BNQ132,Biotech stocks rally as investors bet on the next big tie-up,2016-08-22 15:57:44 +0000,http://www.cnbc.com/id/103884606?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103884606,Biotech stocks rally as investors bet on the next big tie-up
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: VIAB, INCY",2016-08-22 15:43:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VKjnAsmpBQM/nasdaq-100-movers-viab-incy-cm668408,"In early trading on Monday, shares of Incyte topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.9%. Year to date, Incyte has lost"
INCY,INCY:UW,BBG000BNQ132,"ETF’s with exposure to Incyte Corp. : August 22, 2016",2016-08-22 15:35:25 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-incyte-corp-august-22-2016/,"ETF’s with exposure to Incyte Corp. : August 22, 2016"
INCY,INCY:UW,BBG000BNQ132,Hunting For Biotech Stocks? Understand The Earnings Formula First,2016-08-19 20:19:11 +0000,http://www.investors.com/news/technology/biotech-sales-growth-how-much-is-demand-how-much-is-price/,Hunting For Biotech Stocks? Understand The Earnings Formula First
INCY,INCY:UW,BBG000BNQ132,2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now,2016-08-18 17:46:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4a7objOmRS4/2-cancer-therapy-stocks-that-are-ridiculously-cheap-right-now-cm667241,The cancer drug market is already valued at over $100 billion but is still growing at one of the fastest compound annual growth rates  in entire the pharmaceutical industry. The underlying reason for this surge in oncology
INCY,INCY:UW,BBG000BNQ132,2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now,2016-08-18 15:38:00 +0000,http://www.fool.com/investing/2016/08/18/2-cancer-therapy-stocks-that-are-ridiculously-chea.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now
INCY,INCY:UW,BBG000BNQ132,Another Endorsement for Biotech ETFs,2016-08-17 21:56:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hYQcDdHfypE/another-endorsement-for-biotech-etfs-cm666016,"The iShares Nasdaq Biotechnology ETF (NasdaqGS  IBB ) , which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have"
INCY,INCY:UW,BBG000BNQ132,Add Up The Pieces: GURU Could Be Worth $27,2016-08-15 13:34:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YymBHO9_mkg/add-up-the-pieces-guru-could-be-worth-27-cm665193,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : August 12, 2016",2016-08-12 12:18:24 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-breached-its-50-day-moving-average-in-a-bearish-manner-incy-us-august-12-2016/,"Incyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : August 12, 2016"
INCY,INCY:UW,BBG000BNQ132,"Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation",2016-08-11 16:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M3jlCnhmI04/better-buy-inovio-pharmaceuticals-inc-vs-incyte-corporation-cm664161,"Image source  Getty Images.  At first glance, the choice between Inovio Pharmaceuticals (NASDAQ  INO) and Incyte (NASDAQ  INCY) seems like a no brainer for biotech investors. Incyte has the bigger market"
INCY,INCY:UW,BBG000BNQ132,"ETF’s with exposure to Incyte Corp. : August 11, 2016",2016-08-11 16:51:27 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-incyte-corp-august-11-2016/,"ETF’s with exposure to Incyte Corp. : August 11, 2016"
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: INCY, YHOO",2016-08-11 15:49:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l45I9f2-zcs/nasdaq-100-movers-incy-yhoo-cm664047,"In early trading on Thursday, shares of Yahoo topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.3%. Year to date, Yahoo registers a 24.0% gain. And the worst performing Nasdaq"
INCY,INCY:UW,BBG000BNQ132,"Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation",2016-08-11 14:45:00 +0000,http://www.fool.com/investing/2016/08/11/better-buy-inovio-pharmaceuticals-inc-vs-incyte-co.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation"
INCY,INCY:UW,BBG000BNQ132,How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?,2016-08-10 21:57:00 +0000,https://www.thestreet.com/story/13672025/1/how-will-incyte-incy-stock-react-to-price-target-raise-at-barclays.html?puc=yahoo&cm_ven=YAHOO,How Will Incyte (INCY) Stock React to Price Target Raise at Barclays?
INCY,INCY:UW,BBG000BNQ132,Why Ariad Pharmaceuticals Gained 26.9% in July,2016-08-10 15:53:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hx6qONbrA6c/why-ariad-pharmaceuticals-gained-269-in-july-cm663400,"Image Source  Getty Images  What   Shares of Ariad Pharmaceuticals (NASDAQ  ARIA) , a mid cap oncology company, gained close to 27% in July, according to data from S&P Global Market Intelligence"
INCY,INCY:UW,BBG000BNQ132,"Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016",2016-08-10 14:22:10 +0000,http://www.capitalcube.com/blog/index.php/incyte-corp-incy-us-earnings-analysis-q2-2016-by-the-numbers-august-10-2016/,"Incyte Corp. :INCY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016"
INCY,INCY:UW,BBG000BNQ132,"Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline",2016-08-10 13:28:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d1BtdDfLPkE/repros-rprx-q2-loss-narrower-yy-focus-on-pipeline-cm663085,"Repros Therapeutics Inc.RPRX reported a loss of 18 cents per share in the second quarter of 2016, significantly narrower than the year ago loss of 32 cents mainly due to lower research & development (R&D) expenses as well as"
INCY,INCY:UW,BBG000BNQ132,"Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline",2016-08-10 11:38:11 +0000,http://finance.yahoo.com/news/repros-rprx-q2-loss-narrower-113811925.html,"Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline"
INCY,INCY:UW,BBG000BNQ132,Edited Transcript of INCY earnings conference call or presentation 9-Aug-16 2:00pm GMT,2016-08-10 01:03:08 +0000,http://finance.yahoo.com/news/edited-transcript-incy-earnings-conference-010308308.html,Edited Transcript of INCY earnings conference call or presentation 9-Aug-16 2:00pm GMT
INCY,INCY:UW,BBG000BNQ132,Why There Is Upside for Incyte Despite Recent Selloff,2016-08-09 18:46:00 +0000,https://www.thestreet.com/story/13669848/1/why-there-is-upside-for-incyte-despite-recent-selloff.html?puc=yahoo&cm_ven=YAHOO,Why There Is Upside for Incyte Despite Recent Selloff
INCY,INCY:UW,BBG000BNQ132,Incyte beats Street 2Q forecasts,2016-08-09 13:03:29 +0000,http://sg.finance.yahoo.com/news/incyte-beats-street-2q-forecasts-130329863.html,Incyte beats Street 2Q forecasts
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits",2016-08-09 11:13:23 +0000,http://biz.yahoo.com/e/160809/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits"
INCY,INCY:UW,BBG000BNQ132,Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs,2016-08-09 11:10:12 +0000,http://www.publicnow.com/view/A0D6C68D0BC94E6C539C7F5D7F754DD8F6293080,"[at noodls] - $208 million of 2016 second-quarter net product revenues from Jakafi (ruxolitinib), representing 46 percent growth over the same period last year ECHO-301, the first Phase 3 trial evaluating epacadostat, ..."
INCY,INCY:UW,BBG000BNQ132,Q2 2016 Incyte Corp Earnings Release - 07:00 am ET,2016-08-09 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20160809.html?t=incy,Q2 2016 Incyte Corp Earnings Release - 07:00 am ET
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation Q2 16 Earnings Conference Call At 10:00 AM ET,2016-08-09 09:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vF30QZlA1hw/incyte-corporation-q2-16-earnings-conference-call-at-1000-am-et-20160809-00602,Incyte Corporation Q2 16 Earnings Conference Call At 10:00 AM ET
INCY,INCY:UW,BBG000BNQ132,Incyte Corporation Q2 Earnings Climb 271%,2016-08-09 07:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wDFqryCb5IY/incyte-corporation-q2-earnings-climb-271-20160809-00255,Incyte Corporation Q2 Earnings Climb 271%
INCY,INCY:UW,BBG000BNQ132,"Pre-Market Earnings Report for August 9, 2016 :  CHTR, EXC, PPL, HCP, INCY, TDG, COH, LNG, WWAV, NCLH, BR, VRX",2016-08-08 20:18:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpHzUF8KpUI/pre-market-earnings-report-for-august-9-2016-chtr-exc-ppl-hcp-incy-tdg-coh-lng-wwav-nclh-br-vrx-cm662081,"The following companies are expected to report earnings prior to market open on 08 09 2016. Visit our Earnings Calendar for a full list of expected earnings releases.  Charter Communications, Inc. ( CHTR ) is reporting"
INCY,INCY:UW,BBG000BNQ132,"Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More",2016-08-08 16:18:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eseeB-oZiz8/drug-stocks-to-watch-for-earnings-on-aug-9-myl-incy-more-cm661877,The Q2 earnings season is almost approaching its end with 87.7% (as of Aug 5) of the S&P 500 members having already reported results. The Retail sector is the only one at this point that has a substantial number
INCY,INCY:UW,BBG000BNQ132,"Nasdaq 100 Movers: NFLX, QVCA",2016-08-08 16:15:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3IgJ0EwseNc/nasdaq-100-movers-nflx-qvca-cm661852,"In early trading on Monday, shares of Liberty Interactive ( QVCA ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.5%. Year to date, Liberty Interactive has lost about 20.4% of"
INCY,INCY:UW,BBG000BNQ132,"Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More",2016-08-08 14:05:02 +0000,http://finance.yahoo.com/news/drug-stocks-watch-earnings-aug-140502499.html,"Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More"
INCY,INCY:UW,BBG000BNQ132,Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?,2016-08-05 21:12:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FHTTNUonDvU/mylan-myl-q2-earnings-will-the-stock-disappoint-cm661344,"Mylan N.V.MYL is scheduled to report second quarter 2016 results on Aug 9, after market close. Mylan's performance has been impressive with the company beating earnings estimates in three of the last four quarters. Overall, the company has delivered"
INCY,INCY:UW,BBG000BNQ132,What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?,2016-08-05 14:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3WmQUCvgCQo/whats-in-store-for-myriad-genetics-mygn-in-q4-earnings-cm661077,"Myriad Genetics, Inc.MYGN is scheduled to report its fourth quarter fiscal 2016 financial results on Aug 9, after the closing bell. Last quarter, the company posted a positive earnings surprise of 7.89%. Encouragingly, Myriad's earnings outpaced the Zacks Consensus"
INCY,INCY:UW,BBG000BNQ132,Can TransDigm (TDG) Spring a Surprise in Q3 Earnings?,2016-08-05 14:57:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QTTsyJ8jHtU/can-transdigm-tdg-spring-a-surprise-in-q3-earnings-cm661024,"TransDigm Group IncorporatedTDG is set to report third quarter fiscal 2016 results, after the closing bell on Aug 9. Last quarter, the company posted a positive earnings surprise of 12.4%. TransDigm has managed to beat earnings estimates twice in"
INCY,INCY:UW,BBG000BNQ132,Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?,2016-08-05 13:59:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mf6K-gaXvkI/jazz-jazz-q2-earnings-will-the-stock-disappoint-cm660940,"Jazz Pharmaceuticals plcJAZZ is scheduled to report second quarter 2016 results on Aug 9, after the market closes . Last quarter, the company had comfortably surpassed expectations with a positive earnings surprise of 42.75%. Let's see how things have"
INCY,INCY:UW,BBG000BNQ132,BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?,2016-08-05 13:58:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C_9dTkRoWPc/biodelivery-bdsi-q2-earnings-will-the-stock-disappoint-cm660933,"BioDelivery Sciences International, Inc.BDSI is scheduled to report second quarter 2016 results on Aug 9, before the opening bell. Last quarter, the company's loss was in line with expectations. Let's see how things are shaping up for the second"
INCY,INCY:UW,BBG000BNQ132,Allergan (AGN) Q2 Earnings: Will the Stock Disappoint?,2016-08-04 14:59:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RMObNeHtUmc/allergan-agn-q2-earnings-will-the-stock-disappoint-cm660308,Allergan plcAGN is scheduled to report second quarter 2016 results before the opening bell on Aug 8. The company delivered a positive earnings surprise of 1.67% in the first quarter. Let's see how things are shaping up for the
INCY,INCY:UW,BBG000BNQ132,Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings?,2016-08-04 14:58:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ajMCaLJ7V44/celldex-cldx-whats-ahead-for-the-stock-in-q2-earnings-cm660292,"Celldex Therapeutics, Inc.CLDX will be reporting second quarter 2016 results on Aug 8. Let's see how things are shaping up for this Zacks Rank #3 (Hold) stock.Factors at Play Celldex, a development stage, biopharmaceutical company, is focused on the"
INCY,INCY:UW,BBG000BNQ132,ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat,2016-07-29 13:23:01 +0000,http://finance.yahoo.com/news/ariads-aria-stock-q2-earnings-132301754.html,ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
INCY,INCY:UW,BBG000BNQ132,What Do Analysts Recommend for United Therapeutics?,2016-07-22 17:12:23 +0000,http://marketrealist.com/2016/07/united-therapeutics-key-analyst-recommendations-2016/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for United Therapeutics?
INCY,INCY:UW,BBG000BNQ132,Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?,2016-07-21 11:08:11 +0000,http://finance.yahoo.com/news/eli-lilly-lly-may-beat-110811416.html,Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?
INCY,INCY:UW,BBG000BNQ132,"INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers",2016-07-19 20:07:14 +0000,http://biz.yahoo.com/e/160719/incy8-k.html,"INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers"
INCY,INCY:UW,BBG000BNQ132,"Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016",2016-07-19 11:35:00 +0000,http://finance.yahoo.com/news/updated-data-epacadostat-incyte-selective-113500768.html,"[Business Wire] - Incyte Corporation announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology Annual Congress 2016, taking place in Copenhagen, Denmark from October 7-11, 2016."
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Second Quarter Financial Results,2016-07-14 12:38:16 +0000,http://www.publicnow.com/view/D3C12CC3C09FFA4EB2BCA214B619A7D20BC01440,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter 2016 financial results conference call and webcast for 10:00 ..."
INCY,INCY:UW,BBG000BNQ132,"[$$] Incyte, a Biotech Acquisition Target",2016-07-14 09:45:00 +0000,http://www.barrons.com/articles/incyte-a-biotech-acquisition-target-1468489503?mod=yahoobarrons&ru=yahoo,"[$$] Incyte, a Biotech Acquisition Target"
INCY,INCY:UW,BBG000BNQ132,Biotech: 'We Would Not Be Surprised to See Volatility Continue',2016-07-13 15:39:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/07/13/biotech-we-would-not-be-surprised-to-see-volatility-continue/?mod=yahoobarrons&ru=yahoo,Biotech: 'We Would Not Be Surprised to See Volatility Continue'
INCY,INCY:UW,BBG000BNQ132,FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD),2016-06-23 11:49:04 +0000,http://www.publicnow.com/view/F7A903ACA8AB998EADA94401A2EE53047BF05FDF,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 23, 2016-- Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ruxolitinib ..."
INCY,INCY:UW,BBG000BNQ132,Incyte: Ruxolitinib Receives Breakthrough Therapy Designation - Quick Facts,2016-06-23 07:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v3oumiMh1sQ/incyte-ruxolitinib-receives-breakthrough-therapy-designation--quick-facts-20160623-00218,Incyte: Ruxolitinib Receives Breakthrough Therapy Designation - Quick Facts
INCY,INCY:UW,BBG000BNQ132,"NYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race",2016-06-22 22:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B5sHJyDLjd0/nymx-grabs-headlines-mrns-awaits-data-in-2h-psti-takes-small-step-in-dmd-race-20160622-00942,"NYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race"
INCY,INCY:UW,BBG000BNQ132,Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study,2016-06-22 20:49:08 +0000,http://www.publicnow.com/view/32FC2609D104841FFF5EA4A5C9F42809D53ED1D5,[at noodls] - http://www.businesswire.com/news/home/20160622006234/en/ 'We are very pleased to treat the first patient in the ECHO-301 study and advance the Phase 3 program evaluating epacadostat in combination with ...
INCY,INCY:UW,BBG000BNQ132,New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV),2016-06-10 06:49:02 +0000,http://www.publicnow.com/view/DB11F27D64C787A2A6CB838B22F6F47627CDC5C1,"[at noodls] - 62 percent of PV patients treated with Jakafi achieved hematocrit control without phlebotomy, compared to 18 percent of patients treated with best available therapy RESPONSE-2 data complements previous ..."
INCY,INCY:UW,BBG000BNQ132,Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs,2016-06-09 14:09:08 +0000,http://www.publicnow.com/view/6F30D329FE03FE6649F05EC6914E6ED32FA806FC,"[at noodls] - Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over ..."
INCY,INCY:UW,BBG000BNQ132,Lilly : Baricitinib Reduces Joint Damage Progression In Rheumatoid Arthritis,2016-06-09 06:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SYhMuM7Egbk/lilly--baricitinib-reduces-joint-damage-progression-in-rheumatoid-arthritis-20160609-00135,Lilly : Baricitinib Reduces Joint Damage Progression In Rheumatoid Arthritis
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At Goldman Sachs Healthcare Conference; Webcast At 5:00 PM ET,2016-06-08 15:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y7qsBJhPRUE/incyte-to-present-at-goldman-sachs-healthcare-conference-webcast-at-500-pm-et-20160608-00864,Incyte To Present At Goldman Sachs Healthcare Conference; Webcast At 5:00 PM ET
INCY,INCY:UW,BBG000BNQ132,Incyte To Present At Jefferies Healthcare Conference; Webcast At 2:00 PM ET,2016-06-08 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vg_yy_bhz74/incyte-to-present-at-jefferies-healthcare-conference-webcast-at-200-pm-et-20160608-00780,Incyte To Present At Jefferies Healthcare Conference; Webcast At 2:00 PM ET
INCY,INCY:UW,BBG000BNQ132,Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance,2016-06-01 11:53:03 +0000,http://www.publicnow.com/view/2640D3AC6C8CF9282C226D4B67191A121D5795D9,"[at noodls] - www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version."
INCY,INCY:UW,BBG000BNQ132,Incyte to Present at Upcoming Investor Conferences,2016-05-18 13:52:09 +0000,http://www.publicnow.com/view/5A1F96AA24D06AB864E4FE3661D7AC12B4CB7B42,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--May 18, 2016-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Jefferies 2016 Healthcare ..."
INCY,INCY:UW,BBG000BNQ132,Incyte First Quarter Financial Results Conference Call and Webcast,2016-05-09 12:18:02 +0000,http://www.publicnow.com/view/E1B8C3889257929D52ED7185F4482B3D8C77BAAA,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--May 9, 2016-- Incyte Corporation (Nasdaq: INCY) today confirms the details for its first quarter 2016 financial results conference call and webcast for 10:00 a.m. ET ..."
INCY,INCY:UW,BBG000BNQ132,Incyte misses 1Q profit forecasts,2016-05-09 11:20:33 +0000,http://sg.finance.yahoo.com/news/incyte-misses-1q-profit-forecasts-112033878.html,Incyte misses 1Q profit forecasts
INCY,INCY:UW,BBG000BNQ132,Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs,2016-05-09 11:16:04 +0000,http://www.publicnow.com/view/49D5633B3E2C3A08FBF5BD5E8DBB1E09020C7591,"[at noodls] - $183 million of 2016 first-quarter net product revenues from Jakafi (ruxolitinib), representing 59 percent growth over the same period last year. Full year Jakafi net product revenue guidance increased ..."
INCY,INCY:UW,BBG000BNQ132,Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe,2016-05-09 11:16:04 +0000,http://www.publicnow.com/view/BE3EBCDE291028E6D42EC388E718AC3710426200,"[at noodls] - http://www.businesswire.com/news/home/20160509005515/en/ The planned acquisition of a fully-integrated and established pan-European team of 125 employees, including medical, sales and marketing personnel, ..."
INCY,INCY:UW,BBG000BNQ132,Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe,2016-05-09 11:00:00 +0000,http://uk.finance.yahoo.com/news/incyte-ariad-announce-agreement-incyte-110000407.html,Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
INCY,INCY:UW,BBG000BNQ132,Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio,2016-04-15 20:47:05 +0000,http://www.publicnow.com/view/36DD72DBE32EE789DB487210B075ADC03ED701CE,[at noodls] - Sustained R&D productivity has generated 14 clinical development candidates against 11 discrete molecular targets Diverse immuno-oncology and targeted cancer therapy portfolios comprised of both large ...
INCY,INCY:UW,BBG000BNQ132,Incyte to Report First Quarter Financial Results,2016-04-14 12:07:28 +0000,http://www.publicnow.com/view/F0E223270F54710C1C52B2DA764CFDDA5FD1D57F,"[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2016-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2016 financial results conference call and webcast for 10:00 ..."
INCY,INCY:UW,BBG000BNQ132,Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD),2016-04-06 12:00:22 +0000,http://www.publicnow.com/view/70EB7B3C626FBB19E49667A15B1A414A46A36FF7,[at noodls] - Pivotal development program for ruxolitinib in GVHD expected to begin in 2016 Novartis agreement amended to include development and commercialization rights for ruxolitinib in GVHD outside of the U.S. ...
INCY,INCY:UW,BBG000BNQ132,Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics,2016-03-31 11:17:31 +0000,http://www.publicnow.com/view/D4D88B09F62CB78CC7909A0953571A9818073BBF,"[at noodls] - INDIANAPOLIS, March 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON - a pivotal phase 3 global study of baricitinib, ..."
INCY,INCY:UW,BBG000BNQ132,Incyte tops Street 4Q forecasts,2016-02-11 13:19:25 +0000,http://sg.finance.yahoo.com/news/incyte-tops-street-4q-forecasts-131925898.html,Incyte tops Street 4Q forecasts
INCY,INCY:UW,BBG000BNQ132,Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP,2016-01-27 22:05:03 +0000,http://www.publicnow.com/view/60C8342BE0736A25A14466E0F545B492F6A28133,"[at noodls] - --(BUSINESS WIRE)--Jan. 27, 2016-- (Nasdaq: INCY) announced today that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic ..."
INCY,INCY:UW,BBG000BNQ132,Incyte to Report Fourth Quarter/Year-End Financial Results,2016-01-21 13:15:21 +0000,http://www.noodls.com/view/115DF80B4360FFF74ECA02E46DA1DC453CCE76DC,"[at noodls] - --(BUSINESS WIRE)--Jan. 21, 2016-- (Nasdaq: INCY) announced today that it has scheduled its fourth quarter 2015 financial results conference call and webcast for on . ... This is an abstract of the original ..."
INCY,INCY:UW,BBG000BNQ132,Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis,2016-01-19 13:25:03 +0000,http://www.noodls.com/view/6C57E39E0D2E28DE39AF85F9A0F932B43248FB50,"[at noodls] - INDIANAPOLIS, /PRNewswire/ -- (NYSE: LLY) and (NASDAQ: INCY) today announced that Lilly has submitted a new drug application (NDA) to the () for the approval of oral once-daily baricitinib for the treatment ..."
INCY,INCY:UW,BBG000BNQ132,Incyte reports 3Q loss,2015-11-03 12:49:15 +0000,http://sg.finance.yahoo.com/news/incyte-reports-3q-loss-124915052.html,Incyte reports 3Q loss
INCY,INCY:UW,BBG000BNQ132,Incyte reports 1Q loss,2015-04-30 12:28:25 +0000,http://sg.finance.yahoo.com/news/incyte-reports-1q-loss-122825343.html,Incyte reports 1Q loss
INCY,INCY:UW,BBG000BNQ132,Incyte reports 4Q loss,2015-02-12 13:54:42 +0000,http://sg.finance.yahoo.com/news/incyte-reports-4q-loss-135442890.html,Incyte reports 4Q loss
INCY,INCY:UW,BBG000BNQ132,Incyte beats Street 3Q forecasts,2014-10-30 14:12:59 +0000,http://sg.finance.yahoo.com/news/incyte-beats-street-3q-forecasts-141259056--finance.html,Incyte beats Street 3Q forecasts
